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 Abstract 
 
LKB1 tumor suppressor is a master upstream protein kinase responsible for activation of 14 
different AMPK family members including AMPK and several less studied enzymes such as 
MARK, BRSK, SIK and NUAK. These enzymes are together thought to play essential roles 
in controlling cellular energy levels, cell polarity and proliferation. The related NUAK1 and 
NUAK2 are members of the AMPK family and there is increasing interest in these kinases as 
recent work suggests they play important roles in regulating key biological processes 
including Myc driven tumourigenesis, senescence, cell adhesion and neuronal polarity. 
Recent work from our laboratory has shown that NUAK1 phosphorylates and inhibits the 
myosin phosphatase complex MYPT1-PP1β following stimuli that induce cell detachment. In 
this work, I describe the first highly specific protein kinase inhibitors of NUAK kinases 
namely WZ4003 and HTH-01-015. WZ4003 inhibits both NUAK isoforms (IC50 for 
NUAK1 20 nM and NUAK2 100 nM), whereas HTH-01-015 inhibits only NUAK1 (IC50 
100 nM). These compounds display extreme selectivity and do not significantly inhibit the 
activity of 139 other kinases tested including 10 AMPK family members. In all cell lines 
tested, WZ4003 and HTH-01-015 inhibit the phosphorylation of the NUAK substrate 
MYPT1 at Ser445 which can be rescued by overexpressing drug resistant NUAK1[A195T] 
which exhibits approximately 50 times more resistance to both the inhibitors. I also 
demonstrate that administration of WZ4003 and HTH-01-015 significantly inhibit cell 
migration, proliferation and invasion in cells to a similar extent as NUAK1 knock-out/ knock-
down. My data indicate that WZ4003 and HTH-01-015 will serve as useful chemical probes 
to delineate the biological roles of the NUAK kinases. Furthermore, I present the evidence 
that NUAK1 interacts with the SCF-βTRCP complex and undergoes phosphorylation 
mediated degradation. NUAK1 possesses a slightly modified degron sequence that 
specifically binds to the SCF-βTRCP complex on PLK1 mediated phosphorylation of two 
serines in the degron. This interaction is lost upon mutating the serine residues on NUAK1 
degron. Endogenous NUAK1 gets ubiquitylated and degraded on hyperphosphorylation and 
subsequently is protected from this degradation in the presence of NEDDylation inhibitor 
MLN-4924. The knock-out MEFs for the βTRCP1 substrate recognition motif also exhibit 
double the amount of NUAK1 as compared to the wild-type MEFs. Moreover, I provide 
evidence showing that NUAK1 is degraded in G2-M stage of the cell cycle, which is 
mediated by the SCF-βTRCP complex. This degradation is being triggered upon PLK1 
mediated phosphorylation of the degron that can be reversed upon treatment with PLK1 
inhibitor BI-2536. Thus my data suggests that NUAK1 on being phosphorylated by PLK1 
binds to, and is consequently degraded by SCF-βTRCP in the G2-M stage of the cell cycle.  
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Abbreviations 
ABL         Abelson tyrosine kinase 
ACC         acetyl-CoA carboxylase 
AGC         protein kinase A, protein kinase G and protein kinase C 
AICAR     5-aminoimidazole-4-carboxamide riboside 
AMP         adenosine 5‟-monophosphate 
AMPK      AMP activated protein kinase 
APS          ammonium persulfate 
ARK5      AMPK-related kinase 5 (NUAK1) 
ATM        ataxia telangiectasia mutated protein kinase 
ATP         adenosine 5‟-triphosphate 
BRSK      brain-specific kinase 
BSA         bovine serum albumin 
βTRCP     beta-transducin repeat containing protein 
C.elegans Caenorhabditis elegans 
CAMK      calcium/calmodulin-dependent protein kinase 
CAMKK   calcium/calmodulin-dependent protein kinase kinase 
cAMP       cyclic AMP 
CDC2       cell division control protein 2 
CDK         cyclin dependent kinase 
cDNA       complementary deoxyribonucleic acid 
cpm          counts per minute 
cps           counts per second 
CREB       cAMP-responsive element-binding protein 
CRL         Cullin RING ligases 
CRTC2     CREB-regulated transcription coactivator 2 
CT            carboxy terminal 
Da             Dalton 
DMEM      Dulbecco‟s modifided Eagle medium 
DMP         dimethyl pimelimidate 
DMPK      dystrophia myotonica-protein kinase 
DMSO      dimethyl sulphoxide 
DNA-PK   DNA-dependent protein kinase catalytic subunit 
doxy          doxycyclin 
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DTT          dithiothreitol 
DUB        deubiquitin enzymes 
E. coli      Escherichia coli 
ECL        enhanced chemiluminescence immunoblotting 
EDTA     ethylenediaminetetraacetate 
EGTA     ethyle-glycol-tetracetate 
ERK        extracellular signal-regulated kinase 
FBS         foetal bovine serum 
FLAG      DYKDDDDKG peptide 
FRT         Flp recombination target 
GFP         green fluorescent protein 
GSH        glutathione 
GSK3      glycogen synthase kinase-3 
HA           hemagglutinin (YPYDVPDYA peptide) 
HECT      homologous to E6-associated protein C-terminus 
HEK293  human embryonic kidney 293 
HeLa        Henrietta Lack‟s cervical cancer derived cells 
HILIC      hydrophilic interaction liquid chromatography 
HPLC      high performance liquid chromatography 
HRP         horseradish peroxidase 
IB             immunoblot 
IgG           immunoglobulin G 
IκBα          nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 
ILK           integrin-linked kinase 
IMAC       immobilised metal affinity chromatography 
IMEC       immortalised mammalian epithelial cells 
IP             immunoprecipitation/immunoprecipitate 
IPTG        isopropyl-β-D-thio-galactopyranoside 
JNK         C-jun-amino-terminal kinase 
kd             kinase-dead mutant 
LB            Luria Bertani broth 
LC            liquid chromatography 
LDS          lithium dodecyl-sulfate 
LKB          Liver kinase B 
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MALDI    matrix-assisted laser-desoprtion ionization 
MAP        microtubule-associated protein 
MAPK     mitogen-activated protein kinase 
MARK    MAP/microtubule affinity-regulating kinase 
MBS85    myosin binding subunit of 85 kDa 
MEF        mouse embryonic fibroblasts 
MELK     Maternal embryonic leucine zipper kinase 
MLC2     myosin light chain 2 
MLCK    myosin light chain kinase 
MOPS     3-(n-morpholino) propane sulphonic acid 
MRCK    myotonic dystrophy kinase-related CDC42-binding kinase 
M-RIP     myosin phosphatase Rho-interacting protein 
MS          mass spectrometry 
mTOR     mammalian target of rapamycin 
MYPT     myosin phosphatase targeting subunit 
MYPT1 SSS/AAA      MYPT1 S445A/S472A/S910A 
NDR2     nuclear Dbf2-related kinase 2 
NEK2     NIMA-related protein kinase 2 
NEM      N-ethylmaleimide 
NUAK   NUAK family SNF1-like kinase 
NUAK1 3xIL/KK      NUAK1 I400K/L401K/I467K/L468K/I524K/L525K 
NUAK1 SSS/AAA     NUAK1 Ser476A/Ser480A/Ser481A 
OD         optical density 
PAGE     poly-acrylamide gel electrophoresis 
PAK       p21-activated kinase 
Par         partition-defective 
PBS       phosphate buffered saline 
PCR       polymerase chain reaction 
PDB      Protein Data Bank 
PDK1    3-phosphoinositide-dependent protein kinase 1 
PEI        polyethylenimine 
PI3K     phosphatidylinositol-4,5-bisphosphate 3-kinase 
PJS       Peutz-Jeghers syndrome 
PKA     cAMP-dependent protein kinase 
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PKB     protein kinase B 
PKC     protein kinase C 
PLK     Polo-like kinase  
PMSF   phenylmethanesulphonylfluoride 
QIK       Qin-induced kinase 
RBX      Ring-box 
RING     really interesting new gene 
ROCK    Rho-associated protein kinase 
rpm         rotation per minute 
SAD       synapses of the amphid-defective kinase 
SCF       SKP-Cullin-F-box 
SDS       sodium dodecyl sulphate 
shRNA  small hairpin RNA 
SIK        salt-induced kinase 
SILAC   stable isotope labeling with amino acids in cell culture 
siRNA   small interfering RNA 
SKP      S-phase kinase associated protein 
SNARK   SNF1/AMP kinase-related kinase (NUAK2) 
Snf1      sucrose-non-fermenting protein kinase 
SNRK   SNF1-related protein kinase 
SSTK    small serine/threonine kinase 
STK11  serine/threonine protein kinase 11 (LKB1) 
TEMED   N,N,N',N'-tetramethylethylenediamine 
TET       tetracycline 
TFA       trifluoroacetic acid 
TIMAP  TGFβ-inhibited membrane-associated protein 
Tris        Tris(hydroxymethyl)methylamine 
TRITC   tetramethylrhodamine B isothiocyanate 
TSSK     testis-specific serine/threonine-protein kinase 
UBA      ubiquitin associated domain 
USP       ubiquitin specific protease 
WNK     with no K(Lys) protein kinase 
wt          wild type 
ZIPK     zipper-interacting protein kinase 
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Amino acid code 
 
Amino acid or residue  Three letter symbol  One letter symbol 
alanine     Ala    A 
arginine     Arg     R 
asparagine     Asn     N 
aspartate     Asp     D 
cysteine     Cys     C 
glutamate     Glu     E 
glutamine    Gln     Q 
glycine     Gly     G 
histidine    His    H 
isoleucine    Ile    I 
leucine     Leu     L 
lysine      Lys     K 
methionine     Met     M 
phenylalanine    Phe    F 
proline     Pro    P 
serine     Ser    S 
threonine    Thr    T 
tryptophan    Trp    W 
tyrosine    Tyr    Y 
valine        Val                             V 
any amino acid          Xaa    X 
hydrophobic residue                           Hyd                                         Ψ 
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1. Introduction 
 
1.1. Protein Phosphorylation 
The multi-step processes occurring within the cell are very rapid, efficient and tightly 
controlled . These processes involve replication of  its DNA content during cell division, 
various anabolic and catabolic processes, movement and migration and responses to 
environmental changes. These various functions are generally controlled and coordinated by 
a vast array of proteins. In the cell, there is a huge turnover of these proteins with their 
expressions dependent on the timely requirements within the cell. For the proper synthesis 
and function of the proteins, evolution has devised multiple methods for protein regulation 
such as proteolytic cleavage, ligand-binding and post-translational covalent modifications. 
Amidst the various covalent modifications occurring within the cells,  protein 
phosphorylation one of the major regulatory mechanisms deployed in biology. The majority 
of eukaryotic proteins are phosphorylated at multiple residues and phosphorylation is likely 
to control virtually every physiological process. Phosphorylation requires a single ATP 
molecule per modification which introduces a significant change in the local charge of the 
substrate leading to the regulation of every conceivable cellular process including signal 
transduction, anabolism, catabolism, cellular movement, transcription, cytoskeletal 
rearrangement, cell cycle progression, differentiation and apoptosis.  
 
The concept of reversible protein phosphorylation was first discovered by Fischer and Krebs 
when they demonstrated that the transfer of a phosphate group from ATP was required for the 
conversion of glycogen phosphorylase b to phosphorylase a in vitro (Fischer and Krebs, 
1955, Sutherland and Wosilait, 1955, Krebs and Fischer, 1956).  Phosphorylation can cause 
major conformational changes in the modified protein, thereby directly altering its affinity or 
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activity towards ligand or substrate.  The phosphorylated substrate can also be recognised by 
other proteins and serve as a docking site for specific phosphate-binding domains. Such 
modifications might then lead to a change in protein function, localisation within the cell or 
protein stability. Protein phosphorylation is controlled primarily by two groups of enzymes – 
protein kinases and protein phosphatases (Fig. 1.1). 
 
 
Figure 1.1 Effects of protein phosphorylation. Fundamental outcomes of phosphorylation 
of proteins by kinases and dephosphorylation by phosphatases are the regulation of the 
activity and the binding partners.  
   
 
1.2. Protein kinases 
Protein kinases are a large superfamily of enzymes responsible for the catalysis of the γ-
phosphate from a molecule of ATP to the hydroxyl group of a residue in the substrate protein. 
Initial classification of protein kinases were based on the residues that they preferentially 
phosphorylate: Ser/Thr protein kinases, Tyr protein kinases and dual specificity protein 
kinases, which phosphorylate Ser, Thr and Tyr residues. Each protein kinase contain a 
catalytic region called kinase domain (about 250-300 amino acids in length), which performs  
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Figure 1.2 The human kinome. 
Phylogenetic tree of human protein kinases based on kinase domain sequence similarity. 
Adapted from (Manning et al., 2002). 
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the phosphoryl transfer reaction. Besides the kinase domain, the proteins possess additional 
regions and domains that are unique to each kinase allowing them the ability to perform 
functions within the cell. The sequencing of the human genome allowed identification of 520 
protein kinases, which were constructed and organised in a phylogenetic tree based on their 
evolutionary divergences of the kinase domain residues, forming the so called kinome 
(Figure 1.2) (Manning et al., 2002).  
 
The kinase families can be clustered into seven major groups: AGC (containing the PKA, 
PKG and PKC families), CAMK (calcium/calmodulin-dependent protein kinases), CK1 
(Casein kinase 1), CMGC (containing the CDK, MAPK, GSK3, CLK families), STE 
(containing the homologues of yeast Sterile kinases), TK (Tyrosine kinases), and TKL 
(Tyrosine kinase–like) (Manning et al., 2002). 
 
The first kinase structure solved was of the catalytic domain of cyclic adenosine 
monophosphate (cAMP)-dependent protein kinase (PKA) (Knighton et al., 1991). Subsequent 
structures showed that the fold is highly conserved (Hanks and Hunter, 1995). The kinase 
domain consists of two lobes which contain several sub-domains with conserved residues that 
are required for substrate recognition and catalysis. N-terminal lobe contains a GxGxxG 
motif (where “x” is any amino acid) that binds to and coordinates the α and β phosphates of 
ATP in subdomain I and a conserved Lys in the VAIK motif located in subdomain II which 
binds and positions ATP. The C- lobe contains the HRDxxxN motif in subdomain VIB  in 
which Asp is a catalytic base which functions as a proton acceptor for the phosphoryl transfer 
and the Asn residue stabilises the catalytic loop and chelates the secondary Mg
2+
 ion. In the 
highly conserved DFG motif of subdomain VII, Asp chelates the primary Mg
2+
 and ensures 
correct orientation of the γ phosphate of ATP. Subdomain VIII plays a major role in the 
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recognition of peptide substrates via the conserved APE motif, in which the Glu residue 
forms a salt bridge with subdomain XI, thereby promoting stability of the C- lobe. Between 
the DFG and APE motifs, there is a regulatory region called the activation loop (T-loop) 
(Hanks and Hunter, 1995). 
 
To inactivate a kinase by generating the kinase dead or catalytically inactive mutant version 
of the kinase, site directed mutagenesis is employed to specifically mutate the VAIK Lys or 
Asp of DFG motif or the Asp of the HRDxxxN into an alanine residue. 
  
Kinases are known to autophosphorylate themselves, which is often important for their 
activity and/or stability. Most kinases specifically phosphorylate their substrate at conserved 
residues and often on studying various substrates of the same kinase, a possible consensus 
motif sequence can be derived for substrate-recognition for that kinase. The consensus motif  
sequence represents the amino  acid preference for that particular kinase around the Ser/Thr 
or Tyr site on the substrate(s). 
 
Many kinases employ or require “substrate docking sites”, which are sites or domains on the 
substrates that are necessary for the recruitment of the upstream kinases. These docking sites 
play an important role in regulation of  substrate specificity. An example for a docking site-
dependent kinase-substrate interaction is the recruitment of PLK1 on various substrates after 
the conserved Polo-box domain on the substrate is phosphorylated by CDKs or related 
kinases (Neef et al., 2007). 
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Figure 1.3 Structure of a kinase domain. 
(A) Schematic representation of the subdomain structure of a kinase domain. Conserved 
residues involved in substrate binding and catalysis are indicated. (B) Ribbon representation 
of the kinase domain of AMPKα2 (PDB ID: 2H6D). The N-lobe is red, the C-lobe is blue, 
GxGxxG is shown in yellow and the side chains of conserved catalytic and substrate-binding 
residues are represented by sticks. The Figure prepared using PyMol. 
 
 
 
Owing to the varied roles of protein kinases in the cellular signalling pathways, various 
diseases including cancer are linked to the perturbations of the protein phosphorylation 
pathways. Various types of cancers have been reported to be caused due to hyperactivation, 
inactivation and also changes in substrate specificity of the protein kinases. A list of protein 
kinases involved in human cancer are listed below (Table 1.) 
 
 
 
A. 
B. 
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Table 1: Kinases mutated in cancer. Various types of mutations in protein kinases were 
found to be associated with cancer. Molecular basis key as follows, Act : Activated,  Amp : 
Amplified,  Del : Deleted,  Exp : Expression,  GOF : Gain of function, LOF : Loss of 
function,  LH : Loss of heterozygosity,  Meth : Methylation, Mut : Mutation,  OE : 
Overexpression, Splice : Splicing change, SNP : Single nucleotide polymorphism, Trans : 
Translocation (Adapted from http://www.cellsignal.com/reference/kinase_disease.html).  
 
Kinase name Mutation type Cancer caused 
Abl1 Trans 
Chronic myelogenous leukemia (CML) ; acute lymphoblastic 
leukemia (ALL) 
Abl2 Trans, Exp Acute Myeloid Leukemia 
ACK Amp Metastatic potential in primary tumors 
ACVR1B Mut, Splice Pancreatic carcinoma and pituitary tumors 
Akt1 Amp, OE, Act Various cancers 
Akt2 Amp, OE, Mut Primary ovarian and pancreatic tumors 
ALK Trans Large cell lymphomas 
ALK3 LOF Juvenile polyposis syndrome 
ALK5/ TGFβR1 SNP, Mut Various cancers 
ATM LOF Leukemias and lymphomas 
ATR Mut, Splice Stomach and endometrium 
AurB OE Various cancers 
Axl OE Various cancers 
Bcr Trans Chronic myelogenous leukemia 
BMK1/ERK5 Exp Breast and metastatic prostate cancer 
BRAF GOF, LOF Malignant melanoma 
BRD4 Trans Juvenile midline carcinomas 
BRK OE Breast cancer 
BTK LOF Radiation resistance of tumours 
BUB1 LOF Various cancers 
BUB1B Mut, OE Various cancers 
CaMKIII OE, Act Breast cancer 
CDK1 Act, Splice Various cancers 
CDK2 Disregulated Various cancers 
CDK4 Act, GOF, Amp, Meth Various cancers 
CDK6 OE, Trans Leukemias, lymphomas and gliomas 
CHEK1 Mut Stomach, colon and endometrium 
CHK2 Mut Li-Fraumeni's syndrome and various cancers 
COT/TPL2 OE, Amp, Mut Various cancers 
c-Raf Amp Various cancers 
CSF1R/FMS Mut 
Acute myeloid leukemia, chronic myelomonocytic leukemia or 
myelodysplasia 
CSNK1e Mut, LH Mammary ductal carcinoma 
CSNK2a1/2 OE, Act Various cancers 
CTK/MATK OE Breast cancer 
DAPK1 Meth, Exp Various p53 mutated cancers 
DNAPK Mut Mismatch repair-deficient colorectal cancer 
EGFR Amp, OE, GOF Various cancers 
EphA1 Exp Various cancers 
EphA2 OE Various cancers 
EphB2 OE, Mut Various cancers 
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ErbB2/Her2 Amp, OE Breast cancer 
ErbB3/Her3 OE Breast and prostate cancer 
ErbB4/Her4 Exp Various cancers 
FER Exp Prostate cancer 
FES Mut, Trans, LOF Colorectal cancer & acute promyelocytic leukemia 
FGFR1 Mut, Trans Stem cell leukemia lymphoma syndrome 
FGFR2 Mut, Amp Various cancers 
FGFR3 GOF, Trans Multiple myeloma, bladder & cervical cancer 
FGR Amp Hormone-resistant prostate cancer 
FLK1/VEGFR2 Mut Tumour angiogenesis in various cancers 
FLT1/ VEGFR1 Meth, OE Various cancers 
FLT3 GOF, Mut 
Acute myeloid leukemia (AML), acute lymphoblastic 
leukemia, acute promyelocytic leukemia and myelodysplastic 
syndrome 
GUCY2F/CYGF Mut Colon, lung, breast and pancreatic tumors 
HEK/EphA3 Mut Point mutations reported in various cancers 
HIPK1 OE Breast cancer 
HIPK2 LH, Exp Breast and thyroid carcinomas 
HTK/EphB4 OE Various cancers 
IGF1R Mut, SNP, OE Various cancers 
IKKα, IKKβ Exp Linked to apoptosis 
IKKε Amp, Exp Breast cancer 
ILK OE Various cancers 
IRAK2 Mut Anti-apoptotic 
ITK Trans T-cell lymphomas 
Jak1 Mut, Act Various cancers 
Jak2 Trans Breast cancer & acute lymphoblastic leukemia 
Jak3 LOF, Act Acute megakaryoblastic leukemia 
JNK3 Exp Brain tumours 
Kit GOF, LOF, Act, Mut Gastrointestinal stromal tumours (GIST) 
LATS1 Meth, Exp, Mut Likely tumour suppressor 
LATS2 Exp Prostate cancer 
LCK Trans, Mut, Exp, Splice T-cell leukemia, colon and thymus cancers 
LIMK1 OE, Amp, LH Breast and metastatic prostate cancer 
LYN Act Acute myeloid leukemia 
MAP2K1,2 Mut, OE Various cancers 
MAP2K3 Mut, Del Colon cancer 
MAP2K4 LOF, Del Various cancers 
MELK Exp Various cancers 
Met GOF, OE, Trans Renal and gastric carcinomas 
MLK4 Mut Colon cancer 
Mst4 OE Prostate cancer 
NEK2 OE Ewing's tumour & diffuse large B cell lymphoma 
NEK8 OE Breast cancer 
NTRK1/TrkA Mut, Trans Various cancers 
NTRK2/TrkB Mut Various cancers 
NTRK3/TrkC Trans, Mut Various cancers 
NUAK1/ARK5 OE Various cancers 
PAK4 OE Various cancers 
PDGFRα Trans, Del, Mut Atypical CML and GIST 
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PDGFRβ Trans, OE Various cancers 
Pim1,Pim2,Pim3 Trans, OE, Mut Various cancers 
PINK1 Mut, Exp Ovarian cancer 
PKCα Mut, Del, OE, Act Various cancers 
PLK1 Exp Various cancers 
PRKR Mut, Exp, Act Various cancers 
PTK2/FAK OE, Amp, Act Various cancers 
Ret LOF and GOF, Trans 
Endocrine, thyroid, multiple neoplasia and 
phaeochromocytoma 
RON OE, Splice Various cancers 
ROS Trans Glioblastoma 
p70S6K OE, Amp Breast and colon cancers 
SGK1 Exp Breast cancer 
SKY/TYRO3 OE Multiple myeloma and astrocytoma 
SRC Mut, OE, Act Colon and various cancers 
STK11/LKB1 LOF Peutz-Jeghers syndrome 
Syk Meth, Splice Various cancers 
TEK/Tie2 Mut, OE Various cancers 
TGFβR2 LOF Colorectal, gastric and oesophageal cancers 
Yes Amp, Act Various cancers 
ZC1/HGK OE Primary tumours 
  
 
 
1.3. Protein kinase inhibitors 
 
As listed in Table 1, protein kinases play direct and indirect roles in cancer and various other 
diseases. Thus, over the last two decades the protein kinase family has been targeted for 
structure based drug design to generate specific ATP competitive inhibitors. The first protein 
kinase inhibitors reported were isoquinolinesulphonamide derivatives H7 and H8 developed 
by Hiroyoshi Hidaka in 1980s which were shown to inhibit the cyclic-nucleotide dependent 
protein kinases (Hidaka et al., 1984, Cohen, 2002a). Since then various kinases involved in 
disease have been targeted and in 2001 Imatinib or Gleevec was approved for clinical use for 
the treatment of chronic myelogenous leukemia by specifically targetting BCR-Abl tyrosine 
kinase fusion protein (reviewed in (Cohen, 2002a). Till 2012, nearly 25 kinase inhibitors have 
been approved for clinical use and a further 150 odd compounds are undergoing clinical trials 
(Cohen and Alessi, 2013). As of 2013, 50-70% of cancer drug discovery programs in 
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pharmaceutical companies are focussed on the development of protein kinase inhibitors 
(Cohen and Alessi, 2013).  
 
Besides disease targetting, protein kinase inhibitors are valuable tools to dissect the 
biochemical and physiological functions of a kinase in vitro. They are widely used on cells to 
identify protein kinase substrates, phosphorylation motifs as well as identifying novel 
functions of the various kinases. Determining the specificity of an inhibitor is essential before 
using the compound to study kinase functions (Cohen, 2010). A favourite method amidst 
biochemists is to exploit the ATP-competitive property of the inhibitors and develop a drug-
resistant mutant of the kinase which is a perfect control to study the degree of specificity of 
the inhibitor in vivo as well as to pin-point the exact kinase-substrate functions (Cohen, 
2010). A drug-resistant mutant version of a kinase is generally developed either by mutating 
the conserved gate-keeper  Met or Thr into a more bulky residue (Eyers et al., 1999, Clark et 
al., 2012) or by mutating the residue adjacent to the Mg
2+
 binding Asp of the DFG motif in 
subdomain VII (Fig 1.3A) into a bulkier residue (Bonn et al., 2006, Nichols et al., 2009, 
Deng et al., 2011). Previously, studies on Rho-associated protein kinase had revealed that the 
Ala residue (Ala215) adjacent to the magnesium ion binding DFG motif in subdomain VII 
played a vital role in binding to the inhibitor H-1152 via Van der Waals interactions (Jacobs 
et al., 2006). Furthermore it was shown that PKA was almost 50-fold less sensitive to H-1152 
as compared to ROCK since it had a Thr (Thr183) at the equivalent position. Mutation of the 
Thr to an Ala rendered PKA much more sensitive to H-1152 although without affecting the 
basal activity of PKA (Bonn et al., 2006). Our lab had previously successfully applied this 
concept to develop drug resistant LRRK2, a kinase mutated in Parkinsons disease, by 
mutating the Ala2016 to a Thr without altering the intrinsic activity of LRRK2 (Nichols et 
al., 2009, Deng et al., 2011). 
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1.4. LKB1 signalling pathway 
LKB1 (STK11) Ser/Thr protein kinase is a tumour suppressor which is frequently mutated in 
a rare autosomal dominant disorder  called Peutz-Jeghers cancer syndrome (PJS) (Hemminki 
et al., 1998, Jenne et al., 1998). Patients suffering from PJS develop multiple benign 
hamartomatous polyps in their gastrointestinal tract, melanin pigmentation of the lips, palms , 
face, oral mucosa and genitalia (Hemminki, 1999). Furthermore PJS patients are predisposed 
to various tumours including  gastrointestinal adenocarcinomas, cervical, breast, testicular, 
ovarian or pancreatic cancers (Katajisto et al., 2008). More than 30% of non-small cell lung 
carcinomas (Ji et al., 2007) and 20% of cervical cancers (Wingo et al., 2009) have exhibited 
LKB1 mutations.  
 
 LKB1 is ubiquitously expressed but the highest expression is in testis and liver and hence the 
name Liver Kinase B1. Tissue specific knock-out of LKB1 results in various polyps and 
carcinomas consistent with PJS phenotype (reviewed in(Shackelford and Shaw, 2009)), while 
full-body LKB1 homozygous knock-out mice exhibit embryonic lethality (Ylikorkala et al., 
2001). 
 
 LKB1 has been found to be constitutively active via its interaction with two regulatory 
subunits, STE20-related adaptor (STRAD) and mouse protein 25 (MO25). The crystal 
structure of the trimeric LKB1-STRAD-MO25 complex has revealed that the inactive 
pseudokinase STRAD interacts with LKB1 and allosterically promotes the active 
conformation while armadillo-repeat adaptor protein MO25 further stabilizes the complex by 
interacting with the LKB1 activation loop (Figure 1.4) (Zeqiraj et al., 2009). Besides 
activation, STRAD and MO25 interacts with the predominantly nuclear  LKB1 and the 
trimeric complex re-localises to the cytoplasm (Boudeau et al., 2003, Boudeau et al., 2004).   
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Figure 1.4 Structure of the LKB1-STRAD-MO25 complex. LKB1, STRAD and MO25 are 
indicated in red, green and blue, respectively (Zeqiraj et al., 2009). LKB1 T-loop is indicated 
in orange. Non-hydrolysable ATP analogue 5'-adenylylimido-diphosphate (AMP-PNP) that 
was co-crystallized with the complex are shown by the arrows.  
 
LKB1 has been implicated in the regulation of multiple cellular processes such as energy 
metabolism, cell polarity, proliferation and apoptosis (Alessi et al., 2006, Fan et al., 2009). 
These physiological functions of LKB1 are primary brought about by activation of the AMP-
activated protein kinase AMPK and AMPK related kinase family (Fig 1.5). LKB1-STRAD-
MO25 trimeric complex activates AMPK (Hawley et al., 2003, Woods et al., 2003, Shaw et 
al., 2004) and AMPK related kinases (Lizcano et al., 2004, Jaleel et al., 2005) by 
phosphorylating a conserved Thr on the T-loop of the respective kinase domains. 
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Figure 1.5. AMPK-related kinases : (A) Domain structure of AMPK-related kinases that 
are phosphorylated by LKB1 at the indicated T-loop (red) residue on the kinase domain 
(blue). (B) AMPK-family branch from the human kinome. * indicates kinases in the AMPK 
related family which are not phosphorylated and activated by LKB1 complex.  
 
 
1.4.1 AMP-activated protein kinase or AMPK 
The most extensively studied substrate of LKB1 is AMP-activated protein kinase or AMPK 
which is the central sensor and regulator of energy homeostasis within a cell (Hardie, 2007, 
Shackelford and Shaw, 2009). It functions as a heterotrimeric complex consisting of a 
catalytic subunit, AMPKα (2 isoforms in human) and two regulatory subunits AMPKβ (2 
A. B. 
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isoforms in human) and AMPKγ (3 isoforms in human). AMPK is allosterically activated by 
AMP (Yeh and Kim, 1980) upon binding to the AMPKγ submit leading to a conformational 
change (Scott et al., 2007) and further upon inhibition of dephosphorylation of the T-loop by 
PP2C phosphatase isoforms (Hawley et al., 1996, Sanders et al., 2007). The primary 
upstream kinases phosphorylating the T-loop of AMPKα are the LKB1 trimeric complex 
(Hawley et al., 2003, Woods et al., 2003, Shaw et al., 2004) and CaMKK or Ca
2+
/calmodulin-
dependent protein kinase kinase which activates AMPK in response to tissue-specific calcium 
signalling (Hawley et al., 1995, Hurley et al., 2005, Woods et al., 2005). 
 
Metabolic stresses which increase the cellular AMP/ATP ratio leads to the activation of 
AMPK which inhibits the anabolic pathways and activates the catabolic pathways to restore 
energy balance (Hardie, 2007, Hardie et al., 2012). AMPK plays pivotal roles in glucose 
metabolism, protein metabolism, lipid metabolism, mitochondrial biogenesis and autophagy 
(Figure 1.6). 
  
 
Figure 1.6 : Effects of AMPK activation on the cell metabolism. Adapted from (Hardie et 
al., 2012) 
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Besides energy stress, some chemical stimuli like the type 2 diabetes drug metformin 
activates  AMPK (Zhou et al., 2001) possibly by affecting the levels of mitochondrial 
reactive nitrogen species (Zou et al., 2004). Various other reagents like cytokines such as 
leptin, ghrelin, adiponectin, interleukin-6 and natural products such as resveratrol, 
cannabinoids, berberine, salicylate or substances in green tea like epigallocatechin gallate can 
activate AMPK (Hardie, 2007, Steinberg and Kemp, 2009, Hardie et al., 2012, Hawley et al., 
2012). Additionally, potent and specific allosteric activators of AMPK, such as AMP analog 
AICAR (5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide) and A-769662 (also called 
“Abbott compound”) have been developed, which have been extremely helpful in studying 
the downstream functions of AMPK in vitro and in vivo (Hardie, 2007, Steinberg and Kemp, 
2009).  
 
AMPK substrates generally exhibit a consensus motif for AMPK phosphorylation. The 
sequence includes hydrophobic residues at the -5 and +4 positions and basic residues at -4 or 
-3 (or both) positions relative to the Ser/Thr phosphorylation site. A further basic residue at -6 
position is often preferred by the more canonical substrates like acetyl CoA carboxylase 
(ACC). The simplified consensus motif can be written ΨXBXX(S/T)XXXΨ, where Ψ is a 
hydrophobic residue, B is basic, and X is any residue (reviewed in (Hardie et al., 2012)). 
However, presence of this motif doesnot predispose a protein to be an AMPK substrate as 
various factors like protein localisations and tertiary structures play a role.   
 
1.4.2. The family of AMPK-related kinases 
The AMPK family belongs to the CAMK Ser/Thr protein kinase superfamily and are the 
lesser studied downstream substrates of LKB1 (Fig 1.5). LKB1 phosphorylates 12 of the 
AMPK related kinases at the conserved Thr on the T-loop of the kinase domain (Lizcano et 
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al., 2004, Jaleel et al., 2005) whereas MELK and NIM1, although belonging to the same 
family, are not activated by the trimeric tumour suppressor (Fig 1.5B) (Jaleel et al., 2005). 
The AMPK related kinases possess highly homologous kinase domains (Fig 1.7), very similar 
substrate specificities and many of them often employ the AMPK consensus motif to 
phosphorylate their substrates (Zagorska et al., 2010, Hou et al., 2011). 
 
Some of these kinases phosphorylate their substrates and form a RSXS*XP consensus where 
S* is the phosphorylation residue which leads to the formation of a canonical 14-3-3 adaptor 
protein docking motif (Mackintosh, 2004, Al-Hakim et al., 2005, Matenia and Mandelkow, 
2009, Zagorska et al., 2010).  
 
Figure 1.7 : Sequence alignment of the kinase domains of AMPK-related kinases.  
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The AMPK related kinases regulate various cellular functions like cell polarity, migration 
and detachment, neuronal polarity, transcription, cell proliferation etc. (Alessi et al., 2006, 
Bright et al., 2009). As the name suggests, microtubule-affinity regulating kinases or MARKs 
are associated with the cytoskeletal system of the cells and regulates cell polarity (Kemphues 
et al., 1988, Tassan and Le Goff, 2004). MARKs recognize and phosphorylate a relatively 
short consensus motif  [K/R]XX[S/T] which forms a 14-3-3 docking site on the 
phosphorylated substrate (Mackintosh, 2004, Matenia and Mandelkow, 2009). MARKs 
phosphorylate a microtubular protein called Tau which leads to the disruption of 
microtubules (Drewes et al., 1997). MARK4 is atypically ubiquitylated by 29/33 linked 
polyubiquitin chains (Al-hakim et al., 2008) and all four of the MARK isoforms possess a 
UBA or ubiquitin associated domain which has very low affinity for ubiquitin and instead 
stabilises the kinase domain by keeping it in an open conformation for LKB1 mediated T-
loop phosphorylation (Jaleel et al., 2006, Murphy et al., 2007). Besides cell polarity, various 
groups have implicated the MARK isoforms in development of neurones, neurite growth, 
immune system, intracellular transport and also have been suggested as potential therapeutic 
targets for neurodegeneration (reviewed in (Matenia and Mandelkow, 2009)).  
 
The BRSKs or Brain-specific kinases (also known as SAD or Synapses of Amphids 
Defective kinases) are exclusively expressed in brain and have been reported to be essential 
for development of neuronal polarity (Kishi et al., 2005, Barnes et al., 2007, Shelly et al., 
2007). BRSKs are activated by LKB1 (Lizcano et al., 2004) and similar to MARKs, BRSKs 
phosphorylate Tau (Kishi et al., 2005) and BRSK1 has been shown to regulate presynaptic 
neurotransmitter release by localising into synaptosomal membrane lipid rafts (Inoue et al., 
2006, Rodriguez-Asiain et al., 2011).  
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Of the SIKs or salt-inducible kinase family, SIK1 was first identified as a kinase regulating 
steroidogenesis (Takemori et al., 2003) in the adrenal glands of rats kept on a high salt diet 
(Wang et al., 1999). SIK2/QIK is thought to regulate insulin-signalling in adipose tissue by 
phosphorylating insulin receptor substrate IRS1 (Horike et al., 2003). Both SIK1 and SIK2 
has been reported to phosphorylate CRTC2 (CREB-regulated transcription coactivator 2), 
leading to inhibition of CREB-mediated transcription (Screaton et al., 2004, Katoh et al., 
2006). Recently, it has been shown that SIKs phosphorylate and inhibit CRTC3 mediated 
transcription leading to a marked reduction in formation of regulatory macrophages (Clark et 
al., 2012) and inhibition of prostaglandin E2 induced macrophage IL-10 production 
(MacKenzie et al., 2013). Not much is known about SIK3/ QSK except that its thought to be 
involved in skeletal development (Sasagawa et al., 2012) and glucose and lipid metabolism in 
mice (Uebi et al., 2012). Selective and highly potent small molecules inhibitors KIN112 and 
HG-9-91-01 (Clark et al., 2012, MacKenzie et al., 2013) has recently been reported that 
inhibit all three SIK isoforms without significant off-target effects on any of the other AMPK 
family kinases (Clark et al., 2012). These two SIK inhibitors are first of its kind to 
specifically target only a sub-set of kinases within the AMPK-related kinase family. 
  
1.4.3. NUAK family Snf1 like kinases or NUAKs 
NUAK1 (also known as AMPK related kinase 5 or ARK5 and OMPHK1 or Omphalocoele 
Kinase 1) and NUAK2 (also known as SNARK or sucrose non-fermenting AMPK related 
kinase) are two isoforms, both of which are activated upon phosphorylation by the LKB1-
STRAD-MO25 trimeric tumour-suppressor complex at a conserved threonine residue in the 
respective activation loop of the kinase domain (Lizcano et al., 2004). NUAK1 or ARK5 was 
first identified by the group of Hiroyasu Esumi in 2003 as a 661 amino acid AMPK related 
kinase which is activated by Akt upon phosphorylation at Ser600 (Suzuki et al., 2003). Since 
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then, the same group has reported various upstream kinases like PKB (Suzuki et al., 2003) 
and NDR2 (Suzuki et al., 2006) as well as various downstream substrates like ATM (Suzuki 
et al., 2003) and caspase6 (Suzuki et al., 2004a) of NUAK1, but all these data were carried 
out mostly by overexpression of NUAK1 and hence remains largely controversial. The Akt 
mediated phosphorylation of NUAK1 upon IGF1 stimulation is also considered thoroughly 
controversial (Humbert et al., 2010, Hou et al., 2011, Inazuka et al., 2012).  
 
NUAK1 knockout mice show embryonic lethality at E14.5 with the development of 
omphalocoele (Hirano et al., 2006), a congential abdominal defect where the epithelial lining 
of alimentary canal is mal-developed. Over the past decade, various groups have reported 
NUAK1 to be involved in promoting invasiveness and metastatic potential of various cancer 
cells (Kusakai et al., 2004a, Suzuki et al., 2004b, Chang et al., 2012, Chen et al., 2013b, Lu et 
al., 2013) perhaps mainly by increased secretion of matrix metalloproteinases (Suzuki et al., 
2004b). NUAK1 has been shown to directly phosphorylate p53 and thereby control tumour 
cell proliferation (Hou et al., 2011) and also regulate cellular ploidy and senescence by 
mediating  phosphorylation and degradation of a genomic stability factor LATS1 (Humbert et 
al., 2010). Recently, NUAK1 has been reported to be a primary anti-apoptotic factor 
responsible for the survival of tumours expressing deregulated oncogenic MYC 
(myelocytomatosis gene) (Liu et al., 2012) and knocking down NUAK1 by RNAi or by 
treating the MYC driven cancer cells with inhibitor BX-795 triggers apoptosis (Liu et al., 
2012). 
 
Previously, our laboratory has shown that NUAK1 is atypically ubiquitylated by a 29/33 
linked  polyubiquitin chains and interacts with the deubiquitylating enzyme USP9X and this 
atypical ubiquitylation may result in the inhibition of the NUAK1 kinase activity (Al-hakim 
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et al., 2008). In 2010, our laboratory reported the first physiological substrate of NUAK1, the 
MYPT1-PP1β complex wherein, upon cell-detachment agonists NUAK1 phosphorylates 
MYPT1 at Ser445, Ser472 and Ser910 leading to the inhibition of the phosphatase complex 
and promoting 14-3-3 binding at the phosphorylation sites (Zagorska et al., 2010). NUAK1 
and NUAK2 are the only reported human proteins which possess three GILK motifs which 
potentially interact with PP1β (Zagorska et al., 2010). The MYPT1 subunit possesses a 
KVKF motif which directly interacts with the catalytic PP1β while NUAK utilises the 3 
GILK motifs to interact with PP1β subunit of the MYPT1-PP1β complex (Zagorska et al., 
2010). All 3 GILK motifs are essential for efficient binding of NUAK to the phosphatase 
complex and association of MYPT1 to PP1β inhibits the catalytic activity of PP1β from 
dephosphorylating the NUAK activation T-loop phosphorylation (Zagorska et al., 2010). 
Furthermore, on knocking down NUAK1 by RNAi and also in LKB1
-/-
 and NUAK1
-/-  
mouse 
embryonic fibroblasts (MEFs) there is significantly higher number of focal adhesion points 
and accumulation of F-actin stress fibres confirming that inhibition of LKB1-NUAK1 
pathway leads to increased cell adhesion (Zagorska et al., 2010).  
 
NUAK2 or SNARK transcripts were first identified in UV irradiated rat keratinocytes and its 
expression was found to increase upon glucose starvation (Lefebvre et al., 2001). 90% of 
NUAK2 knockout mice are embryonic lethal at E16.5 owing to the development of 
exencephaly (Tsuchihara et al., 2008). Heterozygous NUAK2
-/+
 mice develop mature-onset 
obesity and are more susceptible to chemical carcinogen, azoxymathan (Tsuchihara et al., 
2008). NUAK2 has also been studied to have roles in TNFα signalling (Yamamoto et al., 
2008), sucrose fermentation (Lefebvre et al., 2001, Rune et al., 2009), upregulation of acto-
myosin stress fibres by interacting with myosin phosphatase interacting protein MRIP 
(Vallenius et al., 2011) and promotion of tumour growth and invasive properties in human 
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melanoma (Namiki et al., 2011b). Although NUAK1 and NUAK2 possess 53% sequence 
homology, yet their kinase domains are 82% identical (Fig 1.8). NUAK1 and NUAK2 double 
knockout mice exhibit severe neural tube defects and development of spina bifida, facial 
clefting and exencephaly (Ohmura et al., 2012).   
 
 
Figure 1.8 : Sequence alignment of human NUAK1 and NUAK2. Alignment of NUAK1 
(O60285) and NUAK2 (Q9H093) were carried out using Jalview (Waterhouse et al., 2009). 
Region within the two * denotes the kinase domains.  
 
 
Although NUAKs have been found to exhibit links to cancer and tumour progression, the 
only tool compound available to inhibit the NUAKs is BX-795 (Zagorska et al., 2010, Liu et 
al., 2012) which has been initially reported as a PDK1 inhibitor (Feldman et al., 2005) and 
later on as a potent TBK1/IKKε inhibitor (Clark et al., 2009). BX-795 has a NUAK1 IC50 of 
5nM and it has been further shown to inhibit most of the AMPK-related kinase family 
members including the MARK isoforms with nanomolar IC50 values (Clark et al., 2009). 
Amidst the more generic inhibitors reported, receptor tyrosine kinase inhibitors Sunitinib 
(Demetri et al., 2006), Dovitinib (Trudel et al., 2005) and JAK2 inhibitor TG101348 (Lasho 
et al., 2008) have been shown to inhibit NUAK1with nanomolar IC50 values (Davis et al., 
2011).  
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Developing highly specific and potent inhibitors of the AMPK family members were 
originally deemed a challenging task due to the highly homologous kinase domains of these 
enzymes (Alessi et al., 2006) (Fig 1.7). The early AMPK family inhibitors that were reported 
such as Compound C (also known as dorsomorphin) (Yu et al., 2008) and BX-795 were 
found to significantly inhibit all AMPK family members tested including NUAK isoforms 
with nanomolar IC50 values (Clark et al., 2009). Subsequently a BX-795 derivative termed 
MRT67307 (Clark et al., 2012) was developed that displayed better specificity but 
nevertheless still inhibited SIK, NUAK, and MARK isoforms. However, recently, the success 
of SIK inhibitors KIN112 and HG-9-91-01 (Clark et al., 2012, MacKenzie et al., 2013) 
signifies that it will ultimately be possible to develop specific inhibitors to each of the AMPK 
family members.  
 
The concept of specific NUAK inhibitors first arose in our laboratory when in collaboration 
with Dr. Nathanael Gray (Harvard, USA) it was observed that the 7-membered ring 
structured inhibitors of LRRK2, a kinase mutated in Parkinsons disease, had off-target effects 
on NUAK1 at higher concentrations. One of the most potent and selective inhibitors of 
LRRK2, LRRK2-in-1 inhibited NUAK1 in vitro by almost 80% at 10 µM concentration 
(Deng et al., 2011). Based on the 7-membered ring inhibitor series and the BX-795 derived 
2,4,5-trisubstituted pyrimidine series, Dr. Nathanael Gray's laboratory developed various 
prototypes of potential NUAK inhibitors which shall be further discussed and described in 
details in Chapter 3. 
 
1.5. Ubiquitylation as a regulatory mechanism 
Ubiquitylation is one of the most versatile post translational modifications in the cell which 
controls various mechanisms like cell cycle, DNA repair, immune responses, transcription, 
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viral infection, receptor endocytosis, protein stability etc. (reviewed in(Ikeda and Dikic, 
2008)). The process involves the covalent attachment of a mono or poly ubiquitin small 
protein modifier by a cascade of enzymatic reactions on a conserved Lys residue on the 
substrate which finally determines the fate of the substrate within the cell (reviewed in 
(Teixeira and Reed, 2013)). Similar to phosphorylation and dephosphorylation, the process of 
ubiquitylation is reversible by the action of deubiquitylating enzymes or DUBs which play a 
role in the ubiquitin chain cleavage from substrates (Ikeda and Dikic, 2008). 
 
1.5.1. Ubiquitin 
Ubiquitin was first described as a 8.5 kDa 74 amino acid long UBIP or ubiquitous 
immunopoietic polypeptide involved in thymic lymphocyte differentiation (Goldstein et al., 
1975). The first ubiquitylated substrate reported was Histone H2A, wherein a branched 
polypeptide was found linked via an isopeptide bond at the C-terminus of H2A (Goldknopf 
and Busch, 1977). It was in the 1980s that the role of ubiquitin in ATP dependent proteolytic 
cleavage was identified and was termed as ATP-dependent proteolytic factor or APF1 
(Ciechanover et al., 1980). Eventually this protein has been identified as ubiquitin, a 76 
amino acid highly conserved and heat stable protein which is an essential component of the 
ubiquitin-proteasome system (UPS) deciding the fate of proteins in the biological processes. 
 
Ubiquitin exhibits a very stable β-grasp fold structure (Vijaykumar et al., 1987) and on its 
surface there are two conserved hydrophobic patches (Fig 1.9a), the Ile44 patch consisting of 
Leu8, Ile44, His68 and Val70 and the Ile36 patch consisting of Leu8, Ile36, Leu71 and 
Leu73. These two patches are essential for polyubiquitin chain formation as well as for the 
interactions with proteasome, substrates, E3 ligases and DUBs (Komander and Rape, 2012). 
Recently, crystal structure of an E3 enzyme conjugated with ubiquitin primed E2 has shown 
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that the Ile44 patch of ubiquitin is essential for its docking into the E2 enzyme prior to 
substrate catalysis (Plechanovova et al., 2012). Besides the Ile44 and Ile36 patches, the Phe4 
patch is required for DUB interactions and the TEK patch is essential for mitotic degradation 
of ubiquitin (Komander and Rape, 2012). 
 
 
Figure 1.9 : Structure of Ubiquitin : a) The surface topology of ubiquitin structure is shown 
and the important patches are highlighted. Ile44 patch in blue, Ile 36 patch in green, Phe4 
patch in cyan and TEK box in white. b) The structure of ubiquitin highlighting the 
polyubiquitin chain forming Lys residues and the Met residue (blue spheres). Image taken 
from (Komander and Rape, 2012).  
 
1.5.2. Polyubiquitin chains 
Ubiquitin can modify substrate proteins in its monomeric form (monoubiquitylation) or via 
polyubiquitylation upon conjugation with preceding ubiquitin moieties to form a chain. 
Ubiquitin contains seven Lys residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63) 
and the N-terminal Met1 residue (Fig 1.9b) which interact with each other forming isopeptide 
bonds to form long polyubiquitin chains and each chain architecture determines the 
subsequent fate of the substrates (Ikeda and Dikic, 2008, Komander and Rape, 2012).  Lys48 
linked chains are the most abundant form of polyubiquitylation and responsible for targetting 
the substrate for 26S proteasomal degradation (Ikeda and Dikic, 2008). Lys63 linked chains 
are markedly different from the Lys48 linked chains and have been reported to have roles  in 
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degradation as well as some essential functions in immune signalling and kinase activation 
(Komander et al., 2009, Komander and Rape, 2012). Lys11 chains assume a very compact 
conformation (Bremm et al., 2010) and are preferentially formed in the cell cycle by APC/C 
E3 ligase enzyme (Komander and Rape, 2012, Teixeira and Reed, 2013). Lys29/33 linked 
chains seem to inhibit activity of some AMPK related kinases (Al-hakim et al., 2008). Met1 
chains or linear ubiquitin chains regulate NFκB signalling pathway (Tokunaga et al., 2009), 
while very less is known regarding the roles of Lys6 and Lys27 linked chains.  
 
 
1.5.3. Ubiquitin cascade 
The process of ubiquitylation is a three step process involving the E1-E2-E3 cascade (Fig. 
1.10) (Scheffner et al., 1995). The E1 activating enzyme utilises ATP to activate and bind to 
ubiquitin via a ubiquitin -adenylate intermediate. This intermediate further transfers the active 
ubiquitin to the active site Cys of the E1 via a thiol ester linkage (Schulman and Harper, 
2009). Subsequently the active ubiquitin is transferred from E1 to the E2 active site wherein 
the ubiquitin C-terminal tail docks firmly into the α2 helix of the E2 into a 'folded back' 
conformation which orientates the ubiquitin Gly76 residue for the incoming substrate Lys 
(Plechanovova et al., 2012). The substrate is brought in by the E3 ubiquitin ligase complex 
and the Lys residue on the substrate causes a nucleophillic attack on the Gly76 of the active 
ubiquitin leading to an isopeptide bond formation and the final transfer takes place 
(Plechanovova et al., 2012). The combination of E2 and E3 enzymes generally dictate the 
type of polyubiquitin linkage to be formed on the substrate (Ikeda and Dikic, 2008).  
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Figure 1.10 The Ubiquitin E1-E2-E3 cascade 
 
1.5.4. Types of E3 ligases 
There are over 600 E3 ubiquitin ligases and they are primarily of three types based on their 
modes of ubiquitin transfer. The Really Interesting New Gene (RING) domain (Fig 1.11b) 
(Borden, 2000, Joazeiro and Weissman, 2000, Budhidarmo et al., 2012) and closely related 
U-box domain (Hatakeyama and Nakayama, 2003) families of E3 ubiquitin ligases act as a 
scaffold to allow the direct transfer of ubiquitin from the E2 to a Lys residue on the target 
protein.  In contrast, the Homologous to the E6-AP Carboxyl Terminus (HECT) domain 
family forms an ubiquitin-E3 intermediate before transferring ubiquitin from the E3 onto the 
substrate (Fig 1.11a) (Huibregtse et al., 1995). Recently, a new class of E3 ligases have been 
identified containing two RING domains referred to as RING-in-between-RING or RBR E3 
ligases (Wenzel et al., 2011). RBR E3 ligases like HHARI, parkin, RNF4 etc. act as hybrids 
between RING and HECT E3 ligases by functioning through an intermediate covalent 
thioester in a manner similar to HECT E3 ligases (Wenzel et al., 2011, Metzger et al., 2012). 
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Figure 1.11 : HECT and RING domain E3 ligases a) Mechanism of ubiquitin transfer in 
HECT domain E3 ligases where an intermediate Ub-E3 conjugate is formed before substrate 
transfer. b) RING domain E3 ligases (eg. SCF complex) acts as scaffolds which bring E2 and 
substrate close for direct E2 to substrate ubiquitin transfer. Image adapted from (Kipreos, 
2005). 
 
 
1.6. The Cell Cycle : Cross talk between Phosphorylation and Ubiquitylation 
The cell cycle is highly regulated physiological process wherein a cell undergoes duplication 
of its chromosomes and divides into two daughter cells by a series of phases : G1, S (DNA 
replication), G2 and Mitosis (M) (cell division). The cell cycle is a perfect physiological 
scenario to explain how robust post translational modifications like phosphorylation and 
ubiquitylation cross-talk to success highly regulated processes. Kinases, phosphatases, E3 
ubiquitin ligases, helicases and various other proteins play fundamental roles in controlling 
the progression of the cell through the four phases of cell cycle. This section, however, shall 
primarily focus on the role of various kinases and E3ubiquitin ligases in each stage of the cell 
cycle.  
For the cell to undergo division, the presence of growth factor stimuli and mitogens are 
essential. However, upon withdrawal or absence of mitogens, cells enter early  G1 stage of 
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the cell cycle. The E3 ubiquitin ligase APC/C
Cdh1
 is activated during late mitosis and is a 
central player in the Lys11-linked polyubiquitylation (Jin et al., 2008) and degradation of 
mitotic proteins and DNA replication agonists which leads to mitotic exit (Bassermann et al., 
2013).  APC/C
Cdh1 
degrades Cdc6, a DNA replication promoting protein (Mailand and 
Diffley, 2005) and transcription factor Ets1 which is involved in the expression of Cyclin D 
downstream of Ras-Raf-MAPK pathway (Albanese et al., 1995, Li et al., 2008). In early G1 
stage, APC/C
Cdh1 
keeps the CDK family of kinases in an inactive state by degrading SCF
Skp2
 
thereby promoting the expression of CDK inhibitors p21 and p27 (Bashir et al., 2004, Wei et 
al., 2004). Proteasomal degradation of mitotic cyclins (A and B) and the rapid degradations 
of mitotic Aurora family and polo-like kinase (PLK) family of protein kinases ensure a fast 
exit from mitosis and implementation of early G1 phase of the cell cycle (Bassermann et al., 
2013). 
When growth factors and mitogens become available, cells trigger the late G1 phase for 
preparations to enter the S-phase or DNA replication phase of the cell cycle. At this point 
APC/C
Cdh1 
activity decreases owing primarily due to autoubiquitylation of its E2 (Rape and 
Kirschner, 2004) as well as Cdh1(Listovsky et al., 2004). Reduced activity of APC/C
Cdh1 
triggers dephosphorylation and activation of CDK1 and CDK2 by CDC25A dual specificity 
phosphatase which promotes entry to S-phase (Donzelli et al., 2002). Activation of CDKs are 
further enhanced by degradation of the CDK inhibitors p27 by SCF
Skp2
 (Pagano et al., 1995) 
and p21 by CRL4
CDT2
 (Abbas et al., 2008). Active CDKs further phosphorylate Cdh1 and 
disrupts the APC/C
Cdh1 
complex (Lukas et al., 1999). Ets1 mediated transcription of Cyclin D 
leads to the formation of CDK4/6-cyclin D complexes which phosphorylate and inactivate 
pRb (Retinoblastoma family p107 and p130) dependent cell cycle repression machinery 
(Malumbres and Barbacid, 2001). Thus, at the G1/S border, inhibition of pRb machinery 
leads to activation of E2F mediated transcription of Emi1 (Fbxo5) which binds to and 
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completely inhibits the APC/C
Cdh1 
complex all through S and G2 stage of the cell cycle (Hsu 
et al., 2002, Miller et al., 2006).   
Upon successful entry into S-phase, CDK2-cyclin E and CDK2-cyclin A are the primary 
exponents which initiate DNA and centrosome duplication (Bassermann et al., 2013). Cyclin 
D is phosphorylated by GSK3β and consequently degraded by SCFFbxo4 (Lin et al., 2006). 
CDC7 kinase works along with CDKs to phosphorylate and activate the minichromosome 
maintenance complexes MCM helicases which leads to establishing proper integrity of 
replication forks during chromosome duplication (Malumbres, 2011). As DNA replication 
takes place, various E3 ligases like CRL4
CDT2
 (Abbas and Dutta, 2011) and CRL4
DDB1
 (Senga 
et al., 2006) play vital roles to limit DNA replication to once per cell cycle. Accurate DNA 
replication is crucial for the cells, hence besides having a tightly controlled regulation, 
various kinases and E3 ubiquitin ligases play essential roles in DNA repair mechanism. Upon 
DNA damage, the checkpoint kinases CHK1 and CHK2 are activated via ATR and ATM 
upstream kinases (Matsuoka et al., 1998, Zeng et al., 1998). CHKs phosphorylate the dual 
specificity phosphatase CDC25A which consequently leads to SCF
βTRCP
 mediated 
degradation of CDC25A, thus attenuating CDK activation (Busino et al., 2003). Inhibition of 
CDK activity leads to a halt in cell cycle progression and provides time for DNA repair. 
During checkpoint recovery, PLK1 phosphorylates Claspin and targets it for SCF
βTRCP
 
mediated degradation (Mailand et al., 2006, Peschiaroli et al., 2006). Claspin is an essential 
upstream component for ATR induced CHK1 activation in response to DNA damage (Liu et 
al., 2006). Degradation of Claspin via SCF
βTRCP
 ensures S-phase checkpoint revival and 
further progression of cell cycle. As cells progress into S/G2 border, S phase cyclin E is 
phosphorylated by CDK2 and leads to its degradation via SCF
Fbw7 
(Clurman et al., 1996, 
Koepp et al., 2001).  
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After an accurate replication of DNA, the ribonucleotide reductase family member 2 or 
RRM2 is phosphorylated by CDKs and consequently degraded by SCF
CyclinF
 which leads to 
reduction in the synthesis of dNTP pool in the cell (D'Angiolella et al., 2012). Besides 
controlling cellular dNTP pool, SCF
CyclinF
 also regulates centrosome duplication by targetting 
CP110 for proteasomal degradation (D'Angiolella et al., 2010). PLK4 is an essential kinase 
responsible for centrosome duplication (Kleylein-Sohn et al., 2007) and to avoid 
overduplication of centrosomes, PLK4 undergoes robust autophosphorylation followed by 
SCF
βTRCP
 mediated degradation (Mocciaro and Rape, 2012). Aurora A localises to the 
centrosomes at late S and early G2 stage and plays vital roles like centrosome separation and 
controlling bipolar spindle dynamics (Barr and Gergely, 2007). As G2 phase progresses, 
PLK1 activity increases owing to synergistic activity of Bora and Aurora A (Seki et al., 
2008). PLK1 phosphorylates CDK1 inhibitory kinase WEE1 which gets degraded by 
SCF
βTRCP
 (Watanabe et al., 2004).  Degradation of WEE1 promotes the formation of CDK1-
cyclin B complex  which further phosphorylates and inhibits assembly of cyclin B degrading 
SCF
NIPA
 complex (Bassermann et al., 2007, Illert et al., 2012). Thus, a massive upregulation 
of  CDK1-cyclin B complex  ensures a proper mitotic entry of the cells. In the event of DNA 
damage induced G2 checkpoint silencing, SCF
βTRCP
 plays a vital role in degrading the 
translation inhibitory Eukaryotic Elongation factor 2 kinase (eEF2K) upon AMPK 
phosphorylation (Kruiswijk et al., 2012). This ensures a smooth re-start of the cell cycle post 
G2 checkpoint DNA repair. At the G2/M border, NIMA-related kinase NEK2A localises to 
centrosome and along with Aurora A, initiates centrosome separation and microtubule 
organization (O'Regan et al., 2007).   
During early mitosis, nuclear envelope breakdown, chromatin condensation and assembly of 
mitotic spindles are all carried out by the CDK1-cyclin B complex throughout prophase and 
metaphase (Bassermann et al., 2013). PLK1 and Aurora A play essential roles in maintaining 
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the spindle stability and proper tension between the kinetochores (Bassermann et al., 2013). 
The spindle assembly checkpoint (SAC) complex mediates proper chromosomal attachment 
of sister chromatids to the spindle fibres. Upon proper attachment of kinetochores, SCF
βTRCP
 
mediates degradation of APC/C inhibitor EMI1 following CDK1 and PLK1 phosphorylation 
(Margottin-Goguet et al., 2003). This activates APC/C which interacts with substrate 
recognition subunit CDC20 and plays a key role in mitotic progression and exit. In the event 
of unattached kinetochores, SAC complex proteins MAD2, BUBR1 and BUB3 inhibits 
APC/C
CDC20
 by inhibitory phosphorylation or by mediating CDC20 degradation (Bassermann 
et al., 2013) thus restricting entry to anaphase. Once proper alignment of sister chromatids 
have occured, SAC is inhibited and APC/C
CDC20
 degrades Securin which starts the 
segregation of sister chromatids and hence progresses into anaphase (Zou et al., 1999, Hauf et 
al., 2001). Degradation of mitotic cyclins are commenced by APC/C
CDC20
 complex in 
metaphase and is completed by APC/C
Cdh1 
in late mitosis which leads to sister chromatid 
separation (Acquaviva and Pines, 2006). Aurora B, which functions in the centrometric 
regions of chromosomes, undergoes Lys63 linked polyubiquitylation via CRL3
KLHL9
 and 
CRL3
KLHL13
 complexes which results in relocalisation of Aurora B to the spindle midzone to 
control  mitotic chromosome alignment and cytokinesis (Sumara et al., 2007). Post-
cytokinesis or during late mitosis APC/C
Cdh1 
degrades Geminin to prevent random re-
replication of DNA (McGarry and Kirschner, 1998) and promotes mitotic exit by 
proteasomal degradation of mitotic kinases PLK1 (Lindon and Pines, 2004), Aurora A 
(Castro et al., 2002) and Aurora B (Stewart and Fang, 2005). APC/C
Cdh1 
re-establishes G1 
stage of cell cycle by degradation of cyclin B and thus significantly inhibiting CDK activity 
(Acquaviva and Pines, 2006). 
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1.7. Aims of the study 
Over the last decade, LKB1-NUAK1 pathway has been reported to have various links to 
cancer especially in metastasis, cell proliferation and anti-apoptotic roles in deregulated MYC 
driven tumours. A specific and potent tool compound to inhibit the NUAKs was also not 
available to dissect the roles of the NUAKs. In  collaboration with Dr. Nathanael Gray 
(Harvard, USA), I aim to test various small molecule inhibitors of NUAK1 which would 
ideally be very potent and selective for NUAK isoforms alone with least off-target effects on 
any of the other kinases tested including the homologous AMPK related kinases which has 
always been the prime drawbacks of the earlier inhibitors. Chapter 3 discusses in details the 
story behind the development of NUAK inhibitors. 
 
In chapter 4, the primary focus is to look into any novel functions and regulatory pathways of 
NUAK1 in cells. The idea is to identify physiological pathways where NUAK1 is regulated 
and to identify the enzymes responsible in interacting and conferring further post-
translational modifications on NUAK1. I would also aim to dissect the functions of any novel 
modifications or interactors that might regulate NUAK1. 
 
We had previously published that MYPT1-PP1β is the substrate for NUAK1. In chapter 5, I 
would aim to establish the other myosin phosphatase isoforms MYPT2 and MBS85 as 
potential substrates of NUAK1 as the phosphosites on the isoforms are all conserved with 
MYPT1.  
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2. Materials and Methods 
 
2.1 Materials 
 
2.1.1 Commercial reagents 
Adenosine 5‟-triphosphate sodium salt (ATP), anti-HA-agarose, anti-FLAG-agarose, 
ammonium persulphate (APS), ampicillin, benzamidine, bovine serum albumin (BSA), 
bromophenol blue (BPB), dimethyl pimelimidate (DMP), dimethyl sulphoxide (DMSO), 
ethidium bromide, hydrogen peroxide, iodoacetamide, insulin, epidermal-growth factor 
(EGF), hydrocortisone, MISSION™ shRNAs, nocodazole, puromycin, N-ethylmaleimide 
(NEM), propidium iodide, sodium dodecyl sulphate (SDS), sodium tetraborate, thymidine, N, 
N, N‟, N‟-Tetramethylethylenediamine (TEMED), Phalloidin-Tetramethylrhodamine B 
isothiocyanate (TRITCPhalloidin), Triton-X-100 and Tween-20 were from Sigma-Aldrich 
(Poole, UK). Protein A-agarose, Protein G-sepharose, Glutathione-sepharose, Enhanced 
chemiluminescence (ECL) kit and Hyperfilm MP were from Merck. Dulbecco‟s modified 
eagle medium (DMEM), Opti-MEM reduced serum media, Foetal bovine serum (FBS), tissue 
culture grade Dulbecco‟s phosphate buffered serum (PBS), Trypsin/EDTA solution, L-
glutamine, non-essential amino acids, vitamins, sodium pyruvate and antibiotic/antimycotic 
were from GIBCO (Paisley, UK). [γ32P]-labelled ATP were purchased from Perkin Elmer. 
Acetic acid, acetone, ammonium bicarbonate, ethanol, glycerol, glycine, 4-(2-
Hydroxyethyl)piperazine-1-ethanesulfonic acid (Hepes), isopropanol, magnesium chloride, 
manganese chloride, methanol, 2-mercaptoethanol, orthophosphoric acid, potassium chloride, 
sodium chloride, sodium ethylenediaminetetraacetic acid (EDTA), sodium ethylene glycol 
tetraacetic acid (EGTA), sodium fluoride, sodium β-glycerophosphate, sodium 
orthovanadate, sucrose and Tris(hydroxymethyl)methylamine (Tris) were from BDH 
(Lutterworth, UK) or Sigma-Aldrich (Poole, UK). CHAPS and okadaic acid were from 
Calbiochem (Merck Biosciences Ltd, Nottingham, UK). Calyculin A and polybrene were 
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from Cell Signaling Technology (CST). 6, 24 and 96 well tissue culture plates, cell culture 
dishes, cryovials and Spin-X columns were from Corning Incorporated (NY, USA). 
Cellophane films and All Blue Precision Plus pre-stained protein markers were from BioRad 
(Herts, UK). Cell scrapers were from Costar (Cambridge, USA). 40% (w/v) 29:1 Acrylamide: 
Bis-Acrylamide solution was from Flowgen Bioscience. Pre-cast NuPAGE Novex SDS 
polyacrylamide 4-12% Bis-Tris gels, NuPAGE MES and MOPS running buffer (20X), 10X 
NuPAGE sample reducing agent, 4X NuPAGE LDS sample buffer, Colloidal blue staining 
kit, Alexa Fluor donkey secondary antibodies were from Invitrogen (Paisley, UK). Instant-
Blue stain was from Expedeon, UK. Photographic developer (LX24) and liquid fixer (FX40) 
were from Kodak (Liverpool, UK). X-ray films were from Konica Corporation (Japan). 
Agarose, phenylmethanesulphonylfluoride (PMSF), Geneticin (G418) and Isopropyl-β-D-
thiogalactopyranoside (IPTG) were from Melford Laboratories (Chelsworth, UK). 
Restriction enzymes, DNA ligase and DNA ladder were from New England Biolabs 
(Hertfordshire, UK). Coomassie protein assay reagent (Bradford reagent) was from Pierce 
(Chester, UK). Hygromycin, blasticidin and polyethylenimine (PEI) were from Polysciences 
(Warrington, PA). Skimmed milk (Marvel) was from Premier Beverages (Stafford, UK). The 
CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay kit, Taq DNA polymerase in 
storage buffer A, sequencing grade trypsin and nucleotide mix (dNTP) were from Promega 
(UK). Growth-factor-reduced Matrigel™ invasion chambers were from BD Biosciences. 
Reastain Quick-Diff kit was from Reagena. Sequencing grade AspN was from Roche. P81 
paper and 3mm chromatography paper were from Whatman InterInternational Ltd 
(Maidstone, UK). Plasmid Maxi kits were from Qiagen Ltd (Crawley, UK). Acetonitrile 
(HPLC grade), trichloroacetic acid (TCA) and trifluoroacetic acid (TFA) were from Rathburn 
Chemicals (Walkerburn, UK). Protran BA nitrocellulose membrane was purchased from 
Schleicher and Schuell (Anderman and Co. Ltd., Surrey, UK). HRP-conjugated secondary 
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antibodies and SuperSignal West Dura extended duration substrate were from Thermo-
scientific (Essex, UK).  
 
2.1.2 In-house reagents 
Oligonucleotide primers were custom synthesised by the University of Dundee 
oligonucleotide synthesis service. Bacterial culture medium Luria Bertani broth (LB), 
autoinduction media and LB agar plates were provided by the College of Life Sciences media 
kitchen service. Sakamototide substrate peptide [ALNRTSSDSALHRRR], used for AMPK 
related kinase activity assays, was obtained from the Division of Signal Transduction 
Therapy (DSTT, University of Dundee). Microcystin-LR was kindly provided by Prof. C. 
Mackintosh (University of Dundee, MRC-PPU). 
 
 
 
2.1.3 Antibodies 
2.1.3.1 In-house antibodies 
 
In-house antibodies (Table 2.1) were raised in sheep and affinity purified on the 
approprate antigen. The polyclonal sheep antibody production was carried out by the 
Division of Signal Transduction Therapy (DSTT, University of Dundee). 
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Table 2.1 : List of in-house sheep antibodies 
Antibody Antigen Sheep Bleed 
anti-MYPT1 
 phospho Ser445 
MYPT1 (437-452)  
RLGLRKTGS*YGALAEI 
S508C 1st 
anti-MYPT1  
phospho Ser472 
MYPT1 (466-478) 
GVMRSAS*SPRLSS 
S509C 2nd 
anti-MYPT1  
phospho Ser910 
MYPT1 (903-917) 
RLLGRSAS*YSYLEDRK 
S516C 1st 
anti-MYPT1 Human MBP-MYPT1 (714-1005) S662B 1st 
anti-NUAK1 Human his-NUAK1 S628B 2nd 
anti-PP1β Human PP1β (316-327) S383B 3rd 
anti-GFP GFP S268B 1st 
* indicate phosphorylated residue 
 
2.3.1.2. Commercial/gifted antibodies 
Table 2.2 tabulates antibodies obtained from the indicated commercial sources and 
used at the concentration recommended by the manufacturer/collaborator.  
Table 2.2 : List of commercial antibodies used in this thesis 
Antibody Company/Gift from Catalogue Raised in 
β-TRCP  Cell Signalling 4394 Rabbit 
ACC Cell Signalling 3662 Rabbit 
pSer79 ACC Cell Signalling 3661 Rabbit 
MLC2 Cell Signalling 3672 Rabbit 
pSer19 MLC2 Cell Signalling 3671 Rabbit 
pSer19/Thr18 MLC2 Cell Signalling 3674 Rabbit 
AMPKα Cell Signalling 2532 Rabbit 
pThr172 AMPK Cell Signalling 2535 Rabbit 
p53 Cell Signalling 9282 Rabbit 
 
 
53 
Cyclin B1  Cell Signalling 4135 Mouse 
Cyclin D1  Cell Signalling 2926 Mouse 
Cyclin E  Cell Signalling 4129 Mouse 
Histone H3 pSer10  Cell Signalling 3377 Rabbit 
Histone H3  Cell Signalling 4499 Rabbit 
Cyclin A  Cell Signalling 4656 Mouse 
PLK1 Cell Signalling 4535 Rabbit 
c-MYC Cell Signalling 9402 Rabbit 
N-MYC Cell Signalling 9405 Rabbit 
GAPDH Cell Signalling 2118 Rabbit 
LATS1 Cell Signalling 9153 Rabbit 
ZO1 Abcam ab59720 Rabbit 
GST-HRP Abcam ab58626 - 
HA-HRP Roche 12013819001 - 
FLAG-HRP Sigma A8592 - 
HA monoclonal Roche 11867423001 Rat 
14-3-3 Santa Cruz sc-629 Rabbit 
ERK Cell Signalling 4372 Rabbit 
pERK Cell Signalling 9102 Rabbit 
Ubiquitin Dako Z0458 Rabbit 
Caspase3 FITC conjugated BD Pharmingen 559341 - 
 
 
2.1.4 Plasmids  
Dr. M. Deak, Dr. M. Peggie, Dr. R. Toth and Mr. T. Macartney performed the cloning, 
subcloning and mutagenesis of the constructs described in this thesis. Table 2.3 summarises 
all the mammalian constructs used in this work while Table 2.4 lists the constructs used to 
purify recombinant proteins from E.coli BL21 DE3 cells (2.2.4). 
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Table 2.3 : Mammalian expression constructs 
Protein Expressed Plasmid DU No. 
NUAK1 GFP-NUAK1 pBABE.puro-GFP NUAK1 DU41429 
NUAK1 HA-NUAK1 A195T pcDNA5frtTO HA NUAK1 A195T DU44193 
NUAK1 GFP-HA-NUAK1 S476/480/481A pcDNA5-FRT/TO-GFP HA NUAK1 SSS/AAA DU41375 
NUAK1 GST-HA-NUAK1-Y479/A pEBG-2T-HA NUAK1-Y479/A DU38175 
NUAK1 GST-NUAK1 D196A SSS/AAA pEBG6P NUAK1 D196A S/476/480/481A DU41537 
NUAK1 GST-HA-NUAK1-S480/A pEBG-2T-HA NUAK1-S480/A DU38176 
NUAK1 HA-NUAK1-S476/480/AA pcDNA5-FRT/TO-HA NUAK1-S476/480/AA DU38598 
NUAK1 HA-NUAK1 A195T pBabe.hygro.DU HA-NUAK1 A195T DU40830 
NUAK1 GST-NUAK1 D196A S476A pEBG-6P NUAK1 D196A S476A DU41622 
NUAK1 GST-HA-NUAK1 A195/G pEBG-2T-HA NUAK1 A195/G DU38086 
NUAK1 GST-HA-NUAK1-S481/A pEBG-2T-HA NUAK1-S481/A DU38177 
NUAK1 HA-NUAK1-S476/480/AA pBabe.puro-HA NUAK1-S476/480/AA DU38599 
NUAK1 HA-NUAK1 pBabe.hygro.DU HA-NUAK1 DU40806 
NUAK1 GST-NUAK1 D196A S480A pEBG-6P NUAK1 D196A S480A DU41623 
NUAK1 GST-HA-NUAK1 A195/S pEBG-2T-HA NUAK1 A195/S DU38087 
NUAK1 GST-HA-NUAK1-P482/A pEBG-2T-HA NUAK1-P482/A DU38178 
NUAK1 HA-NUAK1 wt Lentiviral-HA NUAK1 wt DU13246 
NUAK1 HA-NUAK1 A195G pBabe.hygro.DU HA-NUAK1A195G DU40827 
NUAK1 eCFP-NUAK1 pcDNA5frtTO eCFP NUAK1 DU41878 
NUAK1 GST-HA-NUAK1 A195/T pEBG-2T-HA NUAK1 A195/T DU38088 
NUAK1 GST-HA-NUAK1-E483/A pEBG-2T-HA NUAK1-E483/A DU38179 
NUAK1 GFP-wt-NUAK1 pGFP NUAK1 wt DU2153 
NUAK1 HA-NUAK1 Kdead Lentiviral-HA NUAK1 D196/A DU13247 
NUAK1 NUAK1-CFP pcDNA5 FRT/TO NUAK1-CFP DU40837 
NUAK1 NUAK1 A195G pcDNA5frtTO NUAK1 A195G DU41824 
NUAK1 HA-NUAK1 wt pcDNA5-FRT/TO-HA NUAK1 wt DU13418 
NUAK1 GST-HA-NUAK1 A195/N pEBG-2T-HA NUAK1 A195/N DU38089 
NUAK1 GST-HA-NUAK1-S476/480/AA pEBG-2T-HA NUAK1-S476/480/AA DU38180 
NUAK1 HA-NUAK1 T211/A Lentiviral-HA NUAK1 T211/A DU13248 
NUAK1 GST-NUAK1-wt pEBG-2T-HA NUAK1-wt DU2108 
NUAK1 HA-NUAK1 T211/A pcDNA5-FRT/TO-HA NUAK1 T211/A DU13419 
NUAK1 FLAG-NUAK1 pCMV-FLAG NUAK1 wt DU6359 
NUAK1 GST-HA-NUAK1 A195/V pEBG-2T-HA NUAK1 A195/V DU38090 
NUAK1 GST-HA-NUAK1 A195/D pEBG-2T-HA NUAK1 A195/D DU38091 
NUAK1 HA-NUAK1 D196/A pcDNA5-FRT/TO-HA NUAK1 D196/A DU13421 
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NUAK1 GST-HA-NUAK1 A195/K pEBG-2T-HA NUAK1 A195/K DU38092 
NUAK1 NUAK1 pBABE.puro NUAK1 DU38884 
NUAK1 GST-NUAK1-D196/A pEBG-2T-NUAK1-D196/A DU2111 
NUAK1 GFP-HA-NUAK1 wt pcDNA5-FRT/TO-GFP-HA NUAK1 wt DU13422 
NUAK1 HA-NUAK1-S476/480/481/AAA pcDNA5-FRT/TO-HA NUAK1 SSS/AAA DU38911 
NUAK1 HA-NUAK1 wt pCMV-HA NUAK1 wt DU2127 
NUAK1 GST-HA-NUAK-Q473/A pEBG-2T-HA NUAK Q473/A DU38169 
NUAK1 HA-NUAK1 S476/480/481A pcDNA5-FRT/TO-HA NUAK1 S476/480/481A DU41249 
NUAK1 GST-NUAK1 pCMV5 GST NUAK1 DU41891 
NUAK1 GST-HA-NUAK-R474/A pEBG-2T-HA NUAK R474/A DU38170 
NUAK1 HA-NUAK1 S476/480/481A pCMV5-HA NUAK1 S476/480/481A DU41280 
NUAK1 FLAG-NUAK1 D196A pCMV5 FLAG NUAK1 D196A DU44036 
NUAK1 GST-HA-NUAK-E475/A pEBG-2T-HA NUAK E475/A DU38171 
NUAK1 NUAK1 S476/480/481A pBabe.puro NUAK1 S476/480/481A DU41315 
NUAK1 HA-NUAK1-D196/A-dead pCMV-HA NUAK1-D196/A-dead DU2227 
NUAK1 FLAG-NUAK1 A195T pCMV5 FLAG NUAK1 A195T DU44028 
NUAK1 GST-HA-NUAK-S476/A pEBG-2T-HA NUAK S476/A DU38172 
NUAK1 HA-NUAK1 W305/A pCMV-HA NUAK1 W305/A DU13026 
NUAK1 GFP-NUAK1 S476/480/481A pBabe.puro-GFP NUAK1 S476/480/481A DU41316 
NUAK1 GST-HA-NUAK1 K348/R pEBG-HA NUAK1 K348/R DU13256 
NUAK1 HA NUAK1-2-425 I400/K pCMV-HA NUAK1-2-425 I400/K DU17326 
NUAK1 HA-NUAK1 A195T pCMV5 HA NUAK1 A195T DU44037 
NUAK1 HA-NUAK1 wt pBabe.puro-HA NUAK1 wt  DU30763 
NUAK2 GST-HA-NUAK2 pEBG-2T-HA NUAK2-wt DU2044 
NUAK2 HA-NUAK2-wt pCMV NUAK2 wt DU2152 
MARK1  HA-MARK1  pCMV5-HA MARK1  DU1265 
MARK1  GST-HA-MARK1  pEBG-2T-HA MARK1  DU1200 
MARK2  HA-MARK2  pCMV5-HA MARK2  DU1253 
MARK2  GST-HA-MARK2  pEBG-2T-HA MARK2  DU1133 
MARK3  HA-MARK3-wt  pCMV-HA MARK3-wt  DU2268 
MARK3  GST-HA-MARK3  pEBG-2T-HA MARK3  DU2058 
MARK4  HA MARK4-wt  pCMV5-HA MARK4-wt  DU2230 
MARK4  GST-MARK4-wt  pEBG MARK4 wt  DU2135 
BRSK1  HA-BRSK1  pCMV5-HA BRSK1  DU1236 
BRSK1  GST-HA-BRSK1  pEBG-2T-HA BRSK1  DU1175 
BRSK2  HA-BRSK2 wt  pCMV-HA BRSK2 wt  DU2175 
BRSK2  GST-BRSK2 wt   pEBG BRSK2 wt   DU2101 
SIK  HA-SIK-wt  pCMV-2HA SIK wt  DU6208 
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SIK  GST-HA-SIK  pEBG-2T-HA SIK  DU1081 
QIK  HA-QIK  pCMV5-HA  DU1079 
QIK  GST-HA-QIK  pEBG-2T-HA QIK  DU1078 
QSK  HA-QSK  pCMV5-HA QSK  DU1311 
QSK  GST-HA-QSK  pEBG-2T-HA QSK  DU1184 
MYPT1  FLAG-MYPT1   pCMV-FLAG MYPT1 ppp1r12a  DU17632 
MYPT1  GST-MYPT1  pEBG6-MYPT1 ppp1r12a  DU17631 
MYPT2  FLAG-MYPT2  pCMV-FLAG MYPT2  DU30286 
MYPT2  GST-MYPT2  pEBG6P-MYPT2  DU30285 
MBS85  FLAG MBS85  pCMV-FLAG MBS85 wt   DU17960 
MBS85  GST-MBS85 wt  pEBG6-MBS85 wt   DU17958 
MBS85  FLAG-MBS85 wt  pBabe.puro-FLAG MBS85 wt  DU34833 
MYPT3  GST-MYPT3  pEBG6-MYPT3   DU17841 
MYPT3  FLAG-MYPT3  pCMV-FLAG MYPT3   DU17799 
TIMAP  FLAG-TIMAP  pCMV-FLAG TIMAP   DU17798 
PLK1  GST PLK1  pEBG6p PLK1  DU15391 
Nek2a  GST Nek2a  pEBG6P-NEK2a  DU15294 
 
 
 
Table 2.4 : Bacterial expression constructs 
Protein Expressed Plasmid DU No. 
NUAK1  GST-NUAK1-wt  pGEX-6-NUAK1-wt  DU2104 
NUAK1  GST-NUAK1-D196/A-kinase dead  pGEX-6-NUAK1-D196/A-kin-dead  DU2107 
NUAK1  GST-HA-NUAK1 D196A S476/480/481A  pGEX-HA NUAK1 D196A SSS/AAA  DU41207 
MYPT1  GST-MYPT1  pGEX-6-MYPT1 ppp1r12a  DU17840 
MYPT1- PP1β  His-PP1 beta, GST-rat wt MYPT1  POPH-His-PP1β, GST-MYPT1  DU30200 
MYPT1- PP1β  His-PP1 beta, GST-rat wt MYPT1 S445/A+S472/A+S856/A  POPH-His-PP1β, GST-MYPT1 SSS/AAA  DU30200 
MYPT2  GST-MYPT2  pGEX-6-MYPT2 wt  DU30287 
MYPT2  GST-MYPT2-S447/A+S473/A+S525/A  pGEX-6-MYPT2-SSS/AAA  DU34400 
MYPT2- PP1β  His-PP1 beta, GST-MYPT2  POPH-His-PP1β, GST-MYPT2  DU34099 
MYPT2- PP1β  His-PP1 beta, GST-MYPT2 S447/A+S473/A+S525/A  POPH-His-PP1β, GST-MYPT1 SSS/AAA  DU34099 
MBS85  GST-MBS85 wt  pGEX-6-MBS85 wt  DU17959 
MBS85  GST-MBS85-S427/A+S452/A  pGEX-6-MBS85-S427/A+S452/A  DU34094 
MYPT3  GST-MYPT3  pGEX-6-MYPT3   DU17842 
TIMAP  GST-TIMAP  pGEX-6-TIMAP   DU17580 
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2.1.5 Buffers 
Lysis Buffer: 50 mM Tris/HCl pH 7.5, 1 mM EGTA, 1 mM EDTA, 1% (v/v) Triton X-100 
(or 0.3% w/v CHAPS), 1 mM sodium orthovanadate, 50 mM sodium fluoride, 5 mM sodium 
pyrophosphate, 0.27 M sucrose, 0.1% -mercaptoethanol, 1 mM benzamidine and 0.1 mM 
phenylmethanesulphonylfluoride (PMSF). Lysis buffer ensures immediate inhibition of 
protein kinases, phosphatases and proteases during lysis so that the phosphorylation state of 
proteins in the extracts are fixed at the levels present in vivo at the time of extraction. PMSF 
and benzamidine are serine protease inhibitors. EDTA chelates divalent cations including 
Mg
2+
 and thus inhibits metal dependent enzymes such as kinases and many phosphatases. 
EGTA is a chelator with high affinity towards Ca
2+
. Sodium fluoride and sodium 
pyrophosphate inhibit Ser/Thr protein phosphatases and sodium orthovanadate (Na3VO4) 
inhibits protein tyrosine phosphatases. Lysis buffer was stored at 4ºC. -mercaptoethanol and 
protease inhibitors were added fresh before each use.   
Phosphatase lysis Buffer: 50 mM Tris/HCl pH 7.5, 1 mM EGTA, 1 mM EDTA, 1% (v/v) 
Triton X-100, 0.27 M sucrose, 0.1% -mercaptoethanol, 1 mM benzamidine and 0.1 mM 
phenylmethanesulphonylfluoride (PMSF). 
GST bacterial lysis buffer : 50 mM Tris/HCl pH 7.5, 270 mM sucrose, 150 mM NaCl, 0.1 
mM EGTA, 1 mM benzamidine 0.2 mM PMSF and 0.1% -mercaptoethanol. 
GST bacterial elution buffer : 50 mM Tris/HCl pH 7.5, 270 mM sucrose, 150 mM NaCl, 
0.1 mM EGTA, 50 mM glutathione, 1 mM benzamidine 0.2 mM PMSF and 0.1% -
mercaptoethanol. After addition of glutathione re-pH buffer to 7.5. 
Phosphate buffered saline (PBS): 137mM NaCl, 2.7mM KCl, 8.1mM di-sodium hydrogen 
phosphate, 1.5mM potassium dihydrogen phosphate pH 7.4. 
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SDS Lysis Buffer (used for detection of MLC2): Lysis Buffer with 1% (w/v) SDS instead of 
Triton X-100 or CHAPS, and pH adjusted 6.8. SDS is a dentaurating anionic detergent.  
Buffer A: 50mM Tris-HCl pH 7.5, 0.1mM EGTA, and 0.1% -mercaptoethanol.  
TBST: 50 mM Tris-HCl pH 7.5, 0.15 M NaCl and 0.1% (v/v) Tween-20.  
5X SDS-PAGE Sample Buffer: 5% SDS, 5% (v/v) -mercaptoethanol, 250mM Tris-HCl 
pH 6.8, 32.5% (v/v) Glycerol, traces of BPB for adequate color intensity. 
SDS-PAGE Running Buffer: 25mM Tris-HCl pH 8.3, 192mM Glycine, 0.1% (w/v) SDS. 
Western Blotting Transfer Buffer: 48mM Tris-HCl, 39mM Glycine, 20% (v/v) Methanol. 
ECL Solution 1: 0.1M Tris-HCl pH 8.5, 2.5mM Luminol, 0.4mM p-Coumaric acid 
ECL Solution 2: 0.1M Tris-HCl pH 8.5, 5.6mM Hydrogen peroxide. 
TAE buffer: 40mM Tris-acetate pH 8, 1mM EDTA. 
 
2.1.6  Cell lines 
NUAK1
+/+
 and NUAK1
-/- 
mouse embryonic fibroblasts (MEFs) were kindly provided by Dr. 
Shinichi Aizawa (Kobe, Japan). β-TRCP1+/+ and β-TRCP1-/- MEFs were kindly provided by 
Dr. Keiko Nakayama (Sendai, Japan). TET21N neuroblastoma , P4936 B-cell lymphoma 
cells (both cell lines stably expressing doxycyclin inducible repressor of MYC) and 
immortalised mammalian epithelial IMECs (MYC overexpressing and vector control) cells 
were kindly provided by Dr.Victoria Cowling (MRCPPU, University of Dundee).  
 
2.1.7 Instruments  
Countess cell counter, X-Cell SureLock Mini-cell electrophoresis systems and X-Cell II Blot 
modules were from Invitrogen (Paisley, UK). AE6450 Atto Vertical Dual Mini Slab Kits 
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were from Genetic Research Instrumentation. Trans-Blot Cells, automatic western blot 
processors and gel dryer apparatus were from BioRad (Herts, UK). X-omat autoradiography 
cassettes with intensifying screens were from Kodak. Automatic film processor was from 
Konica Corporation. The Procise 494C Sequenator was from Applied Biosystems (Foster 
City, USA). HPLC system components were obtained from Dionex (Camberley, UK). The 
Vydac 218TP54 C18 reverse phase HPLC column was from Separations group. The LTQ-
orbitrap mass spectrometer and Nanodrop was from Thermo Scientific. The PCR 
thermocycler (PTC-200) was from MJ Research. The 96-well Versamax plate reader was 
from Molecular Devices (Wokingham, UK). Thermomixer IP shakers were purchased from 
Eppendorf (Cambridge, UK). Centrifuge tubes, rotors and centrifuges were from Beckmann. 
Biofuge pico microcentrifuge was from Haraeus Instruments (Osterode, Germany). pH 
meters and electrodes were from Horiba (Kyoto, Japan).  Scintillation counter (Tri-Carb 2800 
TR) was from Perkin-Elmer. Vibrax-VR platform shaker was from IKA. Balances were from 
Ohaus. Sonicators were from Sonics and Materials. Speed-vacs were from CHRIST. Gel 
Electrophoresis System (Horison 11-14) was from Life Technologies. Tissue culture class II 
safety cabinets were from Medical Air Technology (Oldham, UK). CO2 incubators were from 
Mackay and Lynn (Dundee, UK). The LiCOR odyssey infrared imaging system was from 
LiCOR biosciences (Cambridge, UK).  
 
2.1.8. Inhibitors   
Table 2.5 summarises the various small molecule inhibitors used in this thesis. Various 
protein kinase inhibitors, phosphatase inhibitors and NEDD8 enzyme inhibitor has been used. 
The inhibitors were either synthesized in house by Dr. Natalia Shpiro (DSTT, University of 
Dundee) or were purchased from commercial sources. 
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Table 2.5 : Details of the various small molecule inhibitors used in this work 
Compound Inhibits Structure 
Mol. wt 
(g/mol) 
Publication 
401 KuDOS DNA-PK 
 
281.31 
(Griffin et al., 
2005) 
AZD8055 mTOR 
 
465.5 
(Chresta et al., 
2010) 
BI 2536 PLK1 
 
521.65 
(Steegmaier et 
al., 2007) 
BIO GSK3/IKK 
 
356.2 
(Tseng et al., 
2006) 
BIRB-0796 p38 MAPK 
 
527.66 
(Regan et al., 
2002) 
BX-795 PDK1/TBK1/IKKε 
 
591.47 
(Feldman et al., 
2005, Clark et 
al., 2009) 
CCT250863 NEK2 
 
490.17 
(Innocenti et 
al., 2012) 
CHIR 99021 GSK3 
 
465.34 
(Ring et al., 
2003) 
D4476 CK1 
 
398.4 
(Rena et al., 
2004) 
ETP 46464 ATR 
 
470.52 
(Toledo et al., 
2011) 
GDC-0941 PI3K 
 
586.57 
(Folkes et al., 
2008) 
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H-1152 ROCK 
 
392.3 
(Sasaki et al., 
2002) 
KU 55933 ATM  
 
395.49 
(Hickson et al., 
2004) 
MK-2206 PKB 
 
480.39 (Li et al., 2009) 
MLN4924 NEDD8 enzymes 
 
479.98 
(Soucy et al., 
2009a) 
RO 3306 CDK1 
 
351.5 (Vassilev, 2006) 
VX-680 Aurora 
 
464.59 
(Harrington et 
al., 2004) 
Calyculin A PP1 & PP2 
 
1009.18 
(Ishihara et al., 
1989) 
Okadaic acid PP1 & PP2 
 
805 
(Ishihara et al., 
1989) 
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2.2 Methods 
 
2.2.1 Transformation and plasmid purification from E.coli 
Competent E.coli DH5α and BL21 DE3 cells were provided by Dr. Maria Deak or Dr. Mark 
Peggie  using a previously described method (Inoue et al., 1990). For each transformation, 
approximately 5-20ng DNA was added to 30µl of competent cells and incubated on ice for 
5min. Cells were then directly spread onto LB agar plates containing 100 µg/ml ampicillin 
and incubated at 37°C overnight. The transformed DH5α  E.coli colonies were transferred 
from the plate and  cultured in 200ml LB containing 200 µg/ml ampicillin at 30-37°C while 
shaking at 200rpm for 16-24 hours. Cells were pelleted by centrifugation at 6000g for 15min 
at 4
o
C. Plasmid DNA was purified using the Qiagen plasmid Maxi kit according to the 
manufacturer‟s instructions. DNA concentration was measured using NanoDrop as per 
manufacturer‟s instructions. 
 
2.2.2 Agarose gel electrophoresis 
1.7 g of agarose was boiled in 170 ml of 1X TAE buffer. 10 µl of 10 mg/ml ethidium 
bromide were added after the boiled agarose solution cooled down to approximately 50-60°C 
and then poured into a the gel casting tray. The gel was allowed to solidify and 
electrophoresis was carried out at 100V for 45min.  
 
2.2.3 Site-directed mutagenesis and DNA sequencing 
Site-directed mutagenesis was performed by Dr. Maria Deak or Mr. Thomas Macartney using 
QuikChange kit (Stratagene) and KOD polymerase (Novagen). Mutations were verified by 
DNA sequencing. The sequencing was performed by DNA sequencing service (School of 
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Life Sciences, University of Dundee) using DYEnamic ET terminator chemistry kit 
(Amersham Biosciences) on Applied Biosystems sequencers. 
 
2.2.4 Purification of recombinant bacterially expressed proteins 
Protein purification from bacteria were either done using the standard LB-IPTG method or by 
using auto-induction media (Studier, 2005). For standard LB-IPTG method, pGEX6P-
MYPT1, pGEX6P-MYPT2, pGEX6P-MLC2, pGEX6P-MBS85, pGEX6P-MYPT3 or 
pGEX6P-TIMAP constructs were transformed into E.coli BL21 DE3. 50 ml of LB containing 
100 μg/ml ampicillin was inoculated with a single colony of transformed cells and grown 
overnight at 37°C. 50 ml of this culture was used to inoculate 500 mL of the same medium. 
The cells were grown at 37°C in a shaking incubator (200 rpm) until OD600 of 0.6-0.7. The 
temperature was reduced to 16ºC and protein expression was induced by the addition of  
isopropyl β-D-1-thiogalactopyranoside (IPTG) to 250 μM final concentration. For the 
polycistronic pOPH-MYPT1-HIS-PP1β, pOPH-MYPT1-HIS-PP1β 
(Ser445Ala+Ser472Ala+Ser910Ala), pOPH-MYPT2-HIS-PP1β and  pOPH-MYPT2-HIS-
PP1β (Ser447Ala+Ser473Ala+Ser525Ala) vectors, 250 ml of LB containing 100 μg/ml 
ampicillin was inoculated with five  single colonies of transformed cells and grown overnight 
at 37°C. 250 ml of this culture was used to inoculate 2 L of autoinduction media containing 
200 µg/ml ampicillin and incubated at 16°C for 48-72 hrs. After the incubation in a shaking 
incubator (200 rpm), cultures were spun for 30 min at 6000g at 4°C. The pellet was 
resuspended in 25 ml of GST bacterial lysis buffer and was sonicated 4 times for 10 sec with 
10 sec breaks at maximum power with a 0.6 cm diameter sonication probe. During the 
sonication the lysate was maintained on ice. Subsequently, the lysate was clarified by 
centrifugation for 15 min at 26,000 g at 4°C. The clarified lysate was incubated with 0.5 ml 
of glutathione-Sepharose (equilibrated in GST bacterial lysis buffer) per 1 L of cultured cells 
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and the suspension was incubated for 2 h at 4°C with gentle agitation. The beads were 
washed three times with GST bacterial lysis buffer containing 0.5 M NaCl and twice in 
Buffer A. For elution of GST-fusion proteins, 25 mM (final concentration) of glutathione in 
GST bacterial lysis buffer pH 7.5 was added to the slurry of beads and incubated for 10 min 
at room temperature. Elution by enzymatic cleavage of the GST-tag from the protein was 
performed where appropriate using PreScission protease (purified at DSTT, University of 
Dundee). This protease cleaves the protein sequence LGVLFQGP between Q and G at the C-
terminal to the GST moiety of the protein expressed using the pGEX6P or pOPH vectors. The 
cleavage reaction was performed at 4°C overnight with 60 μg of GST-PreScission protease 
per 1ml of 1:1 slurry under gentle agitation. The PreScission protease has non-cleavable GST 
tag so it remained bound to the beads. The slurry was transferred on Spin-X column and spun 
for 1 min at 2,000 g. The flow through containing the eluted protein was collected, aliquoted 
and stored at -80ºC. 
 
2.2.5 Cell culture 
HEK293, HEK293T, HEK293 FLP/IN TREX, U2OS, U2OS FLP/IN, MCF7, MDA-MB-
231, MDA-MB-468, HCT116, TET21N, SHSY5Y and T47D cells were grown in Dulbecco‟s 
modified eagle medium (DMEM) supplemented with 10% (v/v) foetal bovine serum (FBS), 
2mM L-glutamine, antibiotic/antimycotic, 1X non-essential amino acids and 1mM sodium 
pyruvate. Immortalised mammalian epithelial cells (IMEC) were cultured in DMEM/F12 
50:50 media (Sigma) with 2mM L-glutamine, antibiotic/antimycotic, 5 mg/ml insulin, 10 
ng/ml EGF and 0.5 mg/ml hydrocortisone. Procedures were done under aseptic conditions 
meeting biological safety category 2 regulations. Cells were grown at 37°C in a 5% CO2 
water-saturated incubator. For the passaging, adherent cells were washed once with PBS and 
then incubated with Trypsin/EDTA for 3-5 min at room temperature or at 37°C. For 
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suspension cells, the cells were centrifuged at 1200g for 3 mins, supernatant was removed, 
resuspended in fresh media and seeded into fresh T75 flask at 1:4 dilution. 
 
2.2.6 Freeze/thawing of cell lines 
Cells in a T75 flask were trypsinised (for adherent culture) and centrifuged at 1000g for 5min 
at room temperature. The supernatant was aspirated and cells were resuspended in 4ml of 
FBS containing 10% DMSO. 1ml aliquots were stored in cryovials in a polystyrene rack at -
80°C or in liquid nitrogen for long-term storage. Cells were thawed in a water bath at 37C 
for 1min and placed into a T75 flask containing 20ml of media. 
 
2.2.7 Transient transfection of cells using polyethylenimine PEI 
Cells were transiently transfected using the polyethylenimine (PEI) method (Durocher et al., 
2002). PEI stock (1mg/ml) was prepared by dissolving it in 20mM Hepes (pH 7.4) and filter-
sterilizing using 0.22um filter. 1ml aliquots were stored at -20°C. Cells were seeded from one 
T75 flask into 6-8 10cm dishes or into 3-4 15cm dishes 16-24hrs prior to transfection. 
Transfection mix was prepared as follows: per plate, to 1ml of serum-free DMEM, 5-10 ug of 
plasmid DNA and 20ul 1mg/ml PEI was added and the mix was immediately vortexed. After 
incubation for 20min at room temperature, the transfection mix was delivered dropwise onto 
the cells. Cells were harvested after 48hrs of transfection.  
 
2.2.8 Stable transfections 
Cell lines with the stable inducible overexpression of  NUAK1wild-type and mutants were 
generated using Flp-In T-Rex System (Invitrogen) following manufacturer's instructions. 
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This system allows for either constitutive overexpression of the protein in U2OS FLP/IN 
cells or tetracycline-inducible expression of the protein of interest in HEK293 FLP/IN TREX 
cells using the pcDNA5/FRT/TO vector encoding the gene of interest.  
 
Retroviral vectors like pRetroSuperior or pBABE carrying the gene of interest were also used 
to transfect NUAK1
-/- 
mouse embryonic fibroblasts. 1 μg of retroviral pBABE-puro 
constructs encoding wild-type or mutants of NUAK1 were co-expressed with CMV-VSVG 
(0.3 μg) and CMV-Gag/Pol (1 μg) constructs in HEK-293T cells. The culture media 
containing retroviruses were collected 48 hrs post‐transfection and filtered through 0.22 μm 
filters directly onto the target cells. NUAK1
-/- 
MEFs, plated at ~70% confluency, were 
infected by transferring the filtered retroviruses directly onto the cells and 10 μg/ml 
polybrene a cationic polymer was added to aid infection. 24 h post‐infection, cells were 
cultured in the presence of 3 μg/ml puromycin for selection of infected cells.  
 
 
2.2.9 Generation of stable shRNA knockdown using lentiviral delivery 
The MISSION™ shRNA system (Sigma-Aldrich) was used to generate cell lines stable 
expressing shRNA against NUAK1 or MYPT1 or PLK1. To generate lentiviral particles, 
HEK293T cells grown on 10-cm dishes were transfected with a plasmid mix containing 3 µg 
of the shRNA-encoding plasmid pLK0.1, 3 µg of pCMV delta R8.2 (packaging plasmid) and 
3 µg of pCMV-VSV-G (envelope plasmid) using the PEI method. 48 hrs post-transfection, 
the virus-containing medium was collected and filtered through a 0.22-mm filter. Target cells 
were plated on a 6-well plate 24 h before the viral infection. Cells were then infected with 2 
ml per well of virus-containing medium supplemented with 10 µg/ml polybrene. 48 hrs post 
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infection the virus-containing medium was replaced with normal DMEM medium 
supplemented with 2-3 µg/ml puromycin. Selected cells were cultured in the presence of 2 
µg/ml puromycin or in normal DMEM media. 
2.2.10  Inhibitor treatment followed by cell detachment  
Inhibitors (final concentrations 10 μM)  were dissolved in DMSO and an equivalent volume 
of DMSO was used as a control. The final concentration of DMSO in the culture medium 
was never more than 0.1% (v/v). Following inhibitor treatment, to induce cell detachment, 
the culture media was aspirated and replaced with EDTA-PBS based cell dissociation buffer 
(GIBCO) supplemented with or without inhibitor and cells were incubated at 37°C in a 5% 
CO2 for 15 min. Detached cells were collected by gentle centrifugation for 3 min at 70 g at 
room temperature and lysed immediately. 
2.2.11 Cell lysis 
Cells were placed on ice, media was aspirated and lysed using 0.4ml of Lysis Buffer for 
10cm dishes or 1 ml for 15 cm dishes using plastic scrappers. Lysates were clarified by 
centrifugation at 16,000-18,000xg for 15min at 4°C and the supernatants were used for 
experiments. For SDS lysis, cells were rapidly lysed on ice and sonicated before resolving in 
SDS-PAGE. 
2.2.12 Protein concentration estimation using Bradford assay 
Bradford method was employed to estimate the protein concentration of lysates (Bradford, 
1976). The assay employs the fact that in an acidic medium Coomassie Brilliant Blue binds to 
proteins and shifts the absorption maxima from 465nm to 595nm. A standard curve was 
generated using BSA standards (1, 0.5, 0.25, 0.125, 0.06 mg/ml). 200 µl of Bradford reagent 
was used per sample and OD595 was measured using a 96-well plate reader. Samples were 
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read in triplicates and concentrations were estimated using the OD595 values from the 
standard curve. 
 
2.2.13 Purification of GST fusion proteins from HEK293 cells 
HEK293 cells were transfected GST-tagged constructs by PEI method and harvested 48hrs 
post-transfection Lysis Buffer. Clarified cell lysates were incubated for 1 hour on a rotating 
platform with glutathione-Sepharose 4B (20 μl beads/5 mg of cell lysate) previously 
equilibrated in PBS. The beads were washed three times with Lysis Buffer containing 0.5 M 
NaCl and two times with Buffer A. GST-tagged proteins were eluted from the resin with an 
equal volume of Buffer A supplemented with 150 mM NaCl, 0.27M sucrose and 40mM 
glutathione (pH 7.5-8) for 10min at room temperature on a rotating platform. The elution was 
repeated and all the elusions were pooled together, filtered through a 0.22um Spin-X column 
aliquoted, snap-frozen in liquid nitrogen and stored at -80°C. 
 
2.2.14 Non covalent coupling of antibodies 
Protein G Sepharose was washed twice in PBS and the antibody was added to the beads at a 
concentration of 1 μg antibody per 1 μl of protein G-Sepharose. The antibody-beads slurry 
was incubated on a shaking platform for at least 30 min at 4°C. The beads were then 
centrifuged and washed three times in PBS to remove any uncoupled antibody, resuspended 
in PBS with 0.02% (w/v) sodium azide and stored at 4ºC for up to one month. 
 
2.2.15 Covalent coupling of antibodies 
Antibodies were covalently coupled to protein G-Sepharose with a dimethyl pimelimidate 
(DMP) cross-linking procedure (Harlow and Lane, 1999). DMP is a homobifunctional cross-
linker that reacts with primary amine groups (Harlow and Lane, 1999). After the non-
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covalent coupling step in 2.2.14, the beads were washed 3 times with 0.1 M sodium borate 
pH 9 and then resuspended in 0.1 M sodium borate pH 9 containing 20 mM freshly added 
DMP and incubated for 30 min at room temperature with gentle mixing. The 0.1 M sodium 
borate with DMP step was repeated. The beads were then washed 4 times with 50 mM 
glycine pH 2.5 to remove all the antibodies that were non covalently coupled to the beads. 
The were further washed twice with 0.2 M Tris-HCl pH 8 to neutralise the pH and then 
incubated in this buffer for a further 2 h at room temp with gentle mixing to ensure that any 
residual DMP was quenched by reaction with the amine group of Tris. The antibody-coupled 
beads were stored in PBS containing 0.02% (w/v) sodium azide at 4ºC for up to one month. 
 
2.2.16 Immunoprecipitation 
For endogenous protein immunoprecipitation, 1 mg of cell lysate was incubated with 5 μg of 
antibody coupled to 5 μl of protein G-Sepharose for 2-16 hrs at 4°C on a rotating wheel. For 
overexpressed protein immunoprecipitation, depending on the tag of the protein, 5 μl of  
FLAG-agarose or HA-agarose or GST-sepharose beads was incubated with 200 μg of cell 
lysate for 2-4 hrs at 4°C on a rotating wheel. The mixture was centrifuged for 1 min at 8,000 
g and the supernatant was removed. The immunoprecipitates were washed twice with 0.5 ml 
of Lysis Buffer containing 0.15 M NaCl and twice with 0.5 ml of Buffer A. Then either they 
were used for further assays or 1xLDS buffer was added and subjected to SDS-PAGE. 
 
2.2.17 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE allows the resolution of proteins based on their electrophoretic mobility which is 
a function of their molecular weight. The anionic detergent, sodium dodecyl sulphate (SDS) 
or lithium dodecyl sulphate (LDS) binds to protein in a constant ratio of about one SDS/LDS 
molecule per 2 amino acids, thus providing a net negative charge which is proportional to the 
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mass of that protein. Mobilities of these proteins along the matrix become a linear function of 
the logarithms of their molecular weights. Resolving gel consisted of  375 mM Tris-HCl pH 
8.6, 0.1% SDS and 8-15% acrylamide. N,N,N',N'-tetramethylethylenediamine (TEMED) and 
ammonium persulphate (APS) were added to initiate polymerisation. The gels were allowed 
to polymerise for 30-60 min under a layer of isopropanol. Stacking gel contained 125 mM 
Tris-HCl pH 6.8, 0.1% SDS, 4% acrylamide, TEMED and APS. Purified proteins, cell lysates 
or immunoprecipitates were resuspended in 1x SDS Sample Buffer containing 1% β-
mercaptoethanol and boiled at 90ºC for 5 min. 10-20 μl sample was loaded into each well and 
electrophoresis was performed in 1x SDS electrophoresis buffer at 90 V for 15 min and then 
at 180 V for the next 60 min. 
 
2.2.18 Commassie staining of gel 
Gels were stained in Instant-Blue (Expedeon, UK) for 15min and then destained in milliQ 
water until the band staining to background contrast was satisfactory.  
 
2.2.19 Gel drying and autoradiography 
Post 2.2.18, gels were incubated in 5% glycerol for 10min and sandwiched between two 
sheets of pre-wet cellophane avoiding air-bubbles. The gel was then dried in a GelAir Dryer 
for 1.5hrs. Dried gels were exposed to Hyperfilm MP for 1-24hrs in an X-Omat 
autoradiography cassette. The cassette was stored in -80°C freezer to improve the signal. 
Films were developed using a Konica auto-developer.  
 
2.2.20 Transfer of proteins onto nitrocellulose membrane and immunoblotting 
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After the completion of SDS-PAGE, gels were sandwiched between pre-wet (in Western 
Blotting Transfer Buffer) nylon sponge pads, Whatman 3mm filter papers and nitrocellulose 
membrane. The sandwich was loaded into BioRad Trans-Blot Cell transfer tanks and transfer 
was carried out at 90V for 1.5hrs or at 0.75A for 1hr. After transfer, non-specific binding of 
antibodies on the nitrocellulose membranes was prevented by “blocking” the membranes 
with 5% (w/v) skimmed milk in TBST for 15-30 mins at room temperature. Primary 
antibodies were then diluted to working concentrations in either milk or BSA-TBST solutions 
and incubated with the membrane at either room temperature for 1 hr (for most HRP 
conjugated antibodies) or for 4°C overnight. Primary antibodies were collected and frozen at 
-20
o
C for future reuse. Membranes were then processed using the BioRad western processor. 
The processor program was set to three times wash with TBST followed by 1 hr HRP-
conjugated secondary antibody incubation and finally a further four times wash with TBST. 
Membranes were incubated with the enhanced chemiluminescence (ECL) substrate and 
exposed to X-ray films. Films were developed using a Konica automatic developer.  
  
2.2.21 Kinase assay 
2.2.21.1 In vitro kinase assays employing a peptide substrate 
In vitro NUAK1 wild-type and mutants' activities were measured using Cerenkov 
counting of incorporation of radioactive 
32P from [γ32P]-labelled ATP into 
Sakamototide substrate peptide [ALNRTSSDSALHRRR]. A typical 50 µl kinase 
reaction consisted of 10mM magnesium acetate, 0.1mM [γ32P] ATP (450-500 
cpm/pmol), 0.1% β-mercaptoethanol, 200 µM of Sakamototide. Control reactions 
contained either no kinase or IPs with GFP control antibody. Reactions were 
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incubated at 30°C for 30min and were eventually terminated by pipetting 40 μl onto a 
2 square cm of P81 paper (which binds substrates that contain a net basic charge at 
acidic pH) which was dropped to a beaker containing 50 mM orthophosphoric acid. 
Papers were washed four times in 50mM orthophosphoric acid to remove any 
unbound radioactivity. Papers were then washed in acetone for 3min and air dried. 
Papers were folded and transferred to 1.5ml tubes and Cerenkov counting was done 
on a liquid scintillation counter. Kinase activity was expressed as specific activity 
(units of activity per mg of protein or lysate used for IP of the protein). One unit of 
activity was the amount of kinase which was needed to incorporate 1 µmol of 
phosphate per 1 µmol of substrate peptide per minute. 
 
2.2.21.2 In vitro kinase inhibitor biochemical IC50 determination 
IC50 value of an inhibitor is defined as the concentration of inhibitor required for 50% 
inhibition of enzyme activity. To determine the  IC50 values of NUAK inhibitors, 
active GST-NUAK1, GST-NUAK1[A195T] and GST-NUAK2 enzymes were 
purified from HEK293 cell as described in 2.2.13. 96 well plates were used to carry 
out peptide kinase assays, each reaction performed in triplicate. Each reaction was set 
up in a total volume of 50 µL containing 100 ng NUAK1(wild-type or A195T mutant) 
or NUAK2 in 50 mM Tris/HCl, pH 7.5, 0.1 mM EGTA, 10 mM magnesium acetate, 
200 µM Sakamototide, 0.1 µM [γ-32P]ATP (450-500 cpm/pmol) and various 
concentrations of inhibitors (from 0.1 nM to 100 µM) dissolved in DMSO. After 
incubation for 30 min at 30 °C, reactions were terminated by adding 25 mM (final) 
EDTA to chelate the magnesium. 40 µl of the reaction mix was spotted onto P81  
paper and immersed in 50 mM orthophosphoric acid. Samples were washed three 
times in 50 mM orthophosphoric acid, then a single acetone rinse followed by air 
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drying. The kinase mediated incorporation of [γ-32P]ATP into Sakamototide was 
quantified by Cerenkov counting. The values were expressed as % of the DMSO 
control. IC50 curves were developed and IC50 values were calculated using GraphPad 
Prism software using non-linear regression analysis. IC50 determination for Aurora 
kinases were carried out at The International Centre for Protein Kinase Proﬁling 
(http://www.kinase-screen.mrc.ac.uk/) using 300 µM substrate peptide 
[LRRLSLGLRRLSLGLRRLSLGLRRLSLG]. 
 
2.2.21.3 In vitro kinase assays employing a protein substrate 
The quantification of the protein substrate phosphorylation was achieved by 
measuring the incorporation of radioactive 
32
P phosphate from [γ-32P]ATP into a 
protein substrate. The kinases used were HIS-NUAK1 and HIS-ROCK2 (both kinases 
were purified from insect cells as described previously (Biondi et al., 2002) in the 
DSTT, University of Dundee). For each reaction, HIS-NUAK1 was used at 100-200 
ng and HIS-ROCK2 was used at 0.5-1 µg. The substrates were used at a 5 µg per 
reaction. Assays were set up in a total volume of 25 μl of  Buffer A containing the 
protein kinase, protein substrate, 10 mM magnesium acetate and 0.1 mM [γ-32P]ATP 
(450-500 cpm/pmol). Reactions were performed at 30ºC in a Thermomixer at 1000 
rpm for indicated times, and terminated by the addition of SDS/LDS Sample Buffer. 
The incorporation of the phosphate into proteins was determined following SDS-
PAGE (see 2.2.17), Coomassie staining (see 2.2.18), destaining and autoradiography 
of the dried gels (see 2.2.19). If required, the proteins bands of interest were then 
excised, transferred to microcentrifuge tubes and 
32
P incorporation was quantified by 
Cerenkov counting in a scintillation counter. One unit of protein kinase activity is the 
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amount of enzyme that catalyses the incorporation of 1 nmole phosphate into the 
substrate in 1 min. 
 
 
 
2.2.22 Phosphatase assay 
The phosphatase activity of MYPT1-HIS-PP1β (wild-type and mutant) and MYPT2-HIS-
PP1β (wild-type and mutant) were carried out using radiolabelled myosin light chain 2 
(MLC2) as substrate. 
 
2.2.22.1 Preparation of radiolabelled MLC2 substrate 
GST-MLC2 was purified from E.coli BL21 DE3 cells as mentioned in section 2.2.4. 
Since myosin phosphatases dephosphorylate MLC2 at Thr 18 and Ser19 sites, active 
HIS-ROCK2 was employed to label the Ser19 site of MLC2 (Totsukawa et al., 2000). 
2 mg of purified GST-MLC2 was incubated with 20 µg of active ROCK2 for 3 hrs at 
30ºC in the presence of 10 mM magnesium acetate and 0.1 mM [γ-32P]ATP (450-500 
cpm/pmol). Glutathione sepharose was added to the reaction mix to re-purify GST-
MLC2 and incubated for 30 min at 4 °C. The slurry was loaded onto a column and 
extensively washed with Buffer A till any unbound residual [γ-32P]ATP was washed 
away from the slurry. The 
32
P-labeled GST-MLC2 was eluted using GST elution 
buffer. 
 
2.2.22.2 Phosphatase assay using MYPT-PP1β complexes 
2 µg of each of the recombinant MYPT-PP1β complexes (wild-type and triple serine 
mutants as in section 2.2.4) was phosphorylated with or without 0.1 µg of active HIS-
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NUAK1 for 30 mins at 30ºC in the presence of 3 µg recombinant 14-3-3ε, 10 mM 
magnesium acetate and 0.1 mM (cold) ATP. Samples were diluted 100 to 500 times in 
buffer A containing 1 mM MnCl2 and 3 mg/ml BSA. 10 µl of the diluted reaction mix 
was incubated at 30ºC for 10 min with the previously purified 
32
P-labeled GST-MLC2 
(10 µM final in 30 µl reaction volume). Reactions were stopped by the precipitation 
of proteins with 100 µl of 20% trichloroacetic acid. Samples were vortexed briefly, 
and the precipitate was pelleted by centrifugation 14,000g for 10 mins. 
32
P 
radioactivity in the supernatants and pellets was measured by Cerenkov counting, and 
the release of phosphate to the supernatant was calculated. 
 
2.2.23 Mass spectrometry 
 
2.2.23.1 Processing of samples for mass spectrometric analysis 
 
Mass spectrometry samples were processed and handled under a laminar flow hood to 
minimise keratin contaminations. Samples were prepared in 1xLDS Sample Buffer, 
reduced by boiling with 1x NuPAGE sample reducing agent, boiled, alkylated with 50 
mM iodoacetamide (incubated in dark for 30mins at room temperature) and subjected 
to electrophoresis on a NuPAGE Bis-Tris 4-12% gel. Gels were stained and destained 
using Instant Blue. Gel pieces were cut into small cubes of about 1 mm and 
sequentially washed on a Vibrax shaking platform with 50% acetonitrile/water, 0.1 M 
NH4HCO3 and 50% acenotrile/50 mM NH4HCO3. All washes were performed for 10 
min using 0.5 ml per gel band and all liquids were removed between washes. Once 
colourless, the gel pieces were shrunk with 0.3 ml acetonitrile for 15 min, aspirated 
and gel pieces were dried in a Speed-Vac. Gel pieces were next swollen in 5 μg/ml 
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AspN or 25mM Triethylammonium bicarbonate with 5 µg/ml of Trypsin and 
incubated overnight at 30ºC on shaker. After incubation, an equivalent volume of 
acetonitrile was added to the digest and incubated for a further 15 min. The 
supernatants were transferred to a clean tube and samples were dried in a SpeedVac. 
To further extract the peptides, 100ul of 50% acetonitrile / 2.5% formic acid were 
added to the gel pieces and incubated for 15min at room temperature on a shaking 
platform. The supernatant was combined with the first dried peptide extract and dried 
using Speed-Vac. The samples were submitted for mass spectrometry immediately or 
stored at -20ºC. 
LC-MS was performed by Dr. D. Campbell, Mr. R. Gourlay and Mr. J. Varghese. 
Tryptic peptides were subjected to LC-MS/MS on a Dionex3000 Nano liquid 
chromatography system coupled with an LTQ-Orbitrap mass spectrometer (for 
peptide mass fingerprinting) or 4000 QTrap (to identify phosphorylation sites). 
Extracted Ion Chromatograms (XIC) were obtained manually using the ABSciex 
Analyst software (Applied Biosystems). Results were searched against the SwissProt 
or IPI human or mouse databases using the Mascot Daemon 
(www.matrixscience.com). Peptide mass fingerprinting data analysis was performed 
using OLMAT (http://www.proteinguru.com/MassSpec/OLMAT). 
 
2.2.23.2  Mapping of phosphosites using HPLC and Edman degradation 
 
Substrate (5 µg) purified from E. coli was incubated with active kinase, for 30 min at 
30°C in Buffer A containing 10 mM magnesium acetate and 0.1 mM [γ-32P]ATP 
(11,000-25,000 cpm/pmol) in a total reaction volume of 25 µl. The reaction was 
terminated by addition of LDS sample buffer with 1x NuPAGE sample reducing 
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agent, boiled, alkylated (as in section 2.2.23.1) and samples were subjected to 
electrophoresis, stained, bands were excised and processed for mass spectrometry as 
in 2.2.23.1. Following digestion, >95% of the 
32
P radioactivity incorporated in the gel 
bands was recovered and samples were then subjected to HPLC on a Vydac C18 
column equilibrated in 0.1% (w/v) trifluoroacetic acid (TFA), with a linear 
acetonitrile gradient at a flow rate of 0.2 ml/minute. Fractions of 0.1 ml were 
collected and phosphopeptides were analysed by LC-MS/MS. The  resultant data files 
were searched using Mascot (www.matrixscience.com) run on an in-house system 
allowing for Phospho (S/T), Phospho (Y), Oxidation (M) and Dioxidation (M) as 
variable modifications. Individual MS/MS spectra were inspected using Xcalibur 2.2 
software. The site of phosphorylation of all the 
32
P labelled peptides was determined 
by solid-phase Edman degradation on an Applied Biosystems 494C sequencer of the 
peptide coupled to Sequelon-AA membrane (Applied Biosystems) as described 
previously(Campbell and Morrice, 2002). HPLC, LC-MS and Edman degradation was 
performed by Mr. Robert Gourlay. 
 
 
2.2.24 Immunofluorescence 
Cells were grown on glass coverslips, washed twice with PBS, fixed in 4% paraformaldehyde 
in PBS at room temperature for 15min, rinsed twice with PBS and permeabilized with 1% 
NP-40 in PBS for 5-10min. Cells were then “blocked” by incubation with 1% donkey serum 
in PBS for 20-30min at room temperature. The primary antibodies were diluted to as par user 
guidelines in 1% BSA in PBS and incubated at either 1 hr at 37
o
C. Cells were washed thrice 
with 1% BSA in PBS for 10min at room temperature. Secondary antibodies (raised in 
donkey) were diluted to 1:500 in 1% BSA in PBS and incubated at room temperature for 1hr. 
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Cells were washed thrice with 1% BSA in PBS for 10min at room temperature. The slides 
were rinsed in distilled water, the excess water was drained on a tissue paper and the slides 
were immediately mounted using ProLong Gold. Slides were allowed to dry for 2-3hrs. 
 
2.2.25 Cell cycle synchronisation 
For G1-arrest, cells at ~50% confluency were treated with 2.5mM of thymidine for 16hrs, 
followed by 3x rinse with PBS, fresh media was added and cells were released for 12hrs, 
followed by a second thymidine block for 16hrs and final 3x PBS rinse and release after 
which cells were harvested for western blotting and flow cytometry analysis every 2hrs. For 
G2/M arrest, the above procedure was performed and cells were released into 10 µM RO-
3306 for 20hrs, after which cells were rinsed 4x with PBS, fresh media was added and 
harvested every 2 hrs.  
 
 
2.2.26  Flow cytometry 
 
2.2.26.1 Flow cytometric analysis for cell cycle distribution 
Cells were trypsinized and the trypsin was quenched using the old medium the cells 
were present, in order to account for floating dead cells. Cells were then washed once 
with room temperature PBS (spin: 350xg, 5min) and fixed in 1ml of ice-cold 70% 
ethanol. After washing twice with PBS, cells were rinsed with 1% FBS in PBS and 
DNA staining was done using FACS Staining Solution (50 µg/ml propidium iodide, 
50 µg/ml RNAse A in 1% FBS in PBS) for 20min in the dark. Cells were analyzed by 
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Ms Arlene Whigham using FACS Canto (BD Biosciences) or FACS Verse (BD 
Biosciences). 
 
2.2.26.2 Flow cytometric analysis for active Caspase 3 apoptotic cells 
Cells were trypsinized and the trypsin was quenched using the old medium the cells 
were present, in order to account for floating dead cells. Cells were then washed once 
with room temperature PBS with 1% FBS (spin: 350xg, 5min) and fixed in 0.5ml 1% 
(w/v) PFA. The cells were incubated at 37°C for 15min and subsequently washed 
once in PBS-FBS. Cells were then further fixed in 1ml of ice-cold 70% ethanol. After 
washing once with 1% FBS in PBS, 20l FITC-Caspase 3 antibody stock solution 
was added to 100l PBS-FBS per sample and add to pelleted cells. The cells were 
incubated in the dark at room temperature for 30mins. Cells were washed once in 
PBS-FBS and then 300l PBS-FBS was added containing 10 µg/ml DAPI. Active 
Caspase 3 in the cells was analysed by Dr. Rosemary Clarke using FACS Verse (BD 
Biosciences). 
 
2.2.27 Wound healing assays 
U2OS or MEF cells were split and approximately equal number of cells were loaded into the 
left and right chambers of the IBIDI Self-insertion inserts (IBIDI 80209). Each insert was 
placed in one well of a 12 well plate and the cells were seeded with or without the treatment 
of the inhibitors.  For the comparison between the NUAK1
+/+
 and NUAK1
-/- 
MEFs, a single 
insert was used and the NUAK1
-/-
 cells were loaded on the right and NUAK1
+/+
 cells on the 
left chamber of the insert. For proper quantification of migration, wound-healing assay on 
NUAK1
+/+
 and NUAK1
-/- 
MEFs were also carried out on separate inserts to avoid any 
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chemotactic stimulation between two different cell lines. The experiments were done in 
triplicates. After overnight incubation at 37 °C and 5% CO2, the insert was removed and the 
migration of cells into the 500 µm gap between the chambers were observed. The wound-gap 
healing properties of the cells were observed over a period of 20 hours under a Nikon Eclipse 
Ti microscope with photography taken every 2 mins by a Photometrics cascade II CCD 
camera. The first 225 frames of the sequence were imported into Volocity software (Perkin 
Elmer). This software was used to generate the quantitative kymograph with time as the 
horizontal parameter and 1 pixel was collected per time point along a line from the edge of 
the field to the centre of the wound. To compare between videos, the length of the line was 
kept constant. 
 
2.2.28 MTS cell proliferation assay 
Cell proliferation assays were carried out colorimetrically in 96 well plates using the 
CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay kit (Promega) following the 
manufacturer's instructions. The solution consists of MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium, inner salt) and an electron 
coupling reagent PMS (phenazine methosulphate). The dehydrogenase enzymes in 
metabolically active cells reduce MTS reagent into a coloured formazan product that is 
soluble in the cell culture media. The absorbance of the formazan can be measured at OD490 
and is directly proportional to the number of live cells in culture. 
 
2.2.29 Cell Invasion assay 
The ability of cells to invade with or without the presence of inhibitors was tested in a 
growth-factor-reduced Matrigel™ invasion chambers according to manufacturer‟s  
instructions and as previously described (Sommer et al., 2013). The cells were serum-
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deprived for 2 hours with or without the presence of 10 µM inhibitor, detached with cell 
dissociation buffer and 5 x 10
5
 cells suspended in DMEM containing  1% (w/v) BSA were 
added to the upper chambers in triplicates and chemoattractant  (DMEM containing 10% 
(v/v) FBS) to the lower wells. The chambers were kept  at 37°C in 5% CO2 for 18 hours. 
Cells that did not invade were removed from the  upper face of the filters and cells that had 
migrated to the lower face of the filters were fixed and stained with Reastain Quick-Diff kit 
(Reagena) according to manufacturer's instructions and images (×10) were captured.  
 
2.2.30 Kinase inhibitor specificity  profiling on a panel of 120-140 protein kinases 
Kinase inhibitor specificity profiling assays were carried out at The International Centre for 
Protein Kinase Proﬁling (http://www.kinase-screen.mrc.ac.uk/) against the panel of 140 
protein kinases as described previously (Bain et al., 2007, Najafov et al., 2011). Results were 
presented as a percentage of kinase activity in DMSO control reactions. Protein kinases were 
assayed in vitro with 1 μM of the inhibitors and the results were presented as an average of 
triplicate reactions ± S.D or in the form of comparative bar charts. Kinase abbreviations are 
as follows: ABL, Abelson tyrosine-protein kinase 1; AMPK, AMP-activated protein kinase; 
ASK, apoptosis signal-regulating kinase; BRK, breast tumor kinase; BRSK, brain-specific 
kinase; BTK, Bruton's tyrosine kinase; CaMK, calmodulin-dependent kinase; CaMKK, 
CaMK kinase; CDK, cyclin-dependent kinase; CHK, checkpoint kinase; CK, casein kinase; 
CLK, CDC-like kinase; CSK, C-terminal Src kinase; DAPK, death-associated protein kinase; 
DDR, discoidin domain receptor; DYRK, dual-specificity tyrosine-phosphorylated and 
regulated kinase; EF2K, elongation-factor-2 kinase; EIF2AK, eukaryotic translation initiation 
factor 2-alpha kinase; EPH, ephrin; ERK, extracellular signal-regulated kinase; FGF-R, 
fibroblast growth factor receptor; GCK, germinal centre kinase; GSK, glycogen synthase 
kinase; HER,  human epidermal growth factor receptor; HIPK, homeodomain-interacting 
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protein kinase; IGF1R, IGF1 receptor; IKK, inhibitory κB kinase; IR, insulin receptor; IRAK, 
Interleukin-1 Receptor-Associated Kinase; IRR, insulin-related receptor; JAK, Janus kinase; 
JNK, c-Jun N-terminal kinase; Lck, lymphocyte cell-specific protein tyrosine kinase; LKB1, 
liver kinase B1; MAPK, Mitogen-activated protein kinase; MAPKAP-K, MAPK-activated 
protein kinase; MARK, microtubule-affinity-regulating kinase; MEKK, MAP kinase kinase 
kinase; MELK, maternal embryonic leucine-zipper kinase; MINK, Misshapen/NIK-
related kinase; MKK, MAPK kinase; MLK, mixed lineage kinase; MNK, MAPK-integrating 
protein kinase; MPSK, myristoylated and palmitoylated serine/threonine-protein kinase; 
MSK, mitogen- and stress-activated protein kinase; MST, mammalian homologue Ste20-like 
kinase; NEK, NIMA (never in mitosis in Aspergillus nidulans)-related kinase; NUAK, novel 
(NUA) family SnF1-like Kinase; OSR, oxidative stress-responsive kinase; PAK, p21-
activated protein kinase; PDGFRA, platelet-derived growth factor receptor-α; PDK, 
Phosphoinositide-dependent kinase; PHK, phosphorylase kinase; PIM, provirus integration 
site for Moloney murine leukaemia virus; PINK, PTEN-induced kinase; PKA, cAMP 
dependent protein kinase; PKB, Protein kinase B; PKC, Protein kinase C; PKD, protein 
kinase D; PLK, polo-like kinase; PRAK, p38-regulated activated kinase; PRK, protein kinase 
C-related kinase; RIPK, receptor-interacting protein kinase; ROCK, Rho-dependent protein 
kinase; RSK, Ribosomal S6 kinase; S6K, p70 ribosomal S6 kinase; SGK, serum- and 
glucocorticoid-induced protein kinase; SIK, salt-induced kinase; smMLCK, smooth muscle 
myosin light-chain kinase; SRPK, serine arginine protein kinase; STK, serine/theronine 
kinase; SYK, spleen tyrosine kinase; TAK, TGFβ activated kinase; TAO, thousand and one 
amino acid; TBK1, TANK-binding kinase 1; TESK,  testis-specific protein kinase; TGFBR, 
 TGFβ receptor; TIE, tyrosine-protein kinase receptor; TLK,  tousled-like kinase; TrkA, 
tropomyocin receptor kinase; TSSK, testis-specific serine/threonine-protein kinase; TTBK, 
tau-tubulin kinase; ULK, Unc-51-like kinase; VEGFR, vascular endothelial growth factor 
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receptor; WNK, with no lysine; YES1, Yamaguchi sarcoma viral oncogene homologue 1; 
ZAP, zeta-chain-associated protein. 
 
2.2.31 Sequence alignments 
Sequence alignments were done using the ClustalW algorithm for multiple sequence 
alignment and visualised using JalView (Waterhouse et al., 2009). 
 
2.2.32 Statistical analysis 
All experiments presented in this thesis were performed at least twice and similar results were 
obtained. Data were analyzed using Student‟s t test or one-way analysis of variance 
(ANOVA) followed by multiple pairwise comparisons (*P < 0.01). Error bars indicate 
standard deviation.  IC50 curves were generated using non-linear regression (curve fit) and 
statistical analysis was calculated using GraphPad Prism or Microsoft Excel. 
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3. Characterisation of novel and highly selective inhibitors of 
NUAKs 
 
3.1. Introduction 
 
AMPK family members possess highly similar substrate specificities and it is likely that in 
biochemical and overexpression-analysis, AMPK family kinases are likely to phosphorylate 
non-physiological substrates. Myosin phosphatase 1 subunit or MYPT1 possess three 
canonical AMPK consensus phosphorylation motifs which are specifically targeted by 
NUAKs alone (Zagorska et al., 2010), but in vitro kinase reactions and overexpression 
studies revealed that AMPK and all the AMPK related family of kinases could phosphorylate 
MYPT1 at those motifs and provide false-positive results. Hence, to avoid having to rely on 
overexpression of AMPK family members would be to develop selective inhibitors to each of 
the AMPK family kinases. This was originally deemed a challenging task due to the highly 
homologous kinase domains of these enzymes (Alessi et al., 2006) (Fig. 1.7).  
 
To date, the pan-AMPK related kinase family inhibitor BX-795 is the only reported 
compound used as a tool inhibitor for NUAK isoforms (Zagorska et al., 2010, Liu et al., 
2012).  
 
In 2011, our lab in collaboration with Dr. Nathanael Gray (Harvard, USA) published the 7-
membered ring structured inhibitor of LRRK2, a kinase mutated in Parkinson‟s disease, 
LRRK2-in-1 (Deng et al., 2011).  Dr. Nathanael Gray observed that some of the compounds 
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with the 7-membered ring backbone had significant off-target effects on NUAK1. Based on 
this observation, Dr. Nathanael Gray's laboratory developed various prototypes of potential 
NUAK inhibitors and the compounds were screened for kinase inhibitor specificity at The 
International Centre for Protein Kinase Proﬁling (http://www.kinase-screen.mrc.ac.uk/) as 
described in section 2.2.30. Out of all the NUAK1 inhibitor prototypes, the ones deemed 
relatively selective for NUAK1 were carried forward for further cell based and biochemical 
assays. 
 
 
There were in total three families of NUAK1 inhibitors based on their structural similarities: 
 
1. The 7-membered ring series: JWE-071, XMD-17-51, DLW-01-122-01, DLW-01-
125-01, XMD-18-42, XMD-18-83 and HTH-01-015 (Fig 3.1) were chosen for cell 
based and biochemical assays. 
 
2. The  2,4,5-trisubstituted pyrimidines: These inhibitors had the same structural 
backbone as BX-795 and TG101348. Amidst the compounds, SJB4115, HMSL10085, 
WZ4002 and WZ4003 (Fig 3.1) were chosen for further assays. 
 
3. The imidizolopyrimidines, loosely based on the structures of sunitinib and its 
derivaties. WZ4074 is the only compound used in this series for this thesis. 
 
 
 
 
 
 
86 
 
 
To study the potency of the NUAK inhibitors in vitro, IC50 values of the inhibitors were 
analysed either on purified NUAK1 alone or on potential drug resistant mutants of NUAK1 
in parallel and on some occasions on purified NUAK2 in parallel to NUAK1 (Section 
2.2.21.2). The inhibitors were sent through the kinase panel at the International Centre for 
Protein Kinase Profiling (http://www.kinase-screen.mrc.ac.uk/) (Section 2.2.30) to ascertain 
the specificity of the inhibitors and to identify off-target effects on other kinases. Finally, to 
identify the potency of the compounds towards inhibiting endogenous NUAK activity in 
cells, various concentrations of the inhibitors were utilised on HEK293 or U2OS or MEFs to 
check the inhibition of cell-detachment induced (EDTA buffer treated) (Section 2.2.10) 
phosphorylation of Ser445 of MYPT1 which has been extensively characterised as a bonafide 
NUAK phosphorylation site in vivo (Zagorska et al., 2010). 
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Figure 3.1 :  Pedigree chart showing the gradual development of NUAK1 inhibitors from generic structures to the following generations 
of more potent and selective tool compounds. 
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3.2. Results 
3.2.1. BX-795 is the only reported potent tool inhibitor of NUAK1 to date 
BX-795 is a pyrimidine backbone (Fig.3.2A) containing small molecule initially developed 
as a potent PDK1 inhibitor (Feldman et al., 2005). Later on, it was extensively used in the 
innate immune signalling system as a very potent TBK1 and IKKε inhibitor which inhibited 
the production of interferon β in poly (I:C) or lipopolysaccharide stimulated macrophages 
(Clark et al., 2009). Specificity studies on BX-795 revealed that the tool compound potently 
inhibited AMPK and many of the AMPK-related kinases at 1 µM including NUAK1, MARK 
isoforms and SIK isoforms (Clark et al., 2009, Clark et al., 2012). The standard IC50 values 
previously calculated for various kinases with BX-795 are listed in Table 3.1. 
 
Kinase IC50 value ATP conc (µM) 
NUAK1 5 nM 100 
MARK1 55 nM 100 
MARK2 53 nM 100 
MARK3 81 nM 100 
MARK4 19 nM 100 
PDK1 111 nM 100 
Aurora B 31 nM 100 
ERK8 140 nM 100 
TBK1 6 nM 100 
IKKε 41 nM 100 
MLK isoforms ≤50 nM 100 
VEGFR 157 nM 100 
 
Table 3.1 : IC50 values for the inhibition of a few protein kinases by BX-795. (Clark et 
al., 2009) 
 
BX-795 has been used extensively to identify MYPT1 as a novel and bonafide substrate of 
NUAK wherein treatment of BX-795 on cells could mimic the effects and phenotypes of the 
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NUAK1 deficient MEFs including loss of phosphorylation of Ser445 of MYPT1 upon 
induction of cell detachment (Zagorska et al., 2010). More recently, BX-795 was used to 
consolidate the RNAi data which suggested that NUAK1 plays a vital antiapoptotic role in 
deregulated oncogenic MYC expressing tumour cells and is an essential factor for tumour 
progression  (Liu et al., 2012). I repeated the IC50 for BX-795 (Fig. 3.2 B) which was similar 
to previously reported 5 nM. BX-795 potently inhibited Ser445 phosphorylation of MYPT1 
at 1 -10 µM concentrations on HEK293 cells (Fig. 3.2.C). Since BX-795 inhibits AMPK in 
vitro (Fig. 3.2 D), there was a moderate loss of canonical AMPK substrate phosphorylation 
Ser79 of ACC between 1-10 µM BX-795 (Fig. 3.2C). Besides the previously mentioned 
kinases, the major off-targets of BX-795 includes JAK2, GCK, CDK2 and MELK (Fig. 
3.2.D). 
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Figure 3.2 : BX-795 is a potent and non selective inhibitor of NUAK1. A) Structure of BX-795. B) NUAK1 IC50 with BX-795 was carried 
out using NUAK1 WT. C) HEK293 cells were treated with the indicated concentrations of BX-795 and the inhibition of NUAK1 induced pS445 
of MYPT1 and AMPK induced pS79 ACC were observed. D) The kinase specificity panel for BX-795 was carried out as described in section 
2.2.30. Arrow indicates NUAK1. 
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3.2.2. Development of potential drug resistant mutants of NUAK1  
 
To study the effect of NUAK1 inhibitors in vivo and in vitro, I developed a NUAK1 drug 
resistant mutant. By sequence alignment, I observed that NUAK1 possessed an Ala residue 
(Ala195) adjacent to the DFG motif (Fig 3.3A) similar to ROCK (Bonn et al., 2006, Jacobs et 
al., 2006) and LRRK2 (Nichols et al., 2009, Deng et al., 2011). Previously, studies on ROCK 
had revealed that the Ala residue adjacent to the magnesium ion binding DFG motif in 
subdomain VII played a vital role in binding to the ROCK inhibitor H-1152 via Van der 
Waals interactions (Jacobs et al., 2006) while PKA which had a Thr at the same position was 
much more resistant to H-1152 and upon mutating the Thr to an Ala, H-1152 potently 
inhibited PKA (Bonn et al., 2006). Our laboratory had previously utilised this strategy to 
develop drug resistant LRRK2 mutants (Nichols et al., 2009, Deng et al., 2011).  In order to 
identify the best possible mutation that would confer maximum drug resistance, we mutated 
Ala195 of NUAK1 into various amino acids and checked for the expression and activity of 
the mutants as compared to wild-type (Fig 3.3B). Out of the 7 mutants tested, 
NUAK1[A195G], NUAK1[A195S] and NUAK1[A195T] had comparable expression and 
were found to be catalytically active (Fig 3.3B).  The NUAK1[A195T] displayed similar 
intrinsic activity as NUAK1 WT and was also expressed at the same levels as wild-type as 
shown in Fig 3.3C.  
 
As shown in figure 3.3B, many of the NUAK1 mutants like A195D, A195K, A195N and 
A195V did not express at comparable levels with the wild-type and owing to either low 
expression or due to severity of the point mutation, the kinase activities were also negligible.  
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Fig 3.3. Development of potential drug resistant mutants of NUAK1: A) NUAK1 had a 
Ala residue similar to ROCK2 and LRRK2 adjacent to the subdomain VII DFG motif . B) 
The various NUAK1 potential drug resistant mutants were purified from transiently 
transfected HEK293 cells and their activities were compared using Sakamototide substrate 
peptide and [γ32P] ATP. C) NUAK1 WT and NUAK1 [A195T] mutant protein expression 
and kinase activity was compared. 
 
 
3.2.3.  The first generation 7-membered ring series inhibitors were potent but less 
selective for NUAK1 
The first generation of 7-membered ring series of NUAK1 inhibitors were JWE-071 (Fig 
3.4A), XMD-17-51 (Fig 3.5A), DLW-01-122-01 (Fig 3.7A) and DLW-01-125-01 (Fig 3.6A).  
 
3.2.3.1. JWE-071 
JWE-071 was one of the first NUAK1 inhibitors received. It had better kinome 
selectivity than any of the previously reported inhibitors of NUAK1 especially BX-
795. JWE-071 inhibited NUAK1 potently with an IC50 of 6 nM. The drug resistant 
mutant NUAK1 [A195T] exhibited 250 times more resistance for the inhibitor while 
NUAK1 [A195S] was 16-17 times more resistant (Fig. 3.4B). Interestingly, mutating 
Ala195 to a smaller Gly residue rendered the kinase 6 times more sensitive to the 
inhibitor (NUAK1 [A195G] IC50 1 nM) (Fig 3.4B). JWE-071 clearly inhibited the 
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NUAK1 mediated phosphorylation of MYPT1 at Ser445 in HEK293 cells at a 
concentration of 10 µM without significant inhibition of AMPK substrate ACC 
(Ser79) (Fig. 3.4.C). The major off-targets of JWE-071 were Aurora A, JAK2, ABL 
and Src and amidst the AMPK related kinases JWE-071 did exhibit some inhibitory 
activity on AMPK, BRSK1 and some of the MARK isoforms (Fig 3.4.D)  
 
3.2.3.2. XMD-17-51 
Along with JWE-071, the closely related inhibitor XMD-17-51 also exhibits high 
potency towards NUAK1 with an IC50 of 1.5 nM (Fig 3.5B) and inhibited Ser445 
phosphorylation on MYPT1 at a concentration of 10 µM in HEK293 cells (Fig 3.5C). 
The NUAK1 [A195T] mutant was 400 times more resistant while NUAK1 [A195S] 
was 10 times more resistant to XMD-17-51 (Fig 3.5B). As with JWE-071, the 
NUAK1[A195G] mutant was approximately twice as sensitive to XMD-17-51 
compared with NUAK1 WT (Fig 3.5B). XMD-17-51 had similar off-target effects as 
JWE-071 suppressing Aurora A & B, Src, JAK2, ABL. Amidst AMPK family 
kinases, XMD-17-51 had moderate activity on AMPK, BRSK1 and some MARK 
isoforms (Fig 3.5D). 
 
 
94 
 
 
 
Figure 3.4 : JWE-071 is a potent and moderately selective inhibitor of NUAK1. A) Structure of JWE-071. B) NUAK1 IC50 with JWE_071 
was carried out using NUAK1 WT, NUAK1 [A195T], NUAK1 [A195S] and NUAK1 [A195G]. C) HEK293 cells were treated with the 
indicated concentrations of JWE-071 and the inhibition of NUAK1 induced pS445 of MYPT1 and AMPK induced pS79 ACC were observed. 
D) The kinase specificity panel for JWE-071 was carried out as described in section 2.2.30.  
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Figure 3.5 : XMD-17-51 is a potent and moderately selective inhibitor of NUAK1. A) Structure of XMD-17-51. B) NUAK1 IC50 with 
XMD-17-51 was carried out using NUAK1 WT, NUAK1 [A195T], NUAK1 [A195S] and NUAK1 [A195G]. C) HEK293 cells were treated 
with the indicated concentrations of XMD-17-51 and the inhibition of NUAK1 induced pS445 of MYPT1 and AMPK induced pS79 ACC were 
observed. D) The kinase specificity panel for XMD-17-51 was carried out as described in section 2.2.30.  
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3.2.3.3. DLW-01-125-01 
DLW-01-125-01 exhibited similar activity as JWE-071 and XMD-17-51 with a 
NUAK1 IC50 of 7 nM and NUAK1 [A195T] exhibiting over 200 times more 
resistance (Fig 3.6B). DLW-01-125-01 inhibited Ser445 phosphorylation of MYPT1 
at 10 µM (Fig.3.6C). Compared to JWE-071 or XMD-17-51, DLW-01-125-01 had 
less off-target effects inhibiting Aurora A & B, and exhibiting moderate inhibition of 
FGFR, Src, ABL and a rather modest inhibition of AMPK or any of the other AMPK-
related kinases (Fig 3.6D) 
 
3.2.3.3. DLW-01-122-01 
DLW-01-122-01 is by far the most selective of all the first generation 7-membered 
ring series of NUAK inhibitors. The only drawback being that DLW-01-122-01 
inhibited Aurora A & B with similar potency as NUAK1. There was hardly any 
inhibition of the AMPK-related kinases exhibited (Fig 3.7D) without much 
compromise for NUAK1 potency (IC50 of 15 nM with NUAK1 [A195T] IC50 of 2 
µM) (Fig 3.7B). DLW-01-122-01 inhibited Ser445 phosphorylation of MYPT1 at 10 
µM without much effect on Ser79 of AMPK substrate ACC (Fig 3.7C). 
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Figure 3.6: DLW-01-125-01 is a potent and selective inhibitor of NUAK1. A) Structure of DLW-01-125-01. B) NUAK1 IC50 with DLW-01-
125-01was carried out using NUAK1 WT and NUAK1 [A195T]. C) HEK293 cells were treated with the indicated concentrations of DLW-01-
125-01 and the inhibition of NUAK1 induced pS445 of MYPT1 and AMPK induced pS79 ACC were observed. D) The kinase specificity panel 
for DLW-01-125-01 was carried out as described in section 2.2.30. 
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Figure 3.7 : DLW-01-122-01 is a potent and very selective inhibitor of NUAK1. A) Structure of DLW-01-122-01. B) NUAK1 IC50 with 
DLW-01-122-01 was carried out using NUAK1 WT and NUAK1 [A195T]. C) HEK293 cells were treated with the indicated concentrations of 
DLW-01-122-01 and the inhibition of NUAK1 induced pS445 of MYPT1 and AMPK induced pS79 ACC were observed. D) The kinase 
specificity panel for DLW-01-122-01 was carried out as described in section 2.2.30.  
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3.2.4 . The second generation 7-membered ring series NUAK1 inhibitor XMD-18-42 was 
highly selective for NUAK1 but still inhibited Aurora C & B 
 
XMD-1842 (Fig 3.10A) was a derivative of the first generation inhibitors and exhibited high 
potency for NUAK1 in vitro with an IC50 of 30 nM while NUAK1[A195T] mutant was 50 
times more resistant (Fig 3.10B). Similar to the earlier generation of 7-membered ring series 
of inhibitors, XMD-18-42 inhibits Ser445 phosphorylation on MYPT1 at 10 μM in HEK293 
cells (Fig 3.10B).  The kinase specificity panel for XMD-18-42 (Fig. 3.10D) showed that it 
potently inhibited Aurora B as well. Furthermore, IC50 analysis of XMD-18-42 for the 
Aurora kinases showed that the inhibitor potently inhibited Aurora B with an IC50 of 54 nM 
and Aurora C with an IC50 of 120 nM (Fig 3.8). 
 
 
Figure 3.8 : XMD-18-42 inhibits Aurora kinases in vitro 
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In the XMD-18-42 related second generation of the 7-membered ring series, XMD-18- 83 
was one of the less selective NUAK1 inhibitor (IC50 17 nM) with off-target effects on ABL, 
DDR2, Lck, CLK2, Src and JAK2 (Fig 3.9) However, one interesting observation was that it 
was the first compound of the 7-membered series which had least off-target effects on the 
Aurora kinases, especially Aurora B.  
 
 
 Figure 3.9 : XMD-18-83 was a less selective inhibitor of NUAK1 but did not inhibit the 
Aurora kinases. (Arrow indicates NUAK1 and * indicates Aurora kinases) 
 
        
 
 
 
XMD-18-83 
    
* 
* 
XMD-18-83 at 1 µM 
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Figure 3.10 : XMD-18-42 is a potent and highly selective inhibitor of NUAK1. A) Structure of XMD-18-42. B) NUAK1 IC50 with XMD-
18-42 was carried out using NUAK1 WT and NUAK1 [A195T]. C) HEK293 cells were treated with the indicated concentrations of XMD-18-42 
and the inhibition of NUAK1 induced pS445 of MYPT1 and AMPK induced pS79 ACC were observed. D) The kinase specificity panel for 
XMD-18-42 was carried out as described in section 2.2.30.  
A.                                                            B.                                                                                                                                                      C.                                     
D. 
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3.2.5. The first and second generation 7-membered ring series had very weak activity on 
NUAK2 
 
Interestingly, DLW-01-122-01 and XMD-18-42 has very weak inhibitory activity on NUAK2 
(Fig. 3.11). At 10 µM concentration of XMD-18-42 (>300 times the IC50 of NUAK1), 
NUAK2 retained >80% of its kinase activity and at 10 µM concentration of DLW-01-122-01 
(>650 times the IC50 of NUAK1), NUAK2 retained >50% of its kinase activity. 
 
 
 
Figure 3.11 : First and second generation 7-membered ring series of NUAK1 
inhibitors exhibit very low activity towards NUAK2 
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3.2.6. The third generation 7-membered ring series HTH-01-015 is a highly potent and 
remarkably specific inhibitor of NUAK1 
 
To develop the most specific and potent inhibitor of NUAK1 and to negate the activity 
against the Aurora kinases, a third generation inhibitor was synthesized termed HTH-01-015 
(Fig. 3.12A). HTH-01-015 was a hybrid of XMD-18-42 and XMD-18-83 that retained the 
specificity of XMD-18-42 and exhibited minimal activity towards the Aurora kinases 
characteristic of XMD-18-83 (Fig.3.12D). HTH-01-015 was remarkably selective for 
NUAK1 with an IC50 of 100 nM with NUAK1 [A195T] being approximately 60 times more 
resistant to the inhibitor (Fig. 3.12B). Similar to its 7-membered ring predecessors, HTH-01-
015 inhibited NUAK2 with an IC50 of  >11 µM (Fig. 3.12C).  
 
HTH-01-015 inhibits Ser445 phosphorylation of MYPT1 at 3-10 µM concentrations in 
HEK293 cells (Fig. 3.13). Consistent with the screening data (Fig 3.12D), HTH-01-015 does 
not inhibit AMPK that is evident from the robust Ser79 ACC signal at 3-10 µM 
concentrations of the inhibitor (Fig. 3.13).  
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Figure 3.12 : HTH-01-015 is a highly potent and remarkably selective inhibitor of NUAK1. A) Structure of HTH-01-015. B) NUAK1 IC50 
with HTH-01-015 was carried out using NUAK1 WT and NUAK1 [A195T]. C) NUAK2 IC50 with HTH-01-015 was carried out using NUAK2 
WT and NUAK1WT in parallel. D) The kinase specificity panel for HTH-01-015 was carried out as described in section 2.2.30.  
(Arrow indicates NUAK1 and * indicates Aurora kinases) 
* 
* 
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Figure 3.13 : HTH-01-015 inhibits NUAK1 in vivo. HEK293 cells treated with or 
without the indicated concentrations of HTH-01-015 for 8 hrs. The cells were induced 
with or without EDTA buffer mediated detachment to activate NUAK1. Cells were 
lysed and immunoblots were carried out with Ser445 MYPT1, MYPT1, Ser79 ACC 
and ACC antibodies.  
 
To further test the efficacy of the inhibitor, HEK293 cells stably expressing NUAK1 WT and 
NUAK1 [A195T] cells were treated with various dilutions of the inhibitors and Ser445 
MYPT1 phosphorylation was checked by immunoblotting. Unlike the NUAK1 WT 
expressing cells (Fig.3.14A), HEK293 cells expressing the drug-resistant NUAK1[A195T] 
did not exhibit any significant decrease of Ser445 MYPT1 phosphorylation even at 30 µM 
HTH-01-015 concentration (Fig.3.14B). 
 
 
Figure 3.14 : HEK293 cells stably expressing NUAK1[A195T] cells do not exhibit 
reduction of Ser445 MYPT1 phosphorylation upon treatment with HTH-01-015. 
A) HEK293 cells expressing NUAK1 WT exhibits reduction of Ser445 MYPT1 
phosphorylation between 3-30 µM. B) Cells expressing NUAK1[A195T] does not 
show any significant reduction of Ser445 MYPT1 phosphorylation even at 30 µM. 
 
 
 
A. B. 
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3.2.7. The BX-795 derived first generation 2,4,5-trisubstituted pyrimidine series of 
NUAK inhibitors were less specific for NUAK1 
 
The 2,4,5-trisubstituted pyrimidine series of inhibitors were developed based on primarily the 
backbone of BX-795 and fusing some of the basic side chains of TG101348. These inhibitors 
were structurally diverse from the 7-membered ring series and hence provided as a perfect 
control to replicate and consolidate the in vitro and in vivo effects of NUAK1 inhibition. 
There were in total three inhibitors in the first generation of 2,4,5-trisubstituted pyrimidine 
series namely: SJB4-115, WZ4002 and HMSL10085.  
 
HMSL10085 was relatively selective for NUAK1 with off-target effects on IGFR, BTK and 
HER4. HMSL10085 had a NUAK1 IC50 of 25 nM (Fig 3.15) and being less selective, it was 
not carried forward for cell based assays. 
 
Figure 3.15 : HMSL10085 was a first generation 2,4,5-trisubstituted pyrimidine 
inhibitor of NUAK1. (Arrow indicates NUAK1 and * indicates Aurora kinases) 
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SJB4-115, similar to HMSL10085, potently inhibited NUAK1 with an in vitro IC50 of 67 
nM (Fig. 3.16). SJB4-115, however was far less selective for NUAK1 as compared to 
HMSL10085 exhibiting off-target effects on JAK2, ERK8, TrkA, Lck, ULK1, Src and 
AMPK related kinase SIK2 (Fig. 3.16). As in HMSL10085, SJB4-115 was not tested further 
on cells.  
 
 
Figure 3.16 : SJB4-115 was a first generation 2,4,5-trisubstituted pyrimidine inhibitor 
of NUAK1 and less selective than HMSL10085. (Arrow indicates NUAK1 and * indicates 
Aurora kinases) 
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3.2.8. The third generation 2,4,5-trisubstituted pyrimidine series WZ4003 is a highly 
potent and remarkably specific inhibitor for both NUAK1 and NUAK2 isoforms. 
 
One of the first generation 2,4,5-trisubstituted pyrimidine series of inhibitors is WZ4002 
(Fig.3.1) that has previously been reported as a potent EGFR inhibitor, and Ambit screening 
against 400 kinases revealed that WZ4002 inhibits a sub-set of the TEC-family kinases as 
well (Zhou et al., 2009). The Ambit screening data also exhibited that WZ4002 inhibited 
NUAK1 by 82% and NUAK2 by 72% at 0.1 μM concentration (Zhou et al., 2009). 
Interestingly, a reversible analog of WZ4002 was used as a control probe with a hundred fold 
lower potency for EGFR inhibition, termed WZ4003 (Fig.3.17A) (Zhou et al., 2009). 
WZ4003 did not have significant inhibitory effect on EGFR or TEC-family kinases, but 
kinase profiling at the International Centre for Protein Kinase Proﬁling, University of Dundee 
revealed that WZ4003 did not lose the inhibitory effect on NUAK1 (Fig 3.17D). 
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Figure 3.17 : WZ4003 is a highly potent and remarkably selective inhibitor of NUAK1 and NUAK2. A) Structure of WZ4003. B) NUAK1 
IC50 with WZ4003 was carried out using NUAK1 WT and NUAK1 [A195T]. C) NUAK2 IC50 with WZ4003 was carried out using NUAK2 
WT and NUAK1 WT in parallel. D) The kinase specificity panel for WZ4003 was carried out as described in section 2.2.30.  
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WZ4003 inhibited NUAK1 with an IC50 of 20 nM with the drug-resistant NUAK1 [A195T] 
exhibiting 45 times more resistance to inhibition (Fig. 3.17B). WZ4003 is the first potent and 
selective inhibitor of both the NUAK isoforms and inhibits NUAK2 in vitro with an IC50 of 
100 nM (Fig. 3.17C). WZ4003 had a more potent inhibition of Ser445 MYPT1 
phosphorylation between 1-10 μM (Fig. 3.18) and consistent with the screening data, Ser79 
of ACC was unaffected suggesting minimal inhibition of AMPK (Fig 3.18).  
 
 
Figure 3.18 : WZ4003 inhibits NUAK activity in vivo. HEK293 cells treated with or 
without the indicated concentrations of WZ4003 for 16 hrs. The cells were induced with or 
without EDTA buffer mediated detachment to activate NUAK1. Cells were lysed and 
immunoblots were carried out with Ser445 MYPT1, MYPT1, Ser79 ACC and ACC 
antibodies.  
 
 
To further test the efficacy of the inhibitor, HEK293 cells stably expressing NUAK1 WT and 
NUAK1 [A195T] cells were treated with various dilutions of WZ4003 and Ser445 MYPT1 
phosphorylation was checked by immunoblotting. Unlike the NUAK1 WT expressing cells 
(Fig.3.19A), HEK293 cells expressing the drug-resistant NUAK1[A195T] did not exhibit any 
significant decrease of Ser445 MYPT1 phosphorylation even at 30 µM WZ4003 
concentration (Fig.3.19B). 
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Figure 3.19 : HEK293 cells stably expressing NUAK1[A195T] cells do not exhibit 
reduction of Ser445 MYPT1 phosphorylation upon treatment with WZ4003. A) 
HEK293 cells expressing NUAK1 WT exhibits reduction of Ser445 MYPT1 phosphorylation 
between 3-30 µM concentration of WZ4003. B) Cells expressing NUAK1[A195T] does not 
show any significant reduction of Ser445 MYPT1 phosphorylation even at 30 µM 
concentration. 
 
 
 
3.2.9. WZ4074, the imidizolopyrimidine series NUAK1 inhibitor was considerably less 
selective than HTH-01-015 or WZ4003. 
 
The only imidizolopyrimidine series inhibitor WZ4074 potently inhibited NUAK1 with an 
IC50 of 33 nM but exhibited many off-target effects including BTK, HER4, MLK isoforms 
(Fig 3.20).  The structure of WZ4074 is loosely based on sunitib and its derivatives and hence 
is structurally diverse than the 7-membered ring series or the 2,4,5-trisubstituted pyrimidine 
series of inhibitors. 
 
WZ4074, owing to its non-selective profile, was not used in further cell based assays to check 
MYPT1 phosphorylation. 
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Figure 3.20: WZ4074 is the only inhibitor in the imidizolopyrimidine series and potently 
inhibits NUAK1 but is much less selective. (Arrow indicates NUAK1 and * indicates 
Aurora kinases). 
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3.2.10. Inhibition of NUAK1 impairs the migration properties of cells 
Previous studies have revealed that RNAi mediated knockdown of NUAK1 slows down the 
rate of migration of cells especially in a wound-healing assay (Chang et al., 2012, Chen et al., 
2013b, Lu et al., 2013). We employed wound-healing assays on NUAK1
+/+
 and NUAK1
-/-
 
MEFs and compared the migration properties between wild-type and NUAK1 deficient cells 
(Fig. 3.21). Clearly, the  NUAK1
-/-
 MEFs migrated much slower into the 500 µm wound 
while within 15-16 hrs, the NUAK1
+/+
 MEFs had already closed the wound (Fig. 3.21). 
 
 
Figure 3.21 : NUAK1 deficient cells migrate slower than the wild-type. A) Wound-
healing assay showing the total migration of cells into the 500 µm wound over 15 hours. B) 
Quantitative kymographs of A. where the arrow indicates direction of migration. 
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To see whether inhibitor treatment of cells (NUAK1
+/+
 MEF and U2OS) would phenocopy 
the slow migration of NUAK1
-/-
 MEFs, wound healing assay was carried out with or without 
the treatment of WZ4003 and HTH-01-015 on cells. NUAK1
+/+
 MEFs on treatment with both 
WZ4003 and HTH-01-015, migrated much slower into the wound as is evident in Fig. 3.22. 
 
 
Figure 3.22 : Treatment of WZ4003 or HTH-01-015 phenocopies slower migration 
properties of NUAK1 deficient cells. A) Wound-healing assay showing the total migration 
of NUAK1
+/+
 MEFs into the 500 µm wound over 15 hours. B) Quantitative kymographs of 
A. where the arrow indicates direction of migration. 
 
 
Similar to the NUAK1
+/+
 MEFs, treatment of WZ4003 and HTH-01-015 inhibitors to highly 
migratory U2OS cells exhibited the same slower phenotype in wound-healing assays (Fig. 
3.23). 
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Figure 3.23: U2OS cells treated with NUAK1 inhibitors migrate slower into the wound. 
A) Wound-healing assay showing the total migration of cells into the 500 μm wound over 12 
hours. B) Quantitative kymographs of A. where the arrows indicate direction of migration.  
 
 
Phalloidin staining revealed that NUAK1
-/-
 MEFs had more actin stress fibres than 
NUAK1
+/+
 MEFs (Figure 3.24). This striking phenotype might explain the NUAK1
-/-
 MEFs 
resistance to cell dissociation. To check whether that NUAK1 inhibitor treated NUAK1
+/+
 
MEFs could mimic the actin stress fibre phenotype of the NUAK1
-/-
 MEFs, the NUAK1
+/+
 
MEFs were treated with or without 10 µM WZ4003 or HTH-01-015 and 
immunofluorescence was carried out using phalloidin-TRITC for actin staining. Both 
WZ4003 and HTH-01-015 treated cells exhibited more actin stress fibres as compared to the 
DMSO treated NUAK1
+/+
 MEFs (Figure 3.24). Hence higher and more prominent actin stress 
fibres could contribute directly to the slower migration phenotype in NUAK1 deficient/ 
inhibited cells.  
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Figure 3.24: NUAK1 inhibitor treatments of NUAK1
+/+
 MEFs lead to more prominent 
actin stress fibres consistent with the NUAK1
-/-
 MEFs phenotype. 
 
 
 
3.2.11. Inhibition of NUAK1 impairs cell proliferation 
To compare the rate of cell proliferation in NUAK1 deficient/inhibited cells and normal cells, 
U2OS and NUAK1
+/+
 MEFs cells with or without 10 µM WZ4003 or HTH-01-015 treated 
were used to assay cell proliferation over 5-6 days. For NUAK1
+/+
 MEFs cell proliferation, 
NUAK1
-/-
 MEFs were used as control cells to compare with the rate of proliferation in 
NUAK inhibitor treated NUAK1
+/+
 MEFs. Inhibitor treated U2OS cells were found to 
proliferate at a significantly slower rate than the DMSO treated cells (Fig. 3.25A). Consistent 
with the U2OS cell proliferation data, NUAK inhibitor treated NUAK1
+/+
 MEFs were 
proliferating at a dramatically slower rate than the DMSO treated NUAK1
+/+
 MEFs. The 
NUAK inhibitor treated NUAK1
+/+
 MEFs exhibited a rate of proliferation exactly similar to 
that of the NUAK1
-/-
 MEFs (Fig. 3.25B). 
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Figure 3.25 : NUAK1 inhibition impairs cell proliferation. A) Both WZ4003 and HTH-
01-015 treated U2OS cells had reduced cell proliferation. B) NUAK1
+/+
 MEFs treated with 
WZ4003 and HTH-01-015 mimicked the slow proliferation rate of NUAK1
-/-
 MEFs. 
 
 
3.2.12. Inhibition of NUAK1 reduces the invasive potential of U2OS cells 
The invasive potential of U2OS cells treated with or without 10 µM HTH-01-015 and 
WZ4003 were compared using the growth factor reduced Matrigel
TM
 invasion chambers as 
mentioned in Section 2.2.29. The DMSO treated U2OS cells clearly invaded more potently 
into the Matrigel
TM
 matrix as compared to the NUAK inhibitor treated cells (Fig. 3.26). 
Snapshots of the inserts were taken and representative images are shown. Number of cells 
invading into the matrix were counted and represented as a standard deviation of the mean of 
triplicate images.  
 
 
Figure 3.26 : NUAK1 inhibition reduced the invasive potential of U2OS cells by 
approximately 3 folds. 
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3.2.13. NUAK1 inhibition and its effect on deregulated MYC driven cancer cells 
 
In 2011, Prof. Martin Eilers and Dr. Daniel Murphy's laboratory reported that NUAK1 was 
an essential factor involved in the survival of MYC driven tumours and cancer cells (Liu et 
al., 2012). They have shown that inhibition of NUAK1 either by RNAi or by using the 
inhibitor BX-795, cancer cells expressing deregulated oncogenic MYC underwent apoptosis 
(Liu et al., 2012). To test this new hypothesis, a panel of cancer cells were chosen to study 
the effect of the NUAK inhibitors on the ones over-expressing oncogenic MYC. Besides 
standard cancer cell lines, Dr. Victoria Cowling (MRCPPU, University of Dundee) provided 
me with IMEC (immortalised mammalian epithelian cells) expressing MYC and vector 
control (VEC) and TET21N neuroblastoma cells expressing doxycyclin inducible repressor 
of N-MYC (Lutz et al., 1996). To test the level of MYC in the cell lines, immunoblot was 
carried out and HEK293, HCT116 and SHSY5Y cells were found to overexpress c-MYC 
while U2OS, MDA-MB-231 and MDA-MB-468 expressed low levels of c-MYC (Fig 
3.27A). TET21N cells were treated with or without 200 ng/ml doxycyclin and the expression 
of N-MYC was ascertained (Fig. 3.27B) 
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Figure 3.27 : Cell lines expressing oncogenic MYC. A) Various cancer cell lines 
were tested for MYC expression. B) Doxycyclin inducible repressor expressing 
TET21N cells were tested for N-MYC by immunoblotting with GAPDH as control.  
 
 
 
 
3.2.13.1 shRNA mediated of knockdown of NUAK1 in TET21N induced cell 
death 
 
Knockdown of NUAK1 was carried out in the high N-MYC expressing TET21N cells 
using two different shRNAs (section 2.2.9) and post puromycin selection, the cells 
were tested for growth and proliferation using the MTS assay (section 2.2.28). 
Strikingly, shRNA mediated knockdown of NUAK1 in TET21N cells led to rapid cell 
death within 5 days of selection (Fig. 3.28). 
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Figure 3.28 : shRNA knockdown of NUAK1 led to cell death in high N-MYC 
expressing TET21N cells. MTS assay was carried out over 5 days and optical density 
at 490 nM was used as the reading for cell proliferation. 
 
 
An interesting observation was that the high sensitivity towards the shRNAs of 
NUAK1 in TET21N cells could not be rescued by addition of 200 ng/ml doxycyclin 
to repress the expression of MYC (Fig. 3.29). Hence, it was essential to ascertain 
whether this robust trigger of cell death was owing to NUAK1 inhibition alone or 
some off-target effects by the shRNA oligos. 
 
                             
Figure 3.29 : MYC repression by 200ng/ml of doxycyclin could not rescue the 
TET21N cell death upon shRNA knockdown of NUAK1. MTS assay was carried 
out over 5 days and optical density at 490 nM was used as the reading for cell 
proliferation.  
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3.2.13.2. Second generation inhibitor XMD-18-42 induced apoptosis mediated 
cell death in high MYC expressing cancer cells. 
The second generation 7-membered ring series inhibitor XMD-18-42 was initially 
used to probe into the role of NUAK1 in MYC driven tumour cells as the WZ4003 
and HTH-01-015 compounds had not yet been elaborated. Interestingly, treatment of 
various concentrations of XMD-18-42 led to reduced cell proliferation and higher rate 
of cell death on IMEC MYC expressing cells as compared to the vector control (Fig. 
3.30) although the cell death was not as striking as the shRNA data (Fig.3.28) . Cell 
proliferation rate was estimated using MTS assay (section 2.2.28). 
 
 
Figure 3.30. XMD-18-42 induced higher rate of cell death in MYC expressing 
IMEC cells as compared to the IMEC vector control cells. Dotted line represents 
Day 0 background counts. % of control represents % cell growth times Day 0 counts.  
 
Consistent with the IMEC cells, XMD-18-42 also suppressed cell proliferation (Fig 
3.31A) and induced higher rate of apoptosis (Fig 3.31B) in TET21N cells as 
compared to TET21N cells treated with doxycyclin (MYC repressed). Apoptosis was 
measured by staining cells with Caspase 3 antibody and number of active Caspase 3 
cells were identified using flow cytometry (Section 2.2.26.2). Unlike the shRNA 
mediated cell death of TET21N in Fig.3.28, cell death induced by XMD-18-42 was 
far more modest (Fig. 3.31). 
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Figure 3.31 : XMD-18-42 induces faster rate of apoptosis in TET21N expressing 
high levels of N-MYC. A) MTS assay to study cell proliferation in TET21N cells 
with or without MYC suppression upon XMD-18-42 treatment. B) Flow cytometric 
measurement  of active Caspase 3 expressing apoptotic cells was carried out to 
compare between TET21N cells with and without N-MYC suppression upon XMD-
18-42 treatment. 
 
  
To assess the role of NUAK1 in the apoptotic cell death induced by XMD-18-42, 
NUAK1 WT and NUAK1 [A195T] were stably overexpressed by retroviral 
transfection and puromycin selection in TET21N cells (Section 2.2.8). MTS assay 
was carried out upon XMD-18-42 treatment on TET21N NUAK1 WT and TET21N 
NUAK1 [A195T] with or without N-MYC suppression. TET21N cells expressing 
NUAK1 WT were moderately more sensitive to XMD-18-42 mediated cell death as 
compared to TET21N NUAK1 [A195T] or upon repression of N-MYC by doxycyclin 
(Fig. 3.32). Overall, this effect was not marked or consistent with the effect seen in 
the shRNA data (Fig. 3.28). 
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Figure 3.32 : TET21N cells stably expressing NUAK1 WT were more sensitive to 
XMD-18-42 induced cell death as compared to TET21N [A195T] and doxycyclin 
treated (MYC repressed) TET21N cells. 
 
 
Besides IMECs and TET21N, effect of XMD-18-42 was tested on HEK293, 
HECT116, MCF-7 and MDA-MB-231 cells (Fig. 3.33A). As in Fig. 3.27A, HEK293 
and HCT-116 had high expression of c-MYC while MCF-7 had low and MDA-MB-
231 had lowest levels of c-MYC. Interestingly, XMD-18-42 seemed to have an effect 
somehwat directly proportional to the level of MYC in the cell lines. HEK293 and 
HCT-116 were most sensitive to the inhibitor, followed by MCF-7 while MDA-MB-
231 had hardly any effect even at 10 µM inhibitor concentrations (Fig. 3.33A). To test 
the effect of XMD-18-42 on a larger panel of MYC driven cancer cell lines, Dr. 
Nathanael Gray's laboratory collaborated with Prof. Tom Look's laboratory at the 
Dana-Farber Cancer Centre (Harvard, USA). Prof. Tom Look's laboratory tested the 
effect of XMD-18-42 on a panel of 10 well established MYC driven tumour cells and 
found that a subset of MYC driven cancer cells were highly sensitive to XMD-18-42 
(Fig.3.33B). 
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Figure 3.33 : XMD-18-42 induces cell death in a sub-set of MYC driven cancer 
cells. A) HEK293, HCT-116, MCF-7 and MDA-MB-231 cells were treated with 
XMD-18-42 and MTS cell proliferation assay was carried out. B) XMD-18-42 was 
tested by Prof. Tom Look's laboratory on the MYC driven cell line panel at Dana 
Farber Cancer Centre (Harvard, USA).  
 
 
3.2.13.3. Aurora B inhibitor AZD1152-HQPA mimics XMD-18-42 induced cell 
death. 
The major off-target effect that XMD-18-42 possess is on the Aurora kinases 
especially Aurora B (XMD-18-42 IC50 Aurora B 54 nM). Moreover, Aurora kinases 
have been previously reported to play significant role in maintaining the malignant 
state of MYC driven B-cell lymphomas (den Hollander et al., 2010). Hence to 
properly evaluate the roles of NUAK1 inhibition and Aurora B inhibition in the 
XMD-18-42 induced cell death, well established Aurora B inhibitor AZD1152-HQPA 
(Barasertib) (Yang et al., 2007) was used in parallel with the NUAK1 inhibitor. 
AZD1152-HQPA did not inhibit NUAK1 (retained >90% activity at 1 µM 
concentration) (Fig 3.34C) and possessed an IC50 of 15.5 nM for Aurora B and 193 
nM for Aurora A.  
 
AZD1152-HQPA clearly mimicked the cell death pattern induced by XMD-18-42 
both in TET21N cells (Fig 3.34A) as well as in the Dana Farber Cancer Centre MYC 
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driven cell line panel (Fig. 3.34B) as tested by Prof Tom Look's laboratory (Harvard, 
USA).  Since AZD1152-HQPA does not inhibit NUAK1 significantly, one could 
argue that the MYC dependent cell death was primarily owing to Aurora B inhibition 
and not just NUAK1 inhibition. To ascertain the contribution of NUAK1 inhibition in 
the cell death of MYC expressing cells, it was important to develop and test specific 
NUAK1 inhibitors which had no off-target on Aurora kinases. 
 
 
 
Figure 3.34: AZD1152-HQPA is a highly specific Aurora B inhibitor which mimicked 
the cell death pattern induced by NUAK1 inhibitor XMD-18-42. A) Structure of 
AZD1152-HQPA and MTS cell proliferation on TET21N cells upon AZD1152-HQPA 
treatment. B) Effect of AZD1152-HQPA on the deregulated MYC expressing cancer cell line 
panel at the Dana Farber Cancer Centre (Prof. Tom Look's laboratory, Harvard, USA). C) 
The kinase specificity panel for AZD1152-HQPA was carried out as described in section 
2.2.30. Blue bar indicates NUAK1 and arrow indicates Aurora B. 
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3.2.13.4. NUAK1 inhibitors with insignificant off-target effects on Aurora 
kinases did not induce MYC expression selective cell death in TET21N cells 
 
Various NUAK1 inhibitors of diverse structures were used to ascertain the 
contribution of NUAK1 inhibition in the MYC overexpression dependent cell death. 
The first and second generation 7-membered ring series of inhibitors JWE-071 and 
XMD-18-42 exhibited the MYC selective induction of cell death and both the 
inhibitors had major off-target effects on Aurora kinases (Fig. 3.4 and Fig. 3.8). The 
second generation XMD-18-83 had no off-target effects on Auroras (Fig. 3.9) and 
consequently did not exhibit any MYC selectivity (Fig. 3.35). Similar to XMD-18-83, 
the third generation 7-membered ring series highly selective and potent NUAK1 
inhibitor HTH-01-015 also did not exhibit MYC selective cell death in TET21N cells 
(Fig. 3.35). 
 
The 2,4,5-trisubstituted pyrimidine series of first and second generation NUAK 
inhibitors did not exhibit any specific MYC selective cell death in TET21N cells. 
HMSL10085, SJB4115 and WZ4003 have no off-target effects on Aurora kinases but 
are potent NUAK inhibitors (Fig. 3.35), hence absence of MYC selective cell death 
puts the whole concept of NUAK and MYC connection under a lot of controversy. 
Finally, the imidizolopyrimidine inhibitor WZ4074 did not have any significant effect 
on cell proliferation of either normal TET21N cells or on MYC repressed TET21N 
cells even at high 10 µM concentration (Fig. 3.35). 
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Figure 3.35: Specific NUAK1 inhibitors with no off-target effects on Aurora 
kinases did not exhibit MYC selective induction of cell death in TET21N cells 
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3.3. Discussion 
 
Over the years, the LKB1 activated NUAK kinases have been found to be overexpressed in 
cancer, playing essential roles in cell migration, detachment and invasion properties (Kusakai 
et al., 2004a, Zagorska et al., 2010, Chang et al., 2012, Lu et al., 2013)and recently has been 
reported to be a vital antiapoptotic factor in deregulated MYC driven tumours (Liu et al., 
2012). Moreover, all the 14 kinases in the AMPK family including NUAK isoforms could 
potentially possess overlapping substrates and regulatory properties owing to their highly 
homologous kinase domains and affinity towards the AMPK consensus phosphorylation 
motifs in the substrates (Zagorska et al., 2010). So, to properly dissect the role of the NUAK 
kinases and their potential contribution to cancer, it was important to develop highly specific 
small molecule tool compounds capable of selective inhibition of the NUAK isoforms. 
Initially, developing specific inhibitors to individual kinases within the AMPK family was 
deemed a rather challenging task owing to their highly homologous kinase domains. But the 
recent success of SIK (Clark et al., 2012) and MELK (Chung et al., 2012) inhibitors offered 
great encouragement that it may ultimately be possible to develop specific inhibitors to each 
of the AMPK family members. The only NUAK inhibitor in use is BX-795 which inhibits 
NUAK1 with nanomolar IC50 but is a rather generic inhibitor potently targetting many of the 
other AMPK family members, PDK1, TAK1, IKKε etc (Clark et al., 2009, Zagorska et al., 
2010, Liu et al., 2012). Besides BX-795, Ambit Biosciences recently reported that may of the 
FDA approved anti-cancer drugs like sunitinib, dovitinib and TG101348 could potentially 
inhibit NUAKs with nanomolar IC50 but non-specific off-target effects on other kinases still 
persisting as a major issue (Davis et al., 2011).  
 
To develop highly specific and potent inhibitors of NUAKs, we collaborated with Dr. 
Nathanael Gray's laboratory in Harvard, USA. The 7-membered ring backbone containing 
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LRRK2in1 was recently reported from our laboratory as a potent and highly selective 
inhibitor of LRRK2 a kinase mutated in Parkinson's disease (Deng et al., 2011). Interestingly, 
LRRK2in1 had off target effects on NUAK1 at 10 µM  concentration. Based on the 7-
membered ring backbone and on the trisubstituted pyrimidine backbone of BX-795, Dr. 
Gray's laboratory developed various generations of NUAK inhibitors (Fig. 3.1). IC50 values 
of all the inhibitors on NUAK1 in vitro is listed in the Table 3.2 below :  
 
Table 3.2 : Summary of NUAK inhibitors. * indicates inhibitor possesses >10 off-targets, 
** indicates inhibitor possesses 2-9 off-targets and *** indicates inhibitor possesses <2 off-
targets in the Dundee protein kinase panel screening. 
 
Series Inhibitor 
IC50 NUAK1 
WT 
IC50 NUAK1 
A195T 
IC50 NUAK2 
WT 
pS445 
MYPT1 
inhibition 
Selectivity 
 
7-membered ring 
JWE-071 6 nM 1500 nM - 10 µM * 
XMD-17-51 1.5 nM 600 nM - 10 µM * 
DLW-01-125-01 7 nM 1500 nM - 10 µM * 
DLW-01-122-01 15 nM 2000 nM - 10 µM ** 
XMD-18-42 30 nM 1000 nM - 10 µM ** 
XMD -18-83 17 nM - - - * 
HTH-01-015 100 nM 5888 nM > 11 µM 10 µM *** 
 
2,4,5-trisubstituted 
pyrimidine 
BX-795 5 nM - - 1-10 µM * 
HMSL10085 25 nM - - - * 
SJB4-115 67 nM - - - * 
WZ4003 20 nM 900 nM 100 nM 3-10 µM *** 
Imidizolopyrimidine WZ4074 33 nM - - - * 
 
To further test these inhibitors, a drug resistant mutant of NUAK1 was developed by 
mutating the Ala residue adjacent to subdomain VII DFG motif in the kinase domain to a 
bulky Thr residue. Based on previous studies, it has been hypothesized that mutating the Ala 
adjacent to the DFG motif into a Thr residue results in alteration of the stearic properties in 
the inhibitor docking pocket of the kinase without affecting the ATP-Mg
2+
 binding properties 
of the kinase (Nichols et al., 2009, Deng et al., 2011). Thus NUAK1 A195T mutant was 
developed which exhibited 40-400 times more resistance to the inhibitors as compared to the 
wild-type (Table 3.2) without altering the stability, expression levels or intrinsic kinase 
activity of NUAK1 (Fig. 3.3). In future, it would be interesting to generate inhibitor resistant 
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NUAK1 A195T knock-in mutations that could be used as a control to verify the  cellular 
responses mediated by NUAK inhibitors which are desensitised by this mutation.  
 
Since the only known well established substrate of NUAK is MYPT1, the inhibitors were 
tested for dose dependent inhibition of cell detachment induced pSer445 MYPT1 as an in 
vivo read out of NUAK activity. In previous work we have found that both NUAK1 and 
NUAK2 isoforms similarly phosphorylate and coimmunoprecipitate with MYPT1 (Zagorska 
et al., 2010). This may explain why in HEK293 cells we observe that the dual NUAK1 and 
NUAK2 WZ4003  inhibitor suppresses MYPT1 pSer445 phosphorylation more effectively 
(Fig, 3.18) than the NUAK1 selective HTH-01-015 inhibitor (Fig, 3.13). The effect of some 
of the inhibitors were also tested in cells stably overexpressing NUAK1 wild-type and A195T 
drug resistant mutant to compare. Besides pSer445 MYPT1, effect of NUAK inhibition in 
deregulated MYC expressing cancer cells were also observed with the inhibitors.  
 
The first generation 7-membered ring series inhibitors potently inhibited NUAK1 and were 
more specific for NUAK as compared to BX-795 (Fig. 3.2). However, these inhibitors had an 
off-target effect on Aurora kinases. All four inhibitors JWE-071 (Fig. 3.4), XMD-17-51 (Fig. 
3.5), DLW-01-122-01 (Fig. 3.7) and DLW-01-125-01 (Fig. 3.6) could inhibit NUAK1 
induced pSer445 MYPT1 at 3-10 µM concentrations. Similar to the first generation, the 
second generation 7-membered ring series XMD-18-42 was very specific for NUAK1(Fig. 
3.10) with off-target effects on Aurora kinases (Fig. 3.8). The first and second generation 7-
membered  ring series of inhibitors were initially tested in deregulated MYC expressing 
cancer cells. For this purpose, Dr. Victoria Cowling provided me with TET21N 
neuroblastoma cells expressing doxycyclin inducible repressor of N-MYC (Lutz et al., 1996) 
and IMEC cells expressing MYC or vector control (Fig. 3.27). Initially shRNAs targetting 
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NUAK1 was used in the N-MYC expressing TET21N cells. Interestingly, upon NUAK 
knockdown, the TET21N cells underwent cell death within 48 hours of puromycin selection 
(Fig. 3.28). But, upon treatment of doxycyclin to repress MYC expression, the cells could not 
be rescued (Fig. 3.29) which signifies that the cell death induced by shRNAs to NUAK1 was 
possibly independent of MYC expression. However, upon treatment of TET21N cells with 
JWE-071 (Fig. 3.35) or XMD-18-42 (Fig. 3.31), cells expressing MYC underwent a 
moderately faster rate of cell death as compared to MYC repressed TET21N cells. MTS 
assay and caspase3 apoptotic cell counting by flow cytometry were carried out in parallel to 
study TET21N cell death upon XMD-18-42 inhibitor treatments (Fig. 3.31). This was 
consistent in IMEC cells wherein XMD-18-42 induced MYC expressing IMEC cells to 
undergo moderately accelerated rate of cell death as compared to vector control (Fig. 3.30). 
Moreover, upon overexpressing NUAK1 A195T drug resistant mutant in TET21N cells, there 
was a moderate rescue of NUAK inhibitor induced cell death as seen in NUAK1 WT 
expressing TET21N cells (Fig. 3.32). 
 
To further confirm whether there was indeed any link between MYC levels and the cell death 
caused by NUAK inhibitors, standard cells lines expressing varied levels of MYC were 
treated with XMD-18-42. Interestingly, there seemed to be a direct proportionality between 
rate of cell death and MYC expression (Fig. 3.33A). XMD-18-42 was further tested on the 
MYC driven cell line panel in Prof. Tom Look's laboratory at the Dana-Farber Cancer Centre 
and a subset of cancer cells were found to be highly sensitive to the inhibitor (Fig. 3.33B). 
However, Prof Tom Look's laboratory reported that the effects of XMD-18-42 on the MYC 
driven cell line panel was a mimic of the Aurora B inhibitor AZD-1152-HQPA (Fig. 3.34). 
Since XMD-18-42 had off-target effects on Aurora B (Fig. 3.8), Dr Gray's laboratory 
developed XMD-18-83 (Fig. 3.9) which could inhibit NUAK1 with similar potency as XMD-
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18-42 but didnot possess any off-target effects on Aurora isoforms. Since XMD-18-83 was 
relatively less selective for NUAK1 as compared to XMD-18-42, Dr. Gray's laboratory 
developed 7-membered ring third generation inhibitor HTH-01-015 (Fig. 3.12) which was a 
hybrid of XMD-18-42 and XMD-18-83 which retained NUAK1 target potency while 
maintaining high selectivity.   
 
HTH-01-015 was highly selective for NUAK1 and ablated pSer445 MYPT1 phosphorylation 
between 3-10 µM concentration in HEK293 cells (Fig. 3.13). HEK293 cells stably 
overexpressing NUAK1 A195T drug resistant mutant however didnot exhibit loss of pSer445 
MYPT1 phosphorylation even at high 30 µM concentration of HTH-01-015 (Fig. 3.14) 
further confirming that pSer445 MYPT1 was indeed the best available read-out for the 
activity of NUAK1 in vivo. One interesting observation in the 7-membered ring series of 
NUAK inhibitors was that they didnot exhibit major inhibitory effect on NUAK2. DLW-01-
122-01 and XMD-18-42 did not inhibit NUAK2 significantly  (Fig. 3.11) whereas HTH-01-
015 had an IC50 value of >11 µM in vitro for NUAK2 (Fig. 3.12C). There are no available 
crystal structures for the NUAK isoforms and since the inhibitors are ATP-competitive in 
nature, one can only speculate that some of the amino acids in the kinase domain of NUAK2 
which are not homologous to NUAK1 (Gly173 in NUAK1 to Arg170 in NUAK2 or Thr73 in 
NUAK1 to Arg71 in NUAK2) could possibly be involved in altering the stearic properties of 
the inhibitor docking pocket in NUAK2 for the 7-membered ring series of inhibitors.  
 
Besides the 7-membered ring series, Dr. Gray's laboratory also developed a series of 
trisubstituted pyrimidine series of inhibitors based on the structural backbone of BX-795 and 
TG-101348 (Fig. 3.1). The first generation pyrimidine series of inhibitors were less specific 
for NUAK1 (Fig. 3.15 and 3.16) as some of them like WZ4002 potently inhibited EGFR and 
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TEC-family kinases (Zhou et al., 2009). The second generation trisubstituted pyrimidine 
based inhibitor was a reversible analog of WZ4002 termed WZ4003 which was a highly 
potent and selective inhibitor of the NUAK isoforms (Fig. 3.17). Unlike the 7-membered ring 
series, WZ4003 potently inhibited both NUAK1 and NUAK2 (IC50 100 nM) (Fig. 3.17C) 
and ablated pSer445 MYPT1 phosphorylation between 3-10 µM (Fig. 3.18) which was 
rescued upon stably overexpressing NUAK1 A195T drug resistant mutant (Fig. 3.19). 
 
Unlike XMD-18-42 or JWE-071, HTH-01-015 and WZ4003 treatment didnot exhibit any 
significant induction of MYC expression dependent cell death in TET21N cells (Fiig. 3.35). 
Most NUAK inhibitors which didnot possess any off-target effects on Aurora isoforms did 
not exhibit the MYC expression dependent cell death in TET21N cells (Fig. 3.35). This data 
signifies that the MYC dependent cell death observed  upon treatment of XMD-18-42 and 
JWE-071 was owing primarily due to Aurora inhibition (den Hollander et al., 2010) and 
perhaps partly on NUAK1 inhibition. Also, one could argue that the highly selective NUAK 
inhibitors like HTH-01-015 and WZ4003 are not  potent enough to exhibit the MYC 
dependent cell death. However, Nathanael Gray has also provided HTH-01-015 and WZ4003 
to his colleagues at the Dana Farber Cancer Centre and they also reported no observed 
striking effects on panels of Myc driven tumour cells tested. A library of NUAK1 RNAi has 
been generated and the data is consistent with the no effects exhibited with the inhibitors. 
More work is required but this does cast some doubt on whether NUAKs are good drug 
targets for treatment of Myc driven tumours.  
 
Since NUAK isoforms have been implicated in cell invasion and migration in cancer 
(Kusakai et al., 2004a, Kusakai et al., 2004b, Suzuki et al., 2004b, Namiki et al., 2011a, 
Namiki et al., 2011b, Chang et al., 2012, Lu et al., 2013), I wanted to test whether treatment 
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of cells with or without the inhibitors could have an effect on the proliferation, invasion and 
migration of various cells. We had previously reported that NUAK1
-/-
 MEFs were more 
adherent than the NUAK1
+/+
 MEFs and NUAK1
-/-
 MEFs had more prominent actin stress 
fibre formation and did not exhibit pSer445 MYPT1 signal upon treatment with cell 
dissociation agonists like EDTA (Zagorska et al., 2010). Interestingly, NUAK1
-/-
 MEFs 
exhibited a more adherent and a slower migration phenotype as compared to the NUAK1
+/+
 
MEFs (Fig. 3.21) and upon treatment of NUAK1
+/+
 MEFs with 10 µM HTH-01-015 and 
WZ4003, the cells mimicked the slow migration phenotype of NUAK1
-/-
 MEFs (Fig.3.22). 
The adherent and slower migration phenotype in the NUAK1 deficient and inhibited cells 
could be a result of more focal adhesion points and higher actin stress fibres formation as 
observed in Fig 3.24. Besides the MEFs, similar slower migration was observed in U2OS 
cells treated with or without 10 µM HTH-01-015 and WZ4003 (Fig. 3.23) thus further 
providing evidence of the possible role of NUAKs in cell migration.  
 
Besides cell migration, treatment of U2OS and NUAK1
+/+
 MEFs with 10 µM HTH-01-015 
and WZ4003 led to slower rate of cell proliferation which in the case of MEFs is consistent 
with the slow proliferating NUAK1
-/-
 MEFs (Fig. 3.25). Previous studies have exhibited the 
role of NUAK1 in cell proliferation wherein NUAK1 directly phosphorylates p53 at Ser15 
and Ser392 (Hou et al., 2011). Further work is required to establish possible role of NUAK 
isoforms in the cell cycle and proliferation. Various groups have also shown that NUAK1 
plays essential roles in cancer cell invasion which was further confirmed in U2OS cells. 
Treatment of U2OS cells with 10 µM HTH-01-015 and WZ4003 led to an approximately 70-
80% decrease in the number of cells invading into the Matrigel matrix as compared to the 
DMSO treated control (Fig. 3.26).  
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Thus, the data in this chapter indicate that WZ4003 and HTH-01-015 represent useful tools to 
dissect the physiological functions of NUAK kinases. These compounds are remarkably 
selective inhibitors, however, ablation of  MYPT1 pSer445 phosphorylation, effects on cell 
migration, invasion, proliferation and MYC dependant cell death analysis indicate that these 
compounds will need to be used at relatively high concentrations of 3 to 10 µM in order to 
maximally suppress NUAK activity in vivo. Since WZ4003 inhibits both NUAK1 and 
NUAK2 while HTH-01-015 is NUAK1 specific, comparing the effects of the inhibitors in 
vivo would also be insightful into the relative contribution of NUAK isoforms in 
physiological processes. In future, it would be interesting to develop more potent NUAK 
inhibitors with an EC50 of < 1 µM instead of 3 to 10 µM which could potentially provide 
further insight into the NUAK-MYC connection in cancer. Better potency is required to 
properly dissect the role of NUAK1 in regulating survival of MYC driven tumours. 
Furthermore, generation of NUAK1 drug resistant A195T knock-in cell lines would help in 
the identification of novel substrates of NUAKs via phosphoproteomic studies with and 
without treatment of inhibitors in parallel to wild-type cells.  
 
Thus, the success of the NUAK specific compounds provide yet further evidence that it is 
indeed possible to generate exquisitely specific inhibitors of the individual AMPK family 
kinases. 
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4. Role of SCF
βTRCP
 in regulating NUAK1 in the cell cycle 
 
4.1. Introduction 
Amidst the RING E3 ubiquitin ligases, the most widely studied ones are the anaphase 
promoting complex/cyclosome (APC/C) and the SKP1-Cullin-F-box (SCF) complexes (Fig 
4.1).  
The APC/C complex (Fig 4.1a) is primarily active in the cell cycle and the APC core is 
formed of atleast 14 different subunits of which APC2 acts as the primary scaffold, APC11 
acts as the E2 recruiting subunit and substrate adaptors Cdh1 or CDC20 which recognise 
substrate destruction motifs or degrons (Barford, 2011, Teixeira and Reed, 2013). 
APC/C
CDC20
 preferentially targets the D-box on substrates (consensus RxxLxxxxN) while 
APC/C
Cdh1 
targets both D-box and the KEN box motifs (consensus KENxxxN/Q) (Glotzer et 
al., 1991, Pfleger and Kirschner, 2000).  
 
    
Figure 4.1 RING domain E3 ligases : a) The multisubunit APC/C complex which interacts 
with either Cdh1 or CDC20 substrate recognition subunits to target substrates for degradation 
primarily by Lys11 linked polyubiquitin chains. b) The SCF complex E3 ligases which 
generally require a phosphodegron on the substrates for docking followed by Lys48 linked 
polyubiquitylation and degradation. Image adapted from (Teixeira and Reed, 2013). 
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In mammals, there are six different types of CRLs or Cullin-RING E3 ligases of which SCF 
(SKP-Cullin-F-box) ubiquitin ligases are the most well characterised (Frescas and Pagano, 
2008). The SCF E3 ubiquitin ligases consists of three essential subunits (Fig 4.1b). The 
RING-subunit ring box 1 or RBX1 catalyses the transfer of a ubiquitin-like NEDD8 molecule 
onto a conserved residue of the Cullin 1 (Cul1) scaffold which leads to autoactivation of the 
complex (Scott et al., 2010). S-phase kinase associated protein 1 or SKP1 is an adaptor which 
recruits the variable F-box or substrate recognition box on the SCF complex (Teixeira and 
Reed, 2013). Phosphorylation of specific motifs on the substrates, referred to as 
phosphodegrons, are generally the docking sites of the F-box sub-units of the SCF complex 
and almost all of the best studied SCF complexes leads to Lys48 link polyubiquitylation and 
degradation of its substrates (Frescas and Pagano, 2008).  
 
The F-box subunit is the SCF substrate recognition motif which generally requires a post-
translation modification (eg. phosphorylation) to interact with the substrate. The 69 identified 
F-box proteins have been classified into three major groups : FBXWs or the WD40 domain 
containing, FBXLs or leucine-rich repeat containing and FBXOs with diverse domains 
(Frescas and Pagano, 2008).  
 
Amidst the 69 F-boxes identified to date, 9 SCF ubiquitin ligases have been extensively 
characterised of which βTRCP is the most highly studied exhibiting roles in cell cycle, DNA 
damage, apoptosis, transcription, translation, telomere length, viral replication, autophagy, 
cell growth and proliferation. A list of most studied SCF
βTRCP
 substrates has been listed in 
Table 4.1. In mammals, there are two distinct homologues of βTRCP namely βTRCP1 
(BTRC, FBXW1, FBW1A and FWD1) and βTRCP2 (FBXW11, FBW11, FBXW1B, FBX1B 
and HOS) with indistinguishable biochemical properties (Frescas and Pagano, 2008). βTRCP 
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binds to its substrate at a well conserved destruction motif or degron DSGxxS or its variants 
(DSG/DDG/ESGxxS/EEG/SSGxxS/E/D motifs) in which the Ser residues require prior 
phosphorylation by an upstream kinase (Table 4.1). 
 
Table 4.1 : Substrates of SCF
βTRCP
 
Substrate Function Kinases Reference 
Atf4 Transcription  (Skaar et al., 2009) 
Auf1 Cytokine translation  (Li et al., 2013) 
β-catenin WNT signalling GSK3, CK1 (Skaar et al., 2009) 
BimEL Apoptosis induction RSK1, RSK2 (Skaar et al., 2009) 
Bora Spindle stability GSK3, PLK3 (Skaar et al., 2009) 
Bst2 HIV infection  (Douglas et al., 2009) 
Cdc25a Cell cycle CHK1, NEK11 (Sorensen et al., 2010) 
Cdc25b Cell cycle  (Skaar et al., 2009) 
Claspin DNA damage PLK1 (Skaar et al., 2009) 
Cortactin Cell motility ERK (Zhao et al., 2012a) 
Cyclin D1 Cell cycle  (Skaar et al., 2009) 
Deptor Cell growth and autophagy CK1 (Wang et al., 2012b) 
Dlg Cell contact and polarity  (Skaar et al., 2009) 
Ef2k Translation PKA, AMPK (Wiseman et al., 2013) 
Emi1 Cell cycle PLK1 (Skaar et al., 2009) 
FancM DNA damage PLK1 (Skaar et al., 2009) 
Fgd1 & Fgd3 Cdc42 regulation  (Skaar et al., 2009) 
Ghr Growth hormone signalling  (Skaar et al., 2009) 
H-Ras GTPase, cell growth,signalling  (Skaar et al., 2009) 
Hsf1 Transcription PLK1 (Skaar et al., 2009) 
HuR mRNA stability IKKα (Chu et al., 2012) 
Ifnr Cytokine signalling  (Skaar et al., 2009) 
IκBα Immune signalling IKKβ (Skaar et al., 2009) 
IL-10R1 Immune signalling  (Jiang et al., 2011) 
Irak1 Immune signalling  (Cui et al., 2012) 
Mcl1 Apoptosis inhibition GSK3 (Skaar et al., 2009) 
Mdm2 DNA damage CK1 (Wang et al., 2012a) 
Myc Cell proliferation  (Popov et al., 2010) 
Nrf2 Transcription GSK3 (Chowdhry et al., 2012) 
p100 & p105 Transcription IKKα, IKKβ (Skaar et al., 2009) 
p53 Tumor suppressor IKK2 (Skaar et al., 2009) 
p63 Epithelial differentiation  (Skaar et al., 2009) 
Pc2 Calcium signalling  (Skaar et al., 2009) 
Pdcd4 Protein synthesis S6K1 (Skaar et al., 2009) 
Per1 & Per2 Circardian rhythm CK1 (Skaar et al., 2009) 
Pfkfb3 Glycolysis   (Tudzarova et al., 2011) 
Phlpp1 Akt signalling  (Zhiqiang et al., 2012) 
Plk4 Cell cycle Auto-PLK4 (Mocciaro and Rape, 2012) 
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Prl-R Growth hormone signalling  (Skaar et al., 2009) 
Pro-caspase 3 Apoptosis  (Skaar et al., 2009) 
Securin Spindle checkpoint  (Skaar et al., 2009) 
Rassf1c DNA damage GSK3 (Zhou et al., 2012) 
Rcan1 Calcineurin-dependent signalling  (Skaar et al., 2009) 
Rest Cell cycle, differentiation  (Skaar et al., 2009) 
Spar Signal transduction PLK2 (Skaar et al., 2009) 
Smad3 TGF signalling  (Skaar et al., 2009) 
Snail EMT GSK3 (Skaar et al., 2009) 
Stat1 Transcription  (Skaar et al., 2009) 
Taz Transcription LATS, GSK3 (Huang et al., 2012) 
Trf1 Telomere length  (Wang et al., 2013) 
Twist EMT IKKβ (Zhong et al., 2013) 
Uhrf1 DNA damage CK1 (Chen et al., 2013a) 
VEGFR Angiogenesis and cell migration CK1 (Shaik et al., 2012) 
Wee1 Cell cycle PLK1, CDK1 (Skaar et al., 2009) 
 
 
βTRCP was first identified in Drosophila as Slimb which was found to negatively regulate 
Wnt and Hedgehog signalling pathway (Jiang and Struhl, 1998). In the absence of Wnt, a 
complex of GSK3β, CK1, APC, and axin associates with and phosphorylates β-catenin at the 
βTRCP interaction degron which targets β-catenin for ubiquitylation followed by 26S 
proteasomal degradation. In the presence of Wnt this process is blocked, leading to the 
accumulation of β-catenin, which functions as a coactivator for the transcription factor 
TCF/LEF-1. The β-catenin/TCF/LEF-1 complex then activates downstream genes in the Wnt 
pathway (Maniatis, 1999) (Fig. 4.2b). Besides Wnt pathway, SCF
βTRCP
 also plays an essential 
role in the inflammatory NFκB activation pathway (Maniatis, 1999) (Fig. 4.2a). A variety of 
signals, like tumor necrosis factor-α (TNFα) lead to the activation of an IκB–kinase complex 
(IKK), which specifically phosphorylates Ser32 and Ser36 on the βTRCP interaction degron 
of IκBα. This phosphorylation leads to SCFβTRCP interaction, Lys48 linked polyubiquitylation 
at Lys21 and Lys22 of IκBα and degradation, resulting in the release and nuclear 
translocation of NFκB (Maniatis, 1999) (Fig. 4.2a).  
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Figure 4.2. The role of the SCF
βTRCP
 in the regulated degradation of (a) IκBα in NFκB 
activation pathway and (b) β-catenin in the Wnt signalling pathway. Image taken from 
(Maniatis, 1999). 
 
SCF
βTRCP
 also plays pivotal roles in S-G2 DNA damage checkpoints as well as in controlling 
the activity of CDK1 in various stages of cell cycle by targetting CDC25 phosphatases, 
claspin and Wee1 for degradation (Bassermann et al., 2013) which has been described in 
details in Section 1.6. Besides cell cycle, SCF
βTRCP
 exhibits diverse substrate specificity and 
it was initially hypothesized that βTRCP could possess both tumour suppressor and 
oncogenic properties. But recently various studies have revealed that βTRCP1 is 
overexpressed in 56% of colorectal cancer tissues exhibiting decreased apoptosis (Ougolkov 
et al., 2004), in pancreatic cancer cells which have constitutively active NFκB (Muerkoster et 
al., 2005) and in hepatoblastomas (Koch et al., 2005). Some breast cancer cells exhibited 
βTRCP2 overexpression (Spiegelman et al., 2002).  
 
In 2003, Prof. Keichi Nakayama's laboratory in Japan reported the βTRCP1-/- mice 
(Nakayama et al., 2003). The mice were generally viable but exhibited reduced fertility 
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owing to impaired spermatogenesis (Nakayama et al., 2003, Guardavaccaro et al., 2003). 
Further studies revealed that the βTRCP1-/- mice exhibited centrosome overduplication, and a 
longer transition through G2-M stage of cell cycle (Frescas and Pagano, 2008). The relatively 
modest phenotype exhibited by the βTRCP1-/- mice may be owing to the redundancy with 
βTRCP2 which can compensate for the loss of βTRCP1 and still target SCFβTRCP substrates 
for degradation (Frescas and Pagano, 2008). 
 
Owing to the links between E3 ubiquitin ligases and cancer, various inhibitors have been 
developed like MG132, lactacystin and bortezomib which inhibit the proteasome thereby 
protecting E3 ubiquitin ligase substrates from degradation (Shirley et al., 2005). In 2003, 
bortezomib was approved by FDA for treatment against multiple myeloma and hence is the 
first and only proteasome inhibitor to enter the drug market (Orlowski and Kuhn, 2008). 
Recently MLN-4924, a specific CRL inhibitor has exhibited promising pre-clinical efficacy 
and has entered into multiple Phase I trials against various malignancies (Soucy et al., 2009a, 
Soucy et al., 2009b). The advantage of MLN-4924 over the other proteasome inhibitors is 
that the small molecule specifically inhibits the neddylation of the cullin and hence inhibits 
the CRL complexes only (Zhao et al., 2012b). Instead of targeting the proteasome, MLN-
4924 inhibits NEDD8-activating enzyme by forming a covalent adduct with NEDD8 which 
can no longer be utilized to neddylate the cullin (Brownell et al., 2010). This leads to the 
accumulation of the substrates which are targetted specifically by CRLs for degradation 
(Zhao et al., 2012b).  
 
In this chapter, I shall provide evidence of how NUAK1 is regulated over the cell cycle via its 
interactions with SCF
βTRCP
 and try to elucidate any role which NUAK1 might possess in the 
cell cycle. 
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4.2. Results 
4.2.1. Identification of NUAK1 interacting proteins using Orbitrap mass spectrometry 
In order to identify novel regulators or interactors for NUAK1, I used the Flp-in U2OS cells  
to generate HA-NUAK1 expressing stable U2OS cell line. For the identification of 
physiological interactors of NUAK1, lysates from U2OS stable cells expressing HA-NUAK1 
or HA-empty control cells were immunoprecipitated with anti-HA agarose (Figure 4.3). After 
in gel tryptic-digest, peptides were subjected to Orbitrap LC-MS mass fingerprint analysis. 
Table 4.2 shows the list of proteins that were present in the HA-NUAK1 lane but not in the 
control sample lane. The list was also filtered for proteins with a molecular weight matching 
the gel section in which they were identified. A Mascot score of >50 was taken as cut-off.  As 
expected, the bait protein, NUAK1, was identified in the gel band corresponding to the 
molecular weight of NUAK1. Importantly, known interactors, USP9X (Al-hakim et al., 
2008), myosin phoshatases MYPT1, MYPT2 and MBS85 (Zagorska et al., 2010), ubiquitin 
(Al-hakim et al., 2008) and PP1β (Zagorska et al., 2010) were identified with significant 
Mascot scores (Table. 4.2).  
 
Figure 4.3 : Large scale immunoprecipitation of HA-NUAK1 for mass spectrometry. 
U2OS FLPIN cells control or with overexpression of HA-NUAK1 were lysed using 1% 
Triton-X lysis buffer. HA-NUAK1 was immunoprecipitated and electrophoresed on a 
polyacrylamide gel that was stained with Instant Blue. The gel was divided into the indicated 
pieces and proteins were identified within these sections by Orbitrap LC/MS. Published 
interactors are indicated in green, bait protein NUAK1 is in red and novel interactors are in 
blue. 
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In addition, NUAK1 was found to interact with βTRCP1 and βTRCP2 which are two 
isoforms of the substrate recognition F-box subunits of the SCF
βTRCP
 E3 ubiquitin ligase 
complex as well as SKP1 which is an adaptor protein which interacts with the F-box domain 
of the  F-box subunit and links it to the Cullin 1 in the SCF complex.  
 
 
Table 4.2 : NUAK1-interacting proteins identified by mass spectrometry. 
The gel pieces indicated in Figure 4.1 were digested with trypsin and proteins were identified 
by Orbitrap mass spectrometry. The identified proteins of importance that were present only 
in the NUAK1 immunoprecipitate (bands 7-12) but not in the control (bands 1-6) are listed. 
Mascot protein score where a value >50 is considered significant. 
 
Gel Band Symbol Protein name Mass [Da] Mascot Peptides Reference 
       
band 7 USP9X USP9X 293699 327 15 (Al-hakim et al., 2008) 
 
MYH9 Myosin-9 227646 179 9 - 
 
UBB Ubiquitin 18295 88 4 (Al-hakim et al., 2008) 
       
band 8 PPP1R12A Myosin phosphatase regulatory subunit 1 (MYPT1) 115610 2798 42 (Zagorska et al., 2010) 
 
PPP1R12B Myosin phosphatase regulatory subunit 2 (MYPT2) 110793 289 18 (Zagorska et al., 2010) 
 
PPP1R12C Myosin binding subunit 85 (MBS85) 85286 123 4 (Zagorska et al., 2010) 
 
UBB Ubiquitin 18295 72 2 (Al-hakim et al., 2008) 
       
band 9 NUAK1 NUAK family Snf1 like kinase 1 74772 4236 234 bait 
       
band 10 βTRCP1 β transducin repeat containing protein 1  66262 315 21 - 
 
βTRCP2 β transducin repeat containing protein 2  61772 208 17 - 
       
band 11 PPP1CB Serine/threonine protein phosphatase PP1β catalytic subunit 37961 489 18 (Zagorska et al., 2010) 
       
band 12 YWHAE 14-3-3 protein epsilon 29326 987 41 (Zagorska et al., 2010) 
 
SKP1 S-phase kinase associated protein 1 18817 51 2 - 
 UBB Ubiquitin 18295 56 2 (Al-hakim et al., 2008) 
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4.2.2. Verification of βTRCP as an interactor of NUAK1 
To verify the interaction between NUAK1 and βTRCP at both the overexpressed and 
endogenous levels, I carried out co-immunoprecipitation experiments and looked for the 
interaction of endogenous NUAK1 and overexpressed FLAG-NUAK1 with endogenous 
βTRCP keeping endogenous MYPT1 as a control for co-immunoprecipitation. Endogenous 
NUAK1 was immunoprecipitated from 5 mgs of U2OS cell lysate and immunoblotting 
analysis revealed that it strongly interacted with MYPT1 and also exhibited a comparatively 
much weaker interaction with βTRCP (Fig. 4.4A). Overexpressed FLAG-NUAK1 strongly 
immunoprecipitated with MYPT1and PP1β (Fig. 4.4B). βTRCP clearly immunoprecipitated 
with overexpressed FLAG-NUAK1 (Fig. 4.4B). 
 
Figure 4.4 : βTRCP co-immunoprecipitates with NUAK1. A) Endogenous NUAK1 was 
immunoprecipitated from 2 mgs of U2OS cell lysate. Immunoprecipitates were analysed by 
immunoblotting with the indicated antibodies. B) Overexpressed FLAG-NUAK1 was 
immunoprecipitated from U2OS cells transfected with a construct for FLAG-NUAK1 for 36 
hrs. Immunoprecipitates were analysed by immunoblotting with the indicated antibodies. 
βTRCP antibody was used which is a βTRCP1 and βTRCP2 dual antibody. βTRCP isoforms 
possess indistinguishable functions within a cell. 
  
 
4.2.3. βTRCP interacts with NUAK1 and NUAK2 but not other AMPK related kinases 
In order to determine if the interaction with βTRCP is specific to NUAK kinases or also 
occurs with other AMPK-related kinases, I transfected HEK293 cells with 10 meembers of 
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the AMPK family kinases (GST-tagged NUAK1, NUAK2, MARK1-4, BRSK1-2 and SIK1-
2). βTRCP1 co-immunoprecipitated with the NUAKs (Figure 4.5). Other than the NUAK 
isoforms, the only other AMPK related kinase found to interact with βTRCP1 albeit very 
weekly was SIK2.  
 
Figure 4.5 :  βTRCP interacts with NUAKs but not other AMPK related kinases. 
HEK293 cells were transfected with expression plasmids for GST-tagged AMPK related 
kinases. 36 hrs after transfection cells were lysed and GST-tagged proteins were 
immunoprecipitated from 5 mg of cell lysates. Immunoprecipitates  were analysed by either 
coomassie staining for GST-tagged proteins or by immunoblotting with βTRCP antibody. 
 
 
4.2.4. Mapping the SCF
βTRCP
 interaction motif or 'degron' on NUAK1 
As outlined in the introduction, βTRCP or the substrate recognition motif SCFβTRCP interacts 
with its substrate via conserved destruction domain or degron on the substrate which bears 
the canonical or slightly modified amino acid sequence of DSGxxS where the two Ser 
residues require prior phosphorylation by an upstream kinase.   
 
I next inspected the sequence of both NUAK1 and NUAK2 to see whether they contained the 
βTRCP degron motif that could account for their interaction with βTRCP.  Sequence analysis 
revealed that NUAK1 and NUAK2 possessed the highly conserved ESGYYS degron motif. 
Both in NUAK1 and NUAK2, the ESGYYS degron is highly conserved within the vertebrate 
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orthologues upto zebrafish (Danio spp.) (Fig. 4.6). In NUAK2 of zebrafish, the degron is 
modified into a ESSCCS motif which could still possess βTRCP interaction properties. 
 
Figure 4.6 Alignment showing the conservation of the ESGYYS degron of NUAK1 and 
NUAK2 within vertebrate orthologues. The sequences used for alignment were obtained 
from Uniprot database. In zebrafish (Danio) there are two orthologues of NUAK1 (Q5RH93 
and LOC561496) and one of NUAK2 (Q1MTK5). Red bar indicates the ESGYYS degron 
and * indicates the two Ser residues which are potential phosphorylation sites on the degron.  
 
 
NUAK1and NUAK2 possess a slightly modified degron with the sequence of ESGYYS (Fig. 
4.7A) which has been found to be conserved within vertebrates (Fig. 4.6). To justify whether 
the ESGYYS motif is indeed the βTRCP interaction motif in NUAK1, I carried out an 
alanine scan of the residues on the degron. On mutating the major residues on the degron, 
there was marked reduction in the interaction with βTRCP especially on mutating the Gly477 
and the two Ser residues Ser476 and Ser480 (Fig. 4.7B). On mutating both the Ser residues to 
Ala, the interaction to βTRCP was virtually lost (Fig. 4.7B)  
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Figure 4.7 :  Identification of the destruction motif or ‘degron’ of NUAK1 as a binding 
site for βTRCP. (A) NUAK1 was identified to possess a slight variant of the canonical 
SCF
βTRCP
 binding domain DSGxxS which is present in the bonafide SCF
βTRCP
 substrates 
IκBα and β-catenin. (B) HEK293 cells were transfected with expression plasmids for GST-
tagged NUAK1 wild-type or indicated mutants. 36 hrs after transfection cells were lysed and 
GST-tagged proteins were immunoprecipitated from 10 mg of cell lysates. 
Immunoprecipitates were analysed by either Instant blue staining for the GST-tagged proteins 
or by immunoblotting with βTRCP antibody. 
 
4.2.5. Phosphorylation of the NUAK1 degron is a requirement for βTRCP interaction 
To identify whether phosphorylation was essential for βTRCP to bind to NUAK1, λ-
phosphatase assay was employed. EDTA inactivated λ-phosphatase was used as control. HA-
NUAK1 was immunoprecipitated from 10 mg of U2OS cell lysate and divided into three 
reactions (each in duplicates) and  λ-phosphatase assay was carried out for 30 mins at 30 ºC. 
The reactions were washed 3x with 1% Triton lysis buffer to remove any dissociated βTRCP. 
Post λ-phosphatase reaction, immunoblotting for βTRCP revealed that λ-phosphatase 
treatment abolished interaction of NUAK1 with βTRCP and this was prevented by EDTA 
mediated inactivation of λ-phosphatase (Fig. 4.8). 
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Figure 4.8 :  Phosphorylation of NUAK1 is required for interaction with  βTRCP. HA-
NUAK1 was immunoprecipitated from stably expressing U2OS cells. λ-phosphatase assay 
was carried out with or without prior inactivation of λ-phosphatase with EDTA. The 
immunoprecipitates were washed thoroughly before immunoblotting. An electrophoretic 
mobility shift of NUAK1 was observed in λ-phosphatase treated NUAK1 immunoprecipitate. 
 
 
4.2.6. Ser476 and Ser480 on the NUAK1 degron are potential phosphosites which may 
be under the regulation of interacting PP1β 
To address whether the two Ser residues on the NUAK1 ESGYYS degron are indeed 
potential phosphosites in vivo, I immunoprecipitated GST-NUAK1 (wild-type and mutants) 
from transiently transfected overexpressing HEK293 cells and carried out high performance 
liquid chromatography with tandem mass spectrometry (LC-MS-MS) on an LTQ-Orbitrap 
mass spectrometer to identify phosphosites (Section 2.2.23.1) (Fig. 4.9). Phosphosites on 
NUAK1 wild-type was compared with Ser476Ala+Ser480Ala mutant. Extracted ion 
chromatogram analysis (XIC) of Ser476+Ser480 phosphopeptide (R.ESGYYSSPER.S+2P) 
was carried out to compare between the intensities of the phosphopeptides in NUAK1 WT 
and mutants. The total signal intensity of the phosphopeptide is plotted on the y-axis and 
retention time is plotted on the x-axis. The m/z (mass/charge ratio) value corresponding to the 
phosphopeptide was detected in NUAK1 WT between 625.8 to 626.8 with a retention time of 
approximately 11 mins. The phosphopeptide was not identified in Ser476Ala+Ser480Ala 
mutant (Fig 4.9). 
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Figure 4.9 :  The Ser476 and Ser480 on the βTRCP interacting degron of NUAK1 are 
potential phosphosites. NUAK1 WT and Ser476Ala+Ser480Ala mutant were 
immunoprecipitated from stably expressing U2OS cells and the protein band was excised for 
phosphopeptide analysis using LTQ Orbitrap. The tryptic peptide R.ESGYYSSPER.S+2P 
intensity between WT and SS/AA mutant was observed by XIC. Arrow indicated the 
NUAK1 band which was excised for LTQ-Orbitrap analysis. 
 
 
4.2.7. Myosin phosphatase non-binding 3IL/KK mutant of NUAK1 has a stronger 
interaction with βTRCP 
Since Fig 4.9 showed that Ser476 and Ser480 are potential in vivo phosphosites, I wanted to 
test whether the NUAK1 interacting MYPT1-PP1β phosphatase could possibly regulate 
βTRCP interaction with NUAK1. MYPT1-PP1β interacts with NUAK1 via the NUAK1 
triple GILK motif. Interestingly, on comparing the degree of βTRCP interaction between the 
NUAK1 wild-type, Ser476Ala, Ser 480Ala, Ser476Ala+Ser480A and 3IL/KK (NUAK1 
triple GILK mutant) mutants, there was clearly a much stronger interaction of 3IL/KK with 
βTRCP (Fig. 4.10). Thus, ablating the interaction of NUAK1 with MYPT1-PP1β  complex 
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indeed increases the potential of NUAK1 to interact with βTRCP. Also, in the 
Ser476Ala+Ser480A mutant of NUAK1, although there is minimal βTRCP interaction, a 
robust increase in PP1β interaction was observed.  
 
Figure 4.10 :  Absence of phosphatase promotes NUAK1 interaction with βTRCP. GST 
tagged NUAK1 WT, S470A, S480A, SS/AA and 3IL/KK mutants were immunoprecipitated 
from transiently transfected HEK293 cells and resolved by SDS-PAGE followed by 
commassie staining or immunoblotting with βTRCP and PP1β antibodies. 
 
 
4.2.8. Prolonged  MLN-4924 treatment on cells leads to accumulation of endogenous 
NUAK1 
To obtain further evidence that NUAK1 expression might be controlled by the SCF
βTRCP
 E3 
ubiquitin ligase complex, I decided to study how inhibition of Cullin-RING ligases 
(CRLs)would impact on the NUAK1 expression. To achieve this, I treated U2OS cells with 
NEDD8 inhibitor MLN-4924 which would inhibit Cullin 1 by inducing deneddylation. If 
NUAK1 was indeed a substrate of SCF
βTRCP
, treatment of cells with MLN-4924 should lead 
to an increase in the expression levels of NUAK1. Indeed, upon treatment of U2OS cells with 
3 µM MLN-4924 over 1,2,4,8 and 24 hours, there was a clear accumulation of NUAK1 over 
time (Fig. 4.11). By 4-8 hours, there was considerable accumulation of NUAK1 whereas 
closely related AMPK family kinase MARK1 had no change in expression levels (Fig. 4.11). 
 
 
151 
 
 
Figure 4.11 :  Time course of MLN-4924 treatment on U2OS cells leads to accumulation 
of endogenous NUAK over time with no change in levels of closely related kinase 
MARK1. Endogenous NUAK1 was immunoprecipitated from U2OS cells treated with 
MLN-4924 over the indicated periods of time. Immunoblotting was carried out to detect 
NUAK1 levels in the immunoprecipitates and to detect MARK1 and GAPDH in the lysates. 
 
4.2.9. Endogenous NUAK1 is degraded upon Calyculin A mediated 
hyperphosphorylation  
Next, I wanted to establish whether increasing phosphorylation at Ser476 and Ser480 would 
lead to enhanced degradation of endogenous NUAK1. In order to do this, I treated U2OS 
cells with PP1 inhibitor Calyculin A with a final concentration of 50 nM over 0, 15 and 180 
minutes. Phosphorylation of ERK was immunoblotted as a control for Calyculin A mediated 
hyperphosphorylation. Upon treatment with Calyculin A over 180 minutes, there was a 
significant degradation of NUAK1 (Fig. 4.12) suggesting that inhibition of phosphatases in 
cells may promote endogenous NUAK1 degradation possibly mediated via SCF
βTRCP
. 
 
Figure 4.12 :  Calyculin A mediated inhibition of phosphatases leads to degradation of 
NUAK1 over time. Endogenous NUAK1 was immunoprecipitated from U2OS cells treated 
with Calyculin A (50 nM) over the indicated periods of time. Immunoblotting was carried out 
to detect NUAK1 levels in the immunoprecipitates and to detect pERK and total ERK in the 
lysates. 
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4.2.10. Hyperphosphorylation leads to polyubiquitylation and degradation of NUAK1 
which is reversed by MLN-4924 
Since endogenous NUAK1 is degraded upon inhibition of phosphatases in cells, I wanted to 
check whether this hyperphosphorylation mediated degradation of NUAK1 was due to SCF 
E3 ligases. If SCF complexes are indeed involved in endogenous NUAK1 degradation, then 
MLN-4924 treatment should inhibit neddylation of the Cullin1 of SCF complex and thus 
protect NUAK1 from hyperphosphorylation mediated degradation. I carried out a time course 
of Calyculin A treatment of U2OS cells with or without the presence of 3 µM MLN-4924. 
Endogenous NUAK1 was immunoprecipitated from 1 mg of the U2OS lysates and 
immunoblotting was carried out. Upon 2-4 hours of Calyculin A treatment, there was a robust 
decrease in NUAK1 levels as observed before (Fig. 4.12) and in the presence of 3 µM MLN-
4924, this Calyculin A mediated degradation of NUAK1 was reversed (Fig. 4.13). 
 
 
 
Figure 4.13 :  Calyculin A mediated inhibition of phosphatases leads to degradation of 
NUAK1 over time which is reversed in the presence of NEDD8 inhibitor MLN-4924. 
Endogenous NUAK1 was immunoprecipitated from U2OS cells treated with Calyculin A (50 
nM) and with or without MLN-4924 over the indicated periods of time. Immunoblotting was 
carried out to detect NUAK1 levels in the immunoprecipitates. 
 
 
Since MLN-4924 inhibits the neddylation of Cullin 1, the SCF complex formation is 
jeopardised and hence there is transfer of ubiquitin chains onto the substrate. To check the 
endogenous polyubiquitylation of NUAK1 in Calyculin A treated U2OS cells with or without 
the presence of 3µM MLN-4924, similar experiment as in Fig. 4.13 was carried out and the 
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cells were lysed in reducing agent free lysis buffer supplemented with 5 mM N-
ethylmaleimide (NEM). NEM is a deubiquitinase inhibitor and hence preserves the 
polyubiquitylation of proteins post-lysis. Endogenous NUAK1 was immunoprecipitated from 
5 mg of cell lysates and immunoblotting was carried out using NUAK1 and Ubiquitin 
antibodies. There was a clear ubiquitylation of NUAK1 upon 30 mins of Calyculin A 
treatment and the ubiquitin signal was consequently reduced owing to degradation of 
NUAK1 over time (Fig. 4.14). However, in MLN-4924 treated cells, there was no significant 
signal of polyubiquitylation at any time point suggesting that NUAK1 was indeed 
polyubiquitylated and degraded by an SCF complex upon phosphatase inhibition (Fig, 4.14). 
 
 
 
 
 Figure 4.14 :  Endogenous NUAK1 undergoes polyubiquitylation upon Calyculin A 
treatment which leads to its degradation over time which is reversed in the presence of 
NEDD8 inhibitor MLN-4924. Endogenous NUAK1 was immunoprecipitated from U2OS 
cells treated with Calyculin A (50 nM) and with or without MLN-4924 over the indicated 
periods of time. Immunoblotting was carried out to detect co-immunoprecipitation of 
ubiquitin with endogenous NUAK1. * indicates a non-specific band. 
 
 
 
 
 
 
* 
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4.2.11. βTRCP1-/- MEFs exhibit double the level and activity of endogenous NUAK1 
To obtain genetic evidence that NUAK1 is a substrate of SCF
βTRCP, βTRCP1 knock-out 
MEFs were tested for NUAK1 activity and expression levels. The βTRCP1 wild-type and 
knock-out MEFs were kindly provided by Dr.Keichi Nakayama (Japan) (Nakayama et al., 
2003). βTRCP1 -/- cells clearly had approximately double the level and activity of endogenous 
NUAK1 as compared to the βTRCP1+/+ MEFs (Fig. 4.15).  
 
 
Figure 4.15 : βTRCP1-/- MEFs exhibit double the level and activity of endogenous 
NUAK1 as compared to the βTRCP1+/+ MEFs. Endogenous NUAK1 was 
immunoprecipitated from 2 mgs of MEF lysates and kinase assay was carried out in 
triplicates along with immunoblotting. The lysates were subjected for immunoblotting with 
βTRCP and GAPDH antibodies. 
 
 
4.2.12. U2OS cells stably expressing Ser476Ala+Ser480Ala+Ser481Ala mutant of 
NUAK1 exhibits faster proliferation rate and higher expression of NUAK1. 
As in Fig. 4.7B, mutating the NUAK1 degron at the two Ser residues leads to a robust loss of 
βTRCP interaction.  Hence, to compare between the NUAK1 WT and the βTRCP non-
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interacting mutant, U2OS FLP-IN cells stably over-expressing HA-NUAK1 wild-type and 
HA-NUAK1 Ser476Ala+Ser480Ala+Ser481Ala mutant (SSS/AAA) were developed. The 
Ser481 was also mutated since an adjacent Ser residue to a βTRCP degron has been reported 
to partially compensate for the βTRCP interaction (Tudzarova et al., 2011). Interestingly, the 
U2OS FLP-IN cells expressing NUAK1 SSS/AAA expressed approximately double the level 
of NUAK1 (Fig. 4.16A) and had a moderately faster proliferation rate (Fig. 4.16B) as 
compared to the U2OS FLP-IN cells overexpressing NUAK1 WT. 
 
Figure 4.16 : U2OS FLP-IN cells overexpressing NUAK1 SSS/AAA mutant had a faster 
proliferation rate and expressed a higher level of NUAK1. A) Immunoblotting of cell 
lysates with HA and β-tubulin antibodies was carried out to compare between the expression 
levels of WT and SSS/AAA mutant of NUAK1. B) MTS cell proliferation assay was carried 
out to compare between cell proliferations of U2OS cells expressing NUAK1 WT and 
NUAK1 SSS/AAA mutant over 5 days. Data was represented as growth of cells times Day 0.  
 
 
4.2.13. βTRCP non binding SSS/AAA mutant of NUAK1 is not degraded upon 
hyperphosphorylation induced with Calyculin A. 
NUAK1 is degraded upon Calyculin A mediated PP1 inhibition which is protected in the 
presence of MLN-4924 (Fig. 4.13). To obtain evidence that phosphorylation of NUAK1 at 
βTRCP interacting residues was critical for regulating stability of NUAK1, I treated U2OS 
NUAK1 WT and U2OS NUAK1 SSS/AAA cells with 0, 0.5 or 3 hrs of Calyculin A 
treatment. Upon treatment with Calyculin A over 3 hrs, there was a significant degradation of 
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NUAK1 WT as compared to the 0.5 hr Calyculin A treatment, whereas there was hardly any 
NUAK1 degradation observed between 0.5 hr and 3 hrs Calyculin A treated U2OS NUAK1 
SSS/AAA (Fig. 4.17).  
 
 
Figure 4.17 : NUAK1 SSS/AAA mutant is resistant towards hyperphosphorylation 
mediated degradation of NUAK1 upon treatment of Calyculin A over time. U2OS cells 
stably expressing NUAK1 WT or SSS/AAA mutant were treated with 50 nM Calyculin A 
over the indicated periods of time and immunoblotting was carried out with HA (NUAK1) 
and β-tubulin antibodies. 
 
  
 
4.2.14. Inhibitor panel to identify the upstream kinase responsible for phosphorylating 
the NUAK1 degron. 
Since SCF
βTRCP
 targets a degron that requires prior phosphorylation, it was important to 
identify the upstream kinase(s) of NUAK1 which may be involved in phosphorylating Ser476 
and Ser480 on the degron. To identify the upstream kinase responsible for phosphorylating 
NUAK1 at the βTRCP interaction residues, a lot of effort was spent initially towards raising 
phospho-antibodies against the Ser476+Ser480 residues of the NUAK1 degron. The 
antibodies raised, however, were not efficient enough to study NUAK1 phosphorylation 
either at overexpressed or at endogenous levels. Hence to  identify the upstream kinase of 
NUAK1, I carried out a protein kinase inhibitor screen and identify the compounds which 
mimic the NUAK1 protection exhibited by MLN-4924. The inhibitor panel consisted of 
inhibitors which targetted kinases which has been previously been reported to be 
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phosphorylating SCF
βTRCP
 substrates on the degron. MLN-4924 exhibits a robust protection 
of NUAK1 upon Calyculin A treatment. Any other kinase inhibitor which could protect 
NUAK1 to the same level could potentially lead to the identification of the upstream kinase 
of NUAK1 phosphorylating the degron. Amidst the protein kinase inhibitors tested, PLK 
inhibitor BI-2536 significantly protected NUAK1 from hyperphosphorylation mediated 
degradation. Besides BI-2536, IKK/GSK inhibitor BIO and ROCK inhibitor H1152 also 
exhibited moderate levels of NUAK1 protection (Fig. 4.18). Since BIO and H1152 were 
considerably less specific inhibitors (http://www.kinase-screen.mrc.ac.uk/), there were not 
used in further experiments. 
 
 
 Figure 4.18 : Inhibitor panel treatment of U2OS NUAK1 WT cells to identify potential 
upstream kinases responsible for hyperphosphorylation mediated degradation of 
NUAK1. U2OS cells stably expressing HA-NUAK1 were treated with the indicated 
inhibitors for 6 hours before lysing them for immunoblot analysis. The inhibitors were used 
at 10 µM final except for MLN-4924 (3 µM), BI-2536 (1 µM) and D4476 (30 µM). 
 
 
4.2.15. PLK1 immunoprecipitates with overexpressed NUAK1 in U2OS cells 
Since Polo-kinases seem to be playing a role in protection of NUAK1 upon 
hyperphosphorylation, I wanted to see whether PLK1 immunoprecipitates with overexpressed 
NUAK1. GST-NUAK1 was immunoprecipitated from 5 mg of transiently transfected 
HEK293 cells and immunoblot was carried out to identify PLK1 and PP1β. PLK1 was found 
to immunoprecipitate with overexpressed NUAK1 (Fig 4.19) along with the previously 
known interactor PP1β (Zagorska et al., 2010). 
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Figure 4.19 : PLK1 co-immunoprecipitates with overexpressed NUAK1. Overexpressed 
GST-NUAK1 was immunoprecipitated from transiently transfected HEK293 cells. GST-
NUAK1 was identified on Instant Blue stained gel and immunoprecipitates were analysed by 
immunoblotting with the indicated antibodies. 
 
 
4.2.16. NUAK1 accumulates in the S phase of the cell cycle. 
Since polo kinases are responsible for phosphorylating the NUAK1 degron, the cell cycle 
might be the best starting point to identify the physiological process wherein SCF
βTRCP
 might 
be playing a role in NUAK1 degradation. Since SCF
βTRCP
 has been implicated as a key cell 
cycle regulator at G2 stage of cell cycle, I synchronised U2OS cells at G2 stage of cell cycle 
by double thymidine block followed by release in 10 µM RO-3306 (reversible CDK1 
inhibitor) (Section 2.2.25). Endogenous NUAK1 was found to be degraded in the G2/M stage 
of cell cycle and levels steadily increase during later G1-S phase (Fig. 4.20). Immunoblot was 
carried out for G2 markers cyclin A and B1 and mitotic marker pSer10 H3. AMPK related 
kinase SIK2 and NUAK upstream kinase LKB1  levels were unchanged throughout the cell 
cycle. NUAK substrate MYPT1 levels also did not alter over the cell cycle. 
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Figure 4.20 : Endogenous NUAK1 is degraded in the G2-M stage of cell cycle and 
accumulates in the S phase. U2OS cells were synchronised at G2/M stage of cell cycle by a 
double-thymidine block followed by release in reversible CDK1 inhibitor RO-3306. 
Immunoblotting was carried out with the indicated antibodies. 
 
 
To examine this further, U2OS FLP-IN cells expressing HA-NUAK1 WT and SSS/AAA 
mutant were synchronised using double thymidine for G1-S and using double thymidine and 
release in 10 µM RO-3306 for G2 stage of the cell cycle. Propidium iodide stained flow 
cytometry analysis was carried out to ascertain the cell cycle progression of the U2OS cells. 
Interestingly, WT NUAK1 was found to be degraded in the G2-M-G1 stages of the cycle 
with clear accumulation in the S phase whereas the SSS/AAA mutant remained relatively 
constant at all stages of the cell cycle (Fig. 4.21). Thus, protection of the βTRCP non-binding 
mutant suggests that the SCF
βTRCP
 may be playing significant roles in controlling NUAK1 
expression in the cell cycle.  
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Figure 4.21 : NUAK1 WT is degraded in the G2-M-G1 stages of the cell cycle unlike the 
βTRCP non-binding SSS/AAA mutant. (ASYN : asynchronous) U2OS cells stably 
expressing HA-NUAK1 WT and SSS/AAA mutants were synchronised with double 
thymidine block release for G1 and S phase and double thymidine block followed by release 
in RO-3306 for G2/M phase. Cell cycle synchronisation efficiency was confirmed by flow 
cytometry propidium iodide staining. Immunoblotting was carried out with indicated 
antibodies. 
 
 
Moreover, immunofluorescence of HA-NUAK1 in the synchronised U2OS FLP-IN cells 
suggest that during S-phase, along with a clear increase in the level of HA-NUAK1, there is 
also a significant translocation of NUAK1 into the nucleus (Fig. 4.22) and hence could 
possibly indicate novel functions of NUAK1 in the DNA replication phase of the cell cycle. 
The HA-NUAK1 Ser476Ala+Ser480Ala+Ser481Ala (SSS/AAA) expression levels and 
localisation within the cells remained relatively unchanged over the cell cycle stages. 
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Figure 4.22 : Besides an increase in the level of NUAK1 in the S-phase, a distinct 
localisation of NUAK1 is observed in the nucleus of the cells in S-phase. U2OS cells 
stably expressing HA-NUAK1 WT and SSS/AAA mutants were synchronised with double 
thymidine block release for G1 and S phase and double thymidine block followed by release 
in RO-3306 for G2/M phase. Cells were fixed in 4% paraformaldehyde, permeabilised and 
immunofluorescence was carried out using HA-monoclonal antibody. 
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4.3 Discussion 
 
NUAK1 is a much less studied kinase as compared to its family member and closely related 
kinase AMPK. The only rigorously characterised substrate known is MYPT1 which gets 
phosphorylated by NUAK1 upon cell detachment (Zagorska et al., 2010). NUAK1 is known 
to undergo ubiquitylation and interacts with USP9X which is thought to be the DUB 
responsible for deubiquitylating NUAK1 (Al-hakim et al., 2008). Recently, p53 was reported 
to be a direct substrate of NUAK1 wherein NUAK1 phosphorylates p53 at Ser15 and Ser392 
leading to a cell cycle arrest at G1/S border and hence playing vital roles in cell proliferation 
(Hou et al., 2011). Besides cell proliferation, NUAK1 has been implicated in metastasis, 
invasion, tumour promotion and antiapoptotic roles in cancer (Kusakai et al., 2004a, Kusakai 
et al., 2004b, Chang et al., 2012, Liu et al., 2012, Lu et al., 2013) but very little is known 
regarding the biochemical mechanisms by which NUAK1 might confer its functions within 
the cancer cells. 
 
In an attempt to identify novel interacting partners of NUAK1, mass fingerprint analysis was 
carried out and components of the SCF
βTRCP
 RING E3 ubiquitin ligase complex was found to 
co-immunoprecipitate with NUAK1 (Fig. 4.3). βTRCP1,  βTRCP2 and SKP1 was found in 
the NUAK1 interactome (Fig. 4.3 and 4.4). As outlined in the introduction, SCF
βTRCP
 is 
instrumental in Wnt, Hedgehog, immune signalling, cell cycle and DNA damage pathways 
(Table 4.1, Fig. 4.2). Hence, the idea of NUAK1 interacting with a highly studied E3 
ubiquitin ligase with diverse functions was indeed quite intriguing. Characteristic of majority 
SCF
βTRCP
 substrates, NUAK1 also possess the DSGxxS  (ESGYYS in NUAK1) degron 
which requires prior phosphorylation at the two Ser residues for βTRCP to interact (Fig. 
4.7A). βTRCP was found to interact with both NUAK1 and NUAK2 (Fig. 4.5) and both the 
 
 
163 
NUAK isoforms possess the ESGYYS degron which is evolutionarily conserved in 
vertebrates upto zebrafish (Danio spp.) (Fig. 4.6).  On performing an alanine scan over the 
degron, βTRCP interaction was lost upon introducing double mutation of the two Ser 
residues (Ser476 and Ser480) on the ESGYYS degron (Fig. 4.7B). The two Ser residues were 
also identified to be potential phosphorylation sites upon LTQ-Orbitrap mass spectrometry 
followed by extracted ion chromatogram (XIC) analysis (Fig. 4.9). The NUAK1 tryptic 
peptide R.ESGYYSSPER.S consisting of the degron sequence was found to be doubly 
phosphorylated with a mass by charge ratio between 625.8 to 626.8 and a retention time of 
approximately 11 mins (Fig. 4.9). Upon mutating the two Ser residues, the intensity peak for 
the phosphopeptide was lost hence suggesting that Ser476 and Ser480 were the two possible 
phosphosites instead of the other Tyr or Ser residues within the tryptic peptide (Fig. 4.9). 
Moreover, upon dephosphorylating NUAK1 with λ-phosphatase, there was a robust loss of 
βTRCP interaction which could be reversed upon inactivating λ-phosphatase with EDTA 
(Fig. 4.8). Hence phosphorylation at the Ser476 and Ser480 residues are essential for βTRCP 
to interact with NUAK1. 
 
Since NUAK1 interacts with MYPT1-PP1β complex, I wanted to check whether interaction 
with the PP1β could be involved in keeping the degron of NUAK1 in a dephosphorylated 
state. To test this idea, I compared the βTRCP interaction of NUAK1 WT, single Ser to Ala 
mutants and double S476A + Ser480A with the MYPT1-PP1β non-binding 3IL/KK mutant 
of NUAK1. NUAK1 interacts with the PP1β subunit of MYPT1-PP1β via three conserved 
GILK motifs (Zagorska et al., 2010). Mutating the triple GILK motifs into GKKK, led to a 
clear loss of PP1β interaction but interestingly had significantly higher βTRCP interaction 
(Fig. 4.10). This data suggests that there is an intrinsic competition between βTRCP and 
PP1β to interact with NUAK1 and one could speculate that upon  NUAK1 phosphorylation at 
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the degron, the MYPT1-PP1β complex might be dissociating from NUAK1. A lot of time 
was invested in developing the Ser476+Ser480 phosphospecific antibody for NUAK1, but 
the antibodies raised were not effective enough to identify phosphorylated NUAK1. 
 
βTRCP was found to robustly co-immunoprecipitate with overexpressed NUAK1 (Fig. 4.4B) 
whereas the co-immunoprecipitation with endogenous  NUAK1 was markedly less (Fig. 
4.4A), hence one could argue that the interaction  may only be an overexpression artefact.  To 
obtain conclusive evidence that βTRCP is indeed playing essential roles in controlling 
expression level of endogenous NUAK1, I carried out a time course treating U2OS cells with 
NEDD8 inhibitor MLN-4924. MLN-4924 inhibits the neddylation of the cullin in the SCF 
complex which consequently fails to transfer ubiquitin chains to degrade the substrate.  
Hence MLN-4924 treatment of cells should ideally lead to an increase in the levels of 
NUAK1 if NUAK1 is indeed a SCF
βTRCP
 substrate. Within 4 hours of 3 µM MLN-4924 
treatment, there was significant increase in the protein levels of endogenous NUAK1 (Fig 
4.11) which clearly suggested that NUAK1 was indeed regulated by an Cullin RING E3 
ligase. Furthermore, upon treating U2OS cells with PP1 inhibitor calyculin A, endogenous 
NUAK1 was found to be degraded within 2-4 hrs of treatment (Fig. 4.12 and 4.13). The 
NUAK1 degradation could be reversed by introducing MLN-4924 to the system (Fig. 4.13). 
Upon blotting for endogenous ubiquitin, NUAK1 was found to be ubiquitylated within 30 
mins of calyculin A treatment and consequently degraded over time (Fig. 4.14). In the 
presence of MLN4924, NUAK1 was not found to be ubiquitylated upon calyculin A 
treatment (Fig. 4.14) suggesting that the SCF complex is inactive owing to deneddylation of 
the cullin. Thus, NUAK1 is ubiquitylated and degraded upon hyperphosphorylation which 
can be reversed by MLN-4924. To further obtain genetic evidence that βTRCP is indeed 
degrading NUAK1, we received βTRCP1-/- MEF cells from Prof Keichi Nakayama's lab in 
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Japan.  βTRCP1-/- MEF cells had approximately double the level of endogenous NUAK1 and 
double the activity (Fig. 4.15). The βTRCP2 isoform may still be playing a role in targetting 
NUAK1 for degradation as the two βTRCP isoforms are functionally indistinguishable. I 
tried to knock-down βTRCP2 isoform in the βTRCP1-/- MEF but the shRNAs to βTRCP2 
was found to be lethal for the cells. Hence, the data suggests that SCF
βTRCP
 may indeed be the 
E3 ligase responsible for regulating the endogenous level of NUAK1.   
 
To obtain further evidence that the calyculin A mediated degradation of NUAK1 was indeed 
brought about by SCF
βTRCP
 , I developed U2OS cells stably expressing NUAK1 WT and 
βTRCP non-binding NUAK1 S476A+S480A+S481A mutant (SSS/AAA mutant). Ser481 
was an additional mutation introduced in NUAK1, as Prof. Salvador Moncada's group in 
London had reported in their studies with PFKFB3 and βTRCP that an additional Ser residue 
adjacent to the βTRCP interaction degron could at times partially compensate for the loss of 
interaction with βTRCP  upon mutating the two Ser residues in the degron (Tudzarova et al., 
2011). NUAK1 SSS/AAA mutant expressing cells expressed double the level of NUAK1 
(Fig. 4.16A) presumably owing to its inability to interact with SCF
βTRCP
 and had a 
moderately faster proliferation  rate as compared to NUAK1 WT expressing cells (Fig. 
4.16B). Upon treatment of the cells with calyculin A over 3 hrs, NUAK1 WT was found to be 
degraded but SSS/AAA mutant did not exhibit significant degradation at 3 hrs of calyculin A 
treatment (Fig. 4.17) thus further consolidating the hypothesis that NUAK1 is degraded by 
SCF
βTRCP
 upon hyperphosphorylation.    
 
The evidence suggests that upon phosphorylation of Ser476 and Ser480, NUAK1 interacts 
with SCF
βTRCP
 and undergoes degradation. Since SCF
βTRCP
 has diverse roles in cells, it was 
important to identify the physiological process wherein NUAK1 needs to be targetted for 
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degradation via SCF
βTRCP
.  To approach this question, the first step was to identify the 
possible upstream kinase(s) responsible for phosphorylating NUAK1 at the degron. For this 
purpose, a panel of kinase inhibitors were employed which specifically target the kinases 
known to phosphorylate βTRCP substrates at the degron (Table 4.1). The idea was to identify 
the kinase inhibitors which could protect NUAK1 from calyculin A mediated degradation. As 
seen in the inhibitor panel, U2OS cells treated with PLK inhibitor BI2536 exhibited robust 
NUAK1expression (Fig. 4.18). Treatment with IKK/GSK inhibitor BIO and H1152 (ROCK 
inhibitor) also exhibited NUAK1 protection but these inhibitors were less specific and hence 
were not considered for further experiments (Fig. 4.18). Since BI2536 is a highly specific 
PLK inhibitor, and PLK1 is known to phosphorylate various βTRCP substrates, I wanted to 
gather further evidence via co-immunoprecipitation studies to identify whether PLK1 
interacts with NUAK1. PLK1 indeed co-immunoprecipitates with overexpressed NUAK1 
(Fig. 4.19), although it is yet unclear whether the interaction is direct or via a NUAK1 
interactor like MYPT1-PP1β.  
 
Since PLK1 has essential roles in the progression of cell cycle especially in the G2/M stage 
(Section 1.6), I synchronised U2OS cells in the cell cycle and found that endogenous NUAK1 
was degraded in the G2/M stage of the cell cycle and slowly started accumulating in the late 
G1/S phase (Fig. 4.20). Strong signals of G2/M cyclins B1 and A and pSer10 H3 mitotic 
signal confirmed the proper synchronisation of cells in G2/M stage (Fig. 4.20). NUAK1 
substrate MYPT1,  NUAK1 related SIK2 or NUAK1 activating LKB1 kinase were 
unchanged in the cell cycle (Fig. 4.20). Further synchronisation experiments on U2OS cells 
expressing NUAK1 WT and NUAK1 SSS/AAA mutant showed that NUAK1 was degraded 
in G2/M stage till early G1 and accumulated in the S phase of the cell cycle (Fig. 4.21). 
NUAK1 SSS/AAA mutant levels, however, were relatively unchanged throughout the cell 
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cycle (Fig. 4.21). Upon staining the HA-NUAK1 in the synchronised U2OS cells for 
immunofluorescence, NUAK1 levels were found to be upregulated in the S phase (consistent 
with the immunoblot data) and there was a significant fraction of NUAK1 migrating to the 
nucleus (Fig. 4.22). NUAK1 migrating to the nucleus during the S or DNA synthetic phase of 
cell cycle suggests the possibility of NUAK1 to be playing important roles in the DNA 
damage or perhaps DNA synthesis processes of the cell. NUAK1 SSS/AAA levels were 
found to be constant throughout the cell cycle with strong NUAK1 signal in the nucleus at all 
the 3 stages of cell cycle (Fig. 4.22).  
 
Thus upon PLK1 mediated phosphorylation, NUAK1 interacts with and is degraded by 
SCF
βTRCP
 in the G2/M stage of the cell cycle and further work is required to identify the 
potential functions of NUAK1 in the cell cycle or perhaps in the cell cycle checkpoints and 
DNA damage pathways.  
 
In future, it would be interesting to dissect the exact role that NUAK1 may be playing in the 
cell cycle or perhaps in the DNA damage checkpoints. For this purpose, the initial step would 
be to identify novel interactors of NUAK1 in the nucleus via phosphoproteomic studies. 
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5. Myosin phosphatase family as potential substrates of NUAK1  
 
5.1. Introduction 
 
Cellular motility, cytokinesis, cell detachment,  smooth muscle contraction and many other 
cellular and muscle functions are activated by phosphorylation of Ser19 and Thr18 of the 
regulatory myosin light chain 2 (MLC2) of the contractile motor protein myosin II (Allen and 
Walsh, 1994, Hirano et al., 2003, Wilson et al., 2005). Phosphorylation at Ser19/Thr18 
promotes the reversible interaction of myosin II with actin filaments via cross-bridges and 
leads to the conversion of chemical energy of ATP into mechanical force or movement 
(Grassie et al., 2011). Hence, the phosphorylation status of myosin II is the primary 
determinant for cellular motility. MLC2 phosphorylation is regulated via phosphorylation and 
consequent dephosphorylation activities of MLCK and various other kinases and myosin 
phosphatases whose catalytic activity is attributable to protein phosphatase type 1 catalytic 
subunit or PP1β (Cohen, 2002b, Bollen et al., 2010). In the case of myosin II, PP1β functions 
as a heterodimeric complex along with a member of the myosin phosphatase targeting 
subunit (MYPT) family (Shimizu et al., 1994).  
 
The MYPT family consists of five members: MYPT1 (or PPP1R12A), MYPT2 (or 
PPP1R12B), myosin binding subunit of 85 kDa (MBS85 or PPP1R12C), MYPT3 (or 
PPP1R16A) and the TGFβ- inhibited membrane-associated protein (TIMAP or PPP1R16B) 
(Fig. 5.1). The MYPT family members reveal high level of sequence similarity and exhibit 
several structural and functional domains (Fig. 5.1). The N-terminal RVxF motif (PP1β-
binding site) is found in all family members which is immediately followed by a region 
containing several ankyrin repeats which aids in protein interactions including 
phosphorylated myosin. MYPT1, MYPT2 and MBS85 contain C-terminal leucine zipper 
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sequences  which are involved in dimerization and protein–protein interaction. The other two 
family members, MYPT3 and TIMAP, lack the leucine zipper domain but contain a C-
terminal prenylation site which targets the proteins to membranes (Hartshorne et al., 2002, 
Grassie et al., 2011). 
 
The MYPT family is primarily regulated by phosphorylation by a variety of protein 
serine/threonine kinases. MYPT1 is phosphorylated  Thr696 and Thr853 by ROCK (Kimura 
et al., 1996) which leads to the dissociation of the phosphatase from myosin and consequently 
leads to decrease in activity (Ichikawa et al., 1996, Velasco et al., 2002a). Both the ROCK 
sites are conserved in MYPT2, while only that corresponding to T696 is conserved in 
MBS85, and neither site is found in TIMAP or MYPT3 (Fig. 5.1) (Grassie et al., 2011). Anna 
Zagorska a previous PhD student in the lab had shown that NUAK1 phosphorylates the 
myosin targeting subunit or MYPT1 after interacting with the PP1β subunit of the complex 
via the conserved GILK motifs. NUAK1 phosphorylates MYPT1 subunit at the three Ser445, 
Ser472 and Ser910 residues that promotes interactions with 14-3-3 isoforms which was 
hypothesized to inhibit the MYPT1-PP1β complex phosphatase activity on MLC2. Besides 
MYPT1 , the other isoforms of myosin phosphatase family MYPT2 and MBS85 also interact 
with NUAK1 (Zagorska et al., 2010) but the exact functional  implications have not yet been 
deciphered. 
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Figure 5.1 The domain structures of the MYPT family members with indicated 
phosphorylation sites.  
 
 
5.1.1. MYPT1 or PPP1R12A 
Smooth muscle MYPT1 was purified from chicken gizzard as a heterotrimeric complex 
composed of a 38 kDa PP1β catalytic subunit, regulatory subunit MYPT1(130 kDa)  and a 20 
kDa small subunit (M20) (Alessi et al., 1992, Hartshorne et al., 2002). MYPT1 interacts with 
PP1β at the N-terminus and with M20 at the C-terminus, thereby forming the holoenzyme of 
MYPT1-PP1β (Hartshorne et al., 2002). M20 is a splice variant of MYPT2 and has been 
detected only in smooth muscle myosin phosphatase (Moorhead et al., 1998). Determination 
of the crystal structure of PP1β in complex with a fragment (residues 1–299) corresponding 
to the N-terminus of MYPT1 (Terrak et al., 2004) showed that MYPT1 interacts with PP1β 
via the KVKF (RVxF) motif or via the myosin phosphatase N-terminal element or MyPhoNE 
(residues 10–17 in MYPT1) consensus sequence RxxQV/I/LK/RxY/W, which is  conserved 
in all MYPT family members (Grassie et al., 2011). 
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 MYPT1 contains a number of phosphorylation sites, of which the Thr696 and Thr853 cause 
inhibition of myosin phosphatase activity. Thr853 is a conserved ROCK phosphorylation site 
whereas several protein kinases, including ROCK, zipper-interacting protein kinase (ZIPK), 
myotonic dystrophy kinase and p21-activated protein kinases are known to phosphorylate the 
Thr696 residue (Grassie et al., 2011). During mitosis, MYPT1 is phosphorylated at several 
residues (Ser432, Ser473 and Ser601) by proline-directed kinases, such as cdc2 (Yamashiro 
et al., 2008) which creates a docking site for PLK1. Interaction with MYPT1-PP1β leads to 
dephosphorylation of the PLK1 activation residue Thr210 which leads to hindering of 
centrosome maturation and leads to mitotic arrest (Yamashiro et al., 2008). 
 
MYPT1 undergoes proteasomal degradation upon interaction with E3 ubiquitin ligase 
sevenin-absentia-homolog 2 (SIAH2) (Twomey et al., 2010). SIAH2 interacts with MYPT1 
via a central region of MYPT1 containing a SIAH-binding motif, which is not conserved in 
other MYPT family members. An activator protein p116Rip or M-RIP interacts directly with 
MYPT1 and myosin, thereby assists in the localisation of myosin phosphatase to myosin and 
increases myosin phosphatase activity on MLC2 (Koga and Ikebe, 2005). It has also been 
reported that 14-3-3s inhibit myosin phosphatase activity by dissociating myosin phosphatase 
from myosin, leading to delocalisation of MYPT1 from stress fibres (Koga and Ikebe, 2008). 
Recently our laboratory has shown that NUAK1 phosphorylates MYPT1 subunit at the three 
Ser445, Ser472 and Ser910 residues that promotes interactions with 14-3-3 isoforms which 
was suggested to inhibit the MYPT1-PP1β complex phosphatase activity on MLC2 
(Zagorska et al., 2010). A key aim of the research presented in this chapter is to obtain 
physiological experimental evidence that phosphorylation of MYPT1 might indeed inhibit 
MYPT1-PP1β protein phosphatase activity. 
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5.1.2. MYPT family 
Besides MYPT1, the four other members of the MYPT family are much less studied. They all 
have the conserved RVxF motif for PP1β interaction. 
 
MYPT2 is predominantly expressed in striated (cardiac and skeletal) muscles and brain. 
MYPT2 has been shown to interact with PP1β and is the regulatory subunit of cardiac myosin 
phosphatase (Moorhead et al., 1998, Mizutani et al., 2010). MYPT2-PP1β  blocks 
angiotensin II-induced sarcomere organization in cultured cardiomyocytes and localises at the 
A band and Z-line of cardiac muscles and also in mitochondria (Okamoto et al., 2006). 
 
MBS85 is an 85 kDa ubiquitously expressed protein that was discovered as a substrate of 
MRCKα which mediates Cdc42-induced actin reorganization (Tan et al., 2001). Recent 
studies have shown that MBS85 undergoes AMPKα2 mediated phosphorylation at Ser452 
which promotes 14-3-3 interaction and is essential for proper progression of mitosis (Banko 
et al., 2011). The AMPK phosphorylation site Ser452 on MBS85 was conserved with Ser472 
of MYPT1 and could possibly be a NUAK1 phosphosite as well and hence required further 
attention. 
  
TIMAP is primarily localized to the plasma membrane of endothelial cells and undergoes 
TGFβ-mediated transcriptional repression (Grassie et al., 2011). TIMAP was reported to bind 
laminin receptor (LAMR1) and recruit PP1β for LAMR1 dephosphorylation (Kim et al., 
2005). Activity of the TIMAP-PP1β complex seems to be regulated by PKA and GSK3 
mediated phosphorylation at Ser333 and Ser337 (Li et al., 2007, Csortos et al., 2008). 
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MYPT3 is predominantly membrane-associated and is expressed primarily in the heart, brain 
and kidneys (Grassie et al., 2011). Contrary to other MYPT family members, MYPT3 
binding to PP1β inhibits its catalytic activity towards MLC2 (Skinner and Saltiel, 2001) and 
requires PKA mediated phosphorylation of MYPT3 to increase the activity of PP1β towards 
phosphorylated MLC2 (Yong et al., 2006). 
 
MYPT2 and MBS85 has been found to immunoprecipitate with overexpressed NUAK1 in 
mass-spectrometric experiments as well as in co-immunoprecipitations (Zagorska et al., 
2010). Hence, I was interested in exploring whether MYPT2 and MBS85 were potential 
substrates of NUAK1.  
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5.2. Results 
 
5.2.1. MYPT1-PP1β wild-type and triple Ser mutant complexes were co-purified from 
bacterial and exhibited similar phosphatase specific activity  
Although MYPT1-PP1β beautifully expresses in mammalian cells, I decided to purify the 
complex from bacterial system because MYPT1 is known to interact with various kinases in 
vivo and hence the major sites may remain pre-phosphorylated and consequently pose 
problems while carrying out biochemical phosphatase assays. In order to express recombinant 
MYPT1-PP1β complex for functional analysis, I decided to express the two subunits of the 
complex together in a polycistronic bacterial expression vector. GST-MYPTI-His-PP1β wild-
type (WT) and GST-MYPTI-His-PP1β triple serine-alanine mutant 
(Ser445Ala+Ser472Ala+Ser910Ala or SSS/AAA) in which all NUAK1 phosphorylation sites 
are mutated, were overexpressed and purified using autoinduction media from E.coli BL-21 
tranformed with the polycistronic pOPTH expression vector (Fig.5.2A) containing the cDNA 
of the proteins. MYPT1 complex was purified by GST-sepharose affinity chromatography 
and the GST tag was cleaved from MYPT1 with Precission protease. The purified proteins 
were resolved by SDS gel electrophoresis (Fig.5.2B) and the purified complexes were 
estimated to be approximately 20% pure. The identity of MYPT1 (130kDa) and the PP1β 
(37kDa) bands were confirmed by QTRAP mass spectrometry analysis. 
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Figure 5.2 : Overexpression of MYPT1-PP1β complexes : (A) The construct used to 
overexpress recombinant MYPT1-PP1β wild-type (WT) and SSS/AAA mutant (mutated at 
the three NUAK1 phosphosites Ser445+Ser472+Ser910 to alanine) complexes from E.coli 
was a polycistronic pOPTH vector with a T7 promoter, translation enhancer element and 
ampicillin resistance gene. A GST tag was linked to MYPT1 and a hexa-His tag on the PP1β. 
(B) The coomassie gel showing the overexpressed wild-type and triple serine mutant GST- 
MYPT1-His-PP1β after a GST-affinity purification and GST cleavage by Precission protease. 
 
In order to establish that the purified recombinant MYPT1-PP1β complexes (WT and 
SSS/AAA) were active, varying amounts of the complexes were incubated with 
32
P-GST-
MLC2 that had been phosphorylated to stoichiometric levels with ROCK kinase. The 
reaction was carried out for 10min at 30 °C. Reactions were terminated by addition of 20% 
TCA to precipitate the protein and the amount of 
32
P inorganic phosphate released in the 
supernatant by virtue of phosphatase activity was assessed. A linear reaction condition was 
achieved between the % release of phosphate from the 
32
P-GST-MLC2 into the supernatant 
and the amount in ng (nanograms) of MYPT1-PP1β (Fig 5.3). The wild type MYPT1-PP1β 
had a specific activity of 1100 U/mg and that of the SSS/AAA was found to be 1000 U/mg, 
thus indicating that mutating the NUAK1 phosphorylation site did not influence the intrinsic 
activity of the MYPT1-PP1β complex.  
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Fig 5.3 : The purified MYPT1-PP1β complexes were active. MYPT1-PP1β wild-type and 
SSS/AAA were overexpressed and purified in parallel. Various amounts of the purified 
MYPT1-PP1β complex (both WT and SSS/AAA) were treated with 32P-GST-MLC2 and a 
linear reaction was established between the protein phosphatase amount in reaction (0.5ng to 
100ng) and % release of phosphate from 
32
P-GST-MLC2 into the supernatant. The specific 
activity of each of the wild-type and SSS/AAA mutant was calculated by considering 20% 
purity. The specific activity of wild type MYPT1-PP1β was 1100 U/mg and that of SSS/AAA 
was 1000 U/mg. 
 
To further confirm that NUAK1 was unable to phosphorylate the MYPT1-PP1β SSS/AAA, 
an autoradiography was carried out using NUAK1 on the bacterially purified MYPT1-PP1β 
WT and SSS/AAA in parallel using [γ32P]ATP. Immunoblots were carried out for MYPT1 
total, MYPT1 Ser445, Ser472, Ser910 and NUAK1 (Fig. 5.4). MYPT1-PP1β SSS/AAA 
could not be phosphorylated significantly by NUAK1. 
                                                       
Figure 5.4 : MYPT1-PP1β SSS/AAA complex is not phosphorylated by NUAK1 
significantly : NUAK1 phosphorylates the MYPT1-PP1β complex at Ser445, Ser472 and 
Ser910. NUAK1 showed significantly lower phosphorylation of the MYPT1-PP1β triple 
serine mutant (SSS/AAA) complex as shown in the autoradiography and the phosphoblots. 
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5.2.2. Phosphorylation by NUAK1 inhibits MYPT1-PP1β phosphatase activity  
In order to investigate whether NUAK1 phosphorylation of MYPT1 influenced its 
phosphatase activity, MYPT1-PP1β complex was incubated with or without NUAK1 with 0.1 
µM [γ-32P]ATP-Mg under the conditions that MYPT1 complex undergoes maximum 
stoichiometric phosphorylation of 3 moles of phosphate per mole of complex. Reaction was 
terminated by addition of excess EDTA to chelate the Mg and intrinsic MYPT1 phosphatase 
activity was assessed following 100 fold dilution. 14-3-3s were used in the assay as it was 
reported that 14-3-3 interaction was essential for the inhibition of MYPT1 binding to myosin 
II (Koga and Ikebe, 2008). Under these conditions, it was found that NUAK1 induced a 
moderate but reproducible and statistically significant (~40%) inhibition of the phosphatase 
activity of the complex towards MLC2 (Fig 5.5). The mutant with all the three NUAK1 
phosphosites mutated to alanine, however, didnot show any inhibition of phosphatase activity 
on NUAK1 phosphorylation (Fig 5.5). 
                                    
Figure 5.5 : NUAK1 phosphorylation at Ser445, Ser472 and Ser910 of MYPT1-PP1β 
complex inhibits the phosphatase activity : The phosphatase activities of the MYPT1-PP1β 
wild-type and SSS/AAA mutant were compared with or without NUAK1 phosphorylation. 
There was a significant inhibition of phosphatase activity of the NUAK1 phosphorylated 
MYPT1-PP1β wild-type complex unlike the SSS/AAA mutant which showed no inhibition 
post NUAK1 phosphorylation. 
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5.2.3. NUAK1 phosphorylates MYPT2 and MBS85 in vitro at phosphosites conserved 
with MYPT1 
 NUAK1 has been found to phosphorylate MYPT1 at residues that lie within an optimal 
AMPK consensus motif LX(R/K)(S/T)X(pS)XXX(L/I) (Dale et al., 1995, Hardie et al., 
2012). Sequence alignment suggests that this AMPK consensus motif is found in MYPT2 
and MBS85 but not in MYPT3 and TIMAP. Fig 5.5 shows the residues in MYPT2 and 
MBS85 that align with the Ser445 and Ser472 residues on MYPT1 that NUAK1 
phosphorylates. Consistent with this, NUAK1 phosphorylates MYPT2 (Fig. 5.7) and MBS85 
(Fig. 5.8). 
 
 
Figure 5.6 NUAK1 phosphosites are conserved in MYPT1, MYPT2 and MBS85 
isoforms. The Ser445 and Ser472 sites on MYPT1 was found to be conserved in MYPT2 and 
MBS85 but not in MYPT3 and TIMAP. Thus MYPT2 and MBS85 may be potential NUAK1 
substrates. All the potential NUAK1 sites on MYPT isoforms are conserved AMPK 
phosphorylation motifs. Image adapted from (Zagorska et al., 2010). 
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In order to map the phosphorylation sites, MYPT2 and MBS85 were radiolabelled by 
NUAK1 using [γ32P]ATP (specific activity 10,000-15,000 cpm/pmol) in vitro, and then 
digested with Trypsin. The resulting peptides were then subjected to HPLC, mass 
spectrometric analysis and solid phase Edman sequencing (Section 2.2.23.2). This analysis 
revealed that NUAK1 phosphorylates MYPT2 at Ser447 and Ser473 (Fig 5.7) and MBS85 at 
Ser427 and Ser452 (Fig. 5.8) in vitro. 
 
 
Figure 5.7. NUAK1 phosphorylates MYPT2 at Ser447 and Ser 473. (A) Time course of 
phosphorylation of MYPT2 by NUAK1 with [γ32P]ATP, incubated at the given time points, 
has been shown in an autoradiography. A kinase inactive (kd) NUAK1(Asp196Ala) was used 
in place of wild-type NUAK1 as a negative control. (B) The schematic domain structure of 
MYPT2 showing the conserved ankyrin repeat domain, leucine zipper motif, PP1β binding 
RVXF motif and the inhibitory regions with NUAK1 and ROCK phosphosites. (C) MYPT2 
phosphorylated by NUAK1 with [γ32P]ATP was in gel digested by trypsin and hplc of the 
peptides were carried out. Two peaks corresponding to each of the two phosphopeptides were 
found. (D) The solid phase Edman sequencing of the hplc derived Ser 447 phosphopeptides 
are shown. (E) same as D, except for Ser473 Edman sequencing is shown. The second peaks 
of the tryptic digest were  miscleavages wherein two phosphopeptides with the same 
phosphosite were identified.  
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Figure 5.8. NUAK1 phosphorylates MBS85 at Ser427 and Ser 452. (A) Time course of 
phosphorylation of MBS85 by NUAK1 with [γ32P]ATP, incubated at the given time points, 
has been shown in an autoradiography. A kinase inactive (kd) NUAK1(Asp196Ala) was used 
in place of wild-type NUAK1 as a negative control. (B) The schematic domain structure of 
MBS85 showing the conserved ankyrin repeat domain, leucine zipper motif, PP1β binding 
RVXF motif and the inhibitory regions with NUAK1 and ROCK phosphosites. (C) MBS85 
phosphorylated by NUAK1 with [γ32P]ATP was in gel digested by trypsin and hplc of the 
peptides were carried out. One peak corresponding to each of the two phosphopeptides were 
found. (D) The solid phase Edman sequencing of the hplc derived Ser 427 phosphopeptides 
are shown. (E) same as D, except for Ser452 Edman sequencing is shown.  
 
 
5.2.4. NUAK1 phosphorylates MYPT3 at an AMPK consensus motif  
In order to map the phosphorylation sites, MYPT3 was radiolabelled by NUAK1 using 
[γ32P]ATP (specific activity 10,000-15,000 cpm/pmol) in vitro as before, and then digested 
with Trypsin. The resulting peptides were then subjected to HPLC, mass spectrometric 
analysis and solid phase Edman sequencing (Section 2.2.23.2). This analysis revealed that 
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NUAK1 phosphorylates MYPT3 at Ser433 (Fig 5.9) at typical AMPK phosphorylation motif 
LDRSVSYQLSP (Ser433 in red). A radioactive signal was observed at Ser431 on the Edman 
sequencing, but carrying out a hplc on NUAK1 phosphorylated trypic peptides of MYPT3 
S433A showed that Ser431 may not be an in vitro  phosphosite for NUAK1 (Fig. 5.9D). 
 
Figure 5.9. NUAK1 phosphorylates MYPT3 at Ser433. (A) Time course of 
phosphorylation of MYPT3 by NUAK1 with [γ32P]ATP, incubated at the given time points, 
has been shown in an autoradiography. A kinase inactive (kd) NUAK1(Asp196Ala) was used 
in place of wild-type NUAK1 as a negative control. (B) MYPT3 phosphorylated by NUAK1 
with [γ32P]ATP was in gel digested by trypsin and hplc of the peptides were carried out. One 
peak corresponding to the single phosphopeptide was found. (C) The solid phase Edman 
sequencing of the hplc derived Ser 433 phosphopeptide is shown.  (D) MYPT3 S433A 
mutant phosphorylated by NUAK1 with [γ32P]ATP was in gel digested by trypsin and hplc of 
the peptides were carried out. 
 
 
 
182 
5.2.5. NUAK1 does not phosphorylate TIMAP with a high stoichiometry  
Compared to MYPT1, MYPT2, MYPT3 and MBS85, the other MYPT isoform TIMAP is not 
significantly phosphorylated by NUAK1 in vitro. Bacterially purified TIMAP was 
phosphorylated by NUAK1 in vitro. Time course of phosphorylation of MYPT3 and TIMAP 
by NUAK1 with [γ32P]ATP was carried out. A kinase inactive (kd) NUAK1(Asp196Ala) was 
used in place of wild-type NUAK1 as a negative control. Compared to the autoradiography 
signal of the other MYPT1 phosphoryated with NUAK1, MYPT3 and TIMAP were much 
weaker and exhibited hardly any 
32
P incorporation at 40 mins of kinase reaction (Fig. 5.10). 
 
 
 
Figure 5.10. NUAK1 doesnot phosphorylate TIMAP. Time course of phosphorylation of 
TIMAP by NUAK1 with [γ32P]ATP has been shown in an autoradiography. A kinase inactive 
(kd) NUAK1 was used in place of wild-type NUAK1 as a negative control. TIMAP was not 
phosphorylated by NUAK1 to the extent of the other MYPT isoforms. 
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5.3. Discussion 
Myosin phosphatases are a family of five isoforms primarily responsible for 
dephosphorylating and inactivating myosin in diverse tissues (Grassie et al., 2011). Previous 
works from Dr. Mitsuo Ikebe's laboratory has shown that p116RIP and 14-3-3 isoforms are 
essential interactors of MYPT1-PP1β complex which determine the localisation of the 
phosphatase to myosin II (Koga and Ikebe, 2005, Koga and Ikebe, 2008). ROCK plays a 
critical role in phosphorylating MYPT1 isoform at Thr696 and Thr853 which leads to 
inhibition of the phosphatase activity of MYPT1-PP1β towards phosphorylated myosin light 
chain 2 (Feng et al., 1999, Velasco et al., 2002b). Recently, Anna Zagorska, a former PhD 
student of our laboratory had shown that NUAK1 controls the cell adhesion properties of the 
cells by controlling the phosphatase activity of MYPT1-PP1β (Zagorska et al., 2010). 
NUAK1 has specific and distinct phosphosites on MYPT1 Ser445, Ser472 and Ser910 
(Stoichiometry of 1.5) (Fig. 5.4) which are independent of the inhibitory ROCK phosphosites 
Thr696 and Thr853 (Zagorska et al., 2010).  
 
To study the effect of NUAK1 on the phosphatase activity of MYPT1-PP1β in vitro on 
radiolabelled MLC2 substrate, I co-purified MYPT1-PP1β complex from bacteria (Fig. 5.2). 
Although MYPT1-PP1β complex can be purified from mammalian systems, there is always a 
possibility of contamination with interacting kinases and pre-phosphorylation of essential 
residues on MYPT1. MYPT1-PP1β complex was for the first time expressed together in the 
same construct; earlier works on the complex had been carried out mostly by separate 
bacterial expression of the two proteins and carrying out an in vitro binding. MYPT1-PP1β 
WT and S445A+S472A+S910A mutant complexes were purified in parallel (Fig. 5.2) and 
their specific activity was calculated and found to be comparable ~1000-1100 U/mg (Fig 
5.3).  The MYPT1-PP1β complex phosphatase activity is moderately inhibited (~40%) by 
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NUAK1 phosphorylation at the MYPT1 Ser445, Ser472 and Ser910 phosphosites and hence 
the MYPT1 complex is unable to dephosphorylate myosin light chain (Fig. 5.5). The 
inhibition, although moderate, was statistically significant and reproducible. Full length 
myosin II instead of the MLC2 subunit could possibly be a more physiological substrate for 
the phosphatase assay and is one aspect which might require more attention in future. 
MYPT1- PP1β complex mutated at the three NUAK1 phosphosites to alanine does not show 
any inhibition of phosphatase activity on phosphorylating with NUAK1 (Fig. 5.5).   
 
Dr. Anne Brunet's laboratory reported that one of the myosin phosphatase isoform MBS85 
was a substrate of AMPKα2 and phosphorylation of MBS85 at Ser452 by AMPKα2 induced 
14-3-3 interaction with MBS85 and regulated the progression of mitosis (Banko et al., 2011). 
Interestingly, Ser452 in MBS85 was conserved with MYPT1 NUAK1 phosphorylation site of 
Ser472 (Fig. 5.6). Both MYPT2 and MBS85 had Ser residues which were conserved with the 
MYPT1 NUAK1 phosphosites (Fig. 5.6). To identify whether NUAK1 phosphorylated 
MYPT2 and MBS85 as well, I carried out phospho-peptide mapping followed by Edman 
sequencing. NUAK1 strongly phosphorylated MYPT2 and MBS85 in vitro. MYPT2 
phosphomapping revealed Ser447 and Ser473 (stoichiometry of 1.2) (Fig. 5.7) as potential 
phosphosites whereas MBS85 phosphomapping showed Ser427 and Ser452 (stoichiometry of 
0.8) (Fig. 5.8) as potential NUAK1 phosphosites. MYPT3 was relatively weakly 
phosphorylated by NUAK1 at Ser433 which was a typical AMPK consensus phosphorylation 
motif but not conserved with the other MYPT isoforms (Fig. 5.9). NUAK1, however, did not 
phosphorylate TIMAP with high enough stoichiometry (Fig. 5.10). Hence, AMPK and 
NUAK may be playing dual roles in phosphorylating myosin phosphatase isoforms especially 
Ser452 of MBS85 in cells and further work is required to properly dissect the mechanism.  
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Thus, the present work has established that NUAK1 phosphorylates and inhibits MYPT1-
PP1β phosphatase activity in vitro and the other MYPT isoforms MYPT2 and MBS85 are 
substrates of NUAK1 in vitro. Further investigation is required looking into a possible 
NUAK1-MYPT isoform interactions in controlling myosin II activity. 
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6. Summary 
The primary aspect my work has been to dissect the physiological roles, identification of 
interacting partners and methods of regulation of AMPK-related kinase NUAK1. Since 
NUAK1 substrate specificity is very closely related to most of the other AMPK family 
members, in collaboration with Dr. Nathanael Gray's laboratory I have developed highly 
selective inhibitors of NUAK kinases (detailed in chapter 3). Based on the chemical 
backbone of generic inhibitors, HTH-01-015 (NUAK1 selective) and WZ4003 (NUAK1 and 
NUAK2 dual inhibitor) could potentially be exciting tools to dissect the possible roles of 
NUAK1 in cancer.  
 
Besides pharmacological inhibition, in chapter 4, I further identified NUAK1 to be regulated 
in the cell cycle upon phosphorylation by PLK1 at the G2/M stage which triggers NUAK1 
interaction with SCF
βTRCP
. SCF
βTRCP
 interaction leads to ubiquitylation and degradation of 
NUAK1 at G2/M stage of cell cycle. NUAK1 tends to accumulate in cells at the S-phase of 
the cell cycle and localises to the nucleus, thus indicating possible roles in the DNA synthetic 
or DNA damage checkpoint regulation of cell cycle. Further work is required to elucidate the 
exact roles of NUAK1 in the cell cycle.  
 
Finally, Anna Zagorska a previous student had identified MYPT1-PP1β as a physiological 
substrate of NUAK1 and in chapter 5, I have shown that NUAK1 regulates the phosphatase 
activity of MYPT1-PP1β in vitro towards myosin light chain 2 substrate. Furthermore, I have 
shown that the other MYPT isoforms MYPT2, MBS85 and possibly MYPT3 are substrates 
of NUAK1 in vitro. Further work is required to validate these in vitro substrates as potential 
in vivo physiological substrates and to identify the possible roles of the interactions.  
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Figure 6. Schematic representation of phosphorylation, activation, ubiquitylation and 
small molecule inhibition of NUAK1. 
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